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II. Abstract: 
 
More than 40,000 patients undergo treatment for superficial venous incompetence (varicose 
veins) in the UK each year. Previously the majority underwent conventional surgery with its 
associated inconvenience and morbidity. Endovenous laser ablation (EVLA) is a relatively 
new minimally invasive technique that abolishes superficial venous reflux and is an 
alternative treatment for some patients. Although early studies have shown it to be safe and 
effective for great saphenous vein (GSV) reflux there remain many questions relating to 
optimizing the technique and the range of patients for whom it is suitable.  
 
This thesis evaluates factors that may influence EVLA efficacy for GSV reflux and other 
sites of deep to superficial venous incompetence (small saphenous, anterior accessory GSV, 
paradoxical reflux). It also assesses changes in venous haemodynamics after EVLA which 
has led to recommendations on improving treatment outcomes. Further, a prospective 
database of patients undergoing EVLA and conventional surgery has been maintained 
(clinical and duplex ultrasound follow-up at 6, 12 & 52 weeks, quality of life data) which 
has provided additional evidence on the management of patients with varicose veins.   
 
Briefly, these studies have confirmed that laser energy density (J/cm) is the crucial factor 
determining successful truncal vein ablation following EVLA and that appropriate patients 
can continue warfarin therapy without compromising the safety or efficacy of treatment.   
 
Other studies demonstrate the transition of ablated truncal veins from a non-compressible 
“thrombosed” vein to becoming non-visible 1 year after EVLA. Further, sapheno-femoral 
junction (SFJ) tributaries remain patent and competent with no adverse impact on clinical 
outcome whilst SFJ neo-vascularisation occurs much less often after EVLA than surgery. 
 
In patients with persistent below-knee GSV incompetence after EVLA residual symptoms 
are more likely and there is a greater need for sclerotherapy for residual varicosities.  A 
RCT subsequently confirmed that extended ablation of the below-knee GSV achieved 
superior outcomes.  
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Chapter 1: 
1. Introduction and literature review 
 
Varicose veins (VVs) are unsightly dilated and tortuous superficial veins mainly occurring in 
the lower limbs and often associated with chronic venous insufficiency (CVI). Although 
varicose veins are common, affecting 30-40% of the population (Evans et al., 1998), many 
remain asymptomatic and only a proportion present for treatment.  Nonetheless a significant 
component of health care resource is consumed in performing about 40,000 National Health 
Service operations in the UK each year at an estimated cost of £20-£25 million (Dept. of Health, 
2001).  
 
1.1 Epidemiology 
Varicose veins are predominantly a condition encountered in Western societies, and their 
incidence increases with age (Evans et al. 1994). About 32% of women and 40% of men, in the 
Edinburgh Vein Study (Evans et al., 1998), had truncal varicosities.  However, other studies 
have found the gender difference reversed with a prevalence of 20-25% in women and 10-15% 
in men (Callam, 1994). Women tend to be over-represented in clinical studies as they are more 
likely to present with varicose veins because of cosmetic concerns. They are also more likely to 
undergo treatment.  
 
1.2 Anatomy 
The veins of the lower extremity are conventionally divided into the deep and superficial venous 
systems. These two venous systems are best thought of as components, along with the calf 
muscles, of a complex vascular reservoir and pump system.  
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Superficial venous system of the lower extremity 
The superficial venous system is composed of a complex web of subcutaneous collecting veins 
and the thicker-walled conduits or truncal veins of the saphenous systems. The collecting veins 
are thin-walled structures that are superficial to the saphenous fascia. They gather the blood 
from the skin and subcutaneous tissue, act as capacitance reservoirs, and passively drain into 
perforator or truncal superficial veins, called saphenous veins.  
 
The great saphenous vein (GSV) and its tributaries represent the most important veins of the 
superficial venous system (Figure 1.1). The GSV begins as the medial continuation of the dorsal 
venous arch in the foot, travels anterior to the medial malleolus, and ascends the medial aspect 
of the leg, ultimately draining into the deep system at the sapheno-femoral junction (SFJ), 
which is normally situated some 4cm infero-lateral to the pubic tubercle. The GSV ascends the 
leg in the saphenous compartment, which is a subcutaneous space that is superficial to the 
muscular fascia and deep to the saphenous fascia in the leg and thigh (Wendell-Smith, 1997; 
Caggiati, 1999; Caggiati et al., 2002).  The saphenous fascia is a membranous layer of the 
subcutaneous tissue that is also known as superficial or Scarpa‟s fascia. The GSV generally has 
two major tributaries below and above the knee; it also receives blood from the external 
pudendal, inferior epigastric, and external circumflex iliac veins just before it drains into the 
femoral vein. Although, the GSV has been said to be duplicated in as many as 20% of subjects, 
the incidence of true duplication is much lower (Ricci and Caggiati, 1999). However, large 
extra-fascial tributary veins, which are termed accessory saphenous veins, can run parallel to the 
GSV and can functionally act as duplicated veins (Ricci and Caggiati, 1999).  
 
 
The small saphenous vein (SSV) is the other principle truncal superficial vein (Figure 1.2). It 
begins on the lateral aspect of the foot, travels posterior to the lateral malleolus, and ascends the 
midline of the calf superficial to the muscular fascia and deep to the saphenous fascia.   
20 
 
  
 
Figure 1.1: Anatomy of the great saphenous vein  
(source: American College of Phlebology: http://www.phlebology.org/pdfs/Ch1_pp1-4.pdf) 
Saphenofemoral Junction 
Great Saphenous Vein 
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Figure 1.2: Anatomy of the small saphenous vein  
(source: American College of Phlebology: http://www.phlebology.org/pdfs/Ch1_pp1-4.pdf) 
  
Popliteal Vein 
Saphenopoplital junction 
Small Saphenous Vein 
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In the majority (≈2/3) of subjects, the SSV drains into the popliteal vein just above the knee via 
the sapheno-popliteal junction (SPJ) (Bergan, 2001). However, the level of the SPJ is much 
more variable than that of the SFJ and this is an important factor in the failure to perform an 
adequate ligation of the junction in a proportion of patients undergoing conventional surgery.  In 
as many as one third of the limbs the SSV drains into a posterior medial tributary of the GSV or 
directly into the GSV (as the vein of Giacomini), or into a deep vein in the thigh via a perforator 
(Bergan, 2001). In many of these cases of variant drainage, a standard SPJ may also be present. 
The SSV is truly duplicated in 4% of the limbs; most often this is segmental, primarily 
involving the mid-portion of the vein (Caggiati, 2001).   
Deep venous system of the Lower Extremity 
The veins of the deep venous system are deep to the fascial investments of the muscles of the 
lower limb. They include the planter vein of the foot, three pairs of tibial veins in the calf, and 
the popliteal and superficial femoral veins behind the knee and in the thigh. In addition, 
numerous venous sinusoids found within the muscles of the lower limb are important 
components of this system. Those in the calf are most important and include the soleal and 
gastrocnemius veins. These sinusoids drain into other deep veins via valved connecting veins. 
All deep veins are important elements of the pumping system and are responsible for returning 
blood from muscles, as well as the blood collected from the superficial veins, back to the heart. 
(Mahadevan, 2008).  
Perforating veins 
Perforating veins connect elements of the superficial venous system with the deep system. 
These veins obliquely perforate the deep fascia and connect the collecting and saphenous veins 
with femoral, popliteal, tibial and sinusoidal veins. The larger perforators contain valves that 
direct flow from the superficial veins to the deep veins and are often accompanied by a 
perforating artery. Four groups of clinically important perforating veins have been identified in 
fairly typical locations and have eponymous names (figure 1.3) (Min et al., 2003).   
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Figure 1.3 Named perforator veins in the lower limb 
(source: American College of Phlebology: http://www.phlebology.org/pdfs/Ch1_pp1-4.pdf) 
Cockett‟s Perforators 
Boyd‟s Perforator 
Hunterian Perforator 
Dodd‟s Perforator 
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Anterior accessory of great saphenous vein (AAGSV) 
A superficial vein accompanying the GSV and situated ventrally to its course on the anterior 
thigh, but usually not in the saphenous compartment, is called as the AAGSV. To emphasize the 
difference between the accessory and main GSV, the former is located more superficially, but it 
can approach the latter in the thigh and enter the saphenous compartment. It most often drains 
into the GSV within 1 cm of the SFJ (Cavezzi et al., 2005), although different patterns of 
communication are possible (figure 1.4).   
 
Figure 1.4: Potential communication between the AAGSV and the GSV/deep venous 
system 
(Source: http://www.phlebologia.com/en/saph_access.asp) 
AAGSV may drain into the GSV (A), directly into the femoral vein below (B) or above (C) the 
SFJ, or even into a tributary of the GSV (D). 
1: GSV    2: Lateral tributary   
3: Cribriform fascia  4: CFV (common Femoral Vein) 
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New Nomenclature of the superficial veins 
In 2001, presidents of the International Union of Phlebology (IUP) and International Federation 
of Associations of Anatomists (IFAA) nominated an International Interdisciplinary Committee 
(IIC) to revise the nomenclature of the deep and superficial veins of the lower extremity. IIC 
issued a document at the pre-congress meeting of the 14th World Congress of IUP, held in 
Rome (September 2001), with the attendance of members of the Federative International 
Committee on Anatomical Terminology (FICAT). The document was published as the 
„Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus 
statement‟ (Caggiati et al., 2002).  This was revised in May 2004 at the second meeting in 
Rome. Figures 1.5 and 1.6 summarise the new nomenclature.  
 
Abbreviations for Figure 1.5 and 1.6: 
 
AAGSV:  Anterior accessory great saphenous vein 
AAGSVC: Anterior accessory great saphenous vein of the calf 
ATCV:  Anterior thigh circumflex vein 
CESSV: Cranial extension of small saphenous vein (Gioacomini vein) 
DVAF:  Dorsal venous arch of foot 
DVNF:  Dorsal venous network of foot 
GSV:   Great saphenous vein 
ISV:   Intersaphenous vein(s) 
MMV:   Medial marginal vein 
PAGSV:  Posterior accessory great saphenous vein 
PAGSVC: Posterior accessory great saphenous vein of the calf 
PV:  Popliteal vein 
PeV:  Perforating veins 
PTCV:   Posterior thigh circumflex vein 
SCIV:   Superficial circumflex iliac vein 
SDMV:  Superficial dorsal metatarsal veins 
SDVP:   Superficial dorsal veins of penis  
SEPV:   Superficial External pudendal vein 
SEV:   Superficial epigastric vein 
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Figure 1.5: New nomenclature for the superficial veins of the lower limb (antero-medial 
view) (Kachlik et al., 2009) 
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Figure 1.6: New nomenclature for the superficial veins of the lower leg (postero-lateral 
view) (Kachlik et al., 2009) 
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1.3 Pathophysiology 
The veins in the lower limbs are not passive conduits but rather complex components of a 
vascular pumping mechanism responsible for actively returning blood to the heart against a 
substantial gravity gradient. This can be achieved only by in the presence of competent valves, 
patent venous flow tracts, and a functional venous pump (calf muscles). Incompetent venous 
valves account for the majority of cases of venous insufficiency. In the erect position, the 
pressure created by the column of blood increases from the heart down to the ankle. Propagation 
towards the heart depends on compression of deep veins by calf muscles augmented by 
functional one-way valves in healthy veins. Thus the calf muscles functions as a “peripheral 
heart” with the valves in the saphenous veins, perforators and deep veins analogous to the 
cardiac valves.  
 
Venous insufficiency develops when a component of the venous system fails. With failure, the 
thin-walled superficial collecting veins are exposed to higher than normal pressures, causing 
dilatation and elongation, resulting in varicose veins. Valvular dysfunction, particularly in the 
superficial veins, is the most frequent cause of varicose veins in patients without skin changes 
or oedema. Venous obstruction and deep venous insufficiency are more frequent in patients 
with varicosities associated with skin changes and may follow a previous deep vein thrombosis. 
Dysfunction of calf pump is the least common cause of varicose veins (Labropoulos et al., 
1996).  
 
Valvular Insufficiency 
The pattern of venous reflux related to incompetent veins depends on which valves fail and 
through which pathway the leaking blood finds its way to the deep venous system or into the 
varicosities. Incompetence of the SFJ and GSV is the most common cause of significant 
varicose veins and is responsible for about 60-70% of cases whilst SPJ and SSV reflux accounts 
for their development in some 30% of patients (Labropoulos, 1994a).  Of the remainder 
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perforator incompetence is the cause in most instances. These different patterns of reflux may 
occur on their own, or in combination with each other. A small proportion of varicosities arise 
because of incompetence of pelvic veins (ovarian vein, tributaries of the internal iliac vein).  
 
Incompetence within the tributaries of the GSV can also lead to varicose veins. These include 
the anterior accessory great saphenous vein (AAGSV) and posterior-medial tributary reflux, 
which may or may not be associated with SFJ incompetence.  
 
Venous Obstruction 
Deep vein thrombosis, intrinsic venous stenosis (May-Thurner Syndrome) and external 
compression (pelvic tumour) are the main causes for venous obstruction. When the calf muscle 
pump functions normally, it generates sufficient pressure to move blood against gravity. 
However, if the outflow tract is obstructed, pressure elevations can result in dilatation and 
secondary valvular incompetence. These forces may lead to perforator incompetence and 
subsequent venous hypertension and secondary superficial venous insufficiency leading to 
chronic venous insufficiency (CVI). CVI due to venous obstruction will not be considered in 
this thesis as the treatment strategy is different for these patients.  
 
1.4 Risk factors and aetiology of varicose veins 
The pathogenesis of primary varicose veins is almost certainly multi-factorial and it has been 
suggested that both genetic and acquired factors may underlie their development (Cornu-
Thenard et al., 1994; Chiesa et al., 2005). Pregnancy has an association with the development of 
a variety of venous disorders including spider teleangiectasia and varicose veins (Sadick, 1992) 
affecting 10-20% of pregnant women (Sumner, 1981). The diameters of both competent and 
incompetent superficial veins increase during pregnancy and decrease postpartum, gradually 
returning to their baseline values (Boivin et al., 2000). It has been suggested that hormonal or 
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other systemic factors may play a role in the development of postpartum varicose veins (Cordts 
and Gawley, 1996; Mashiah, 1999).  
 
Despite the widely held belief that pregnancy may be an important aetiological factor in the 
development of superficial venous incompetence there is some evidence that this merely 
promotes the development of varicosities in patients with pre-existing venous insufficiency 
(Sparey et al., 1999). 
 
Other evidence has implicated diet as having a role in the development of varicose veins 
although the available literature does not allow a firm conclusion to be made (Adhikari et al. 
2000). Despite these hypotheses a recent demographic study supports a multi-factorial aetiology 
with characteristics such as sex, advanced age, number of pregnancies, and family history of 
venous disease all contributing to their development (Chiesa et al., 2005). The relative 
contribution of each of these risk factors is difficult to ascertain although further demographic 
evidence from the Framingham study indicate that obesity, high systolic blood pressure, 
cigarette smoking and low levels of physical activity may also be important (Brand et al., 1988).  
 
1.5 Symptoms & complications 
The relationship between varicose veins and symptoms is controversial.  Whilst it has been 
suggested that they might cause aching, heaviness, pruritus, and oedema (Browse, 1999) 
asymptomatic superficial venous reflux (duplex ultrasound) is present in up to 39% of the 
population (Labropoulos et al., 1995; Labropoulos et al., 1996). In the Edinburgh Vein Study 
lower limb symptoms were common irrespective of the presence of varicose veins with 48% of 
all women complaining of aching legs.  Pruritus was positively associated with the severity of 
varicosities in men and similarly heaviness, aching and itching in women.  However the level of 
agreement between symptoms and truncal vein incompetence was too low to be of clinical 
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value. Further, the majority of lower limb symptoms seemed to have a non-venous cause 
(Bradbury et al., 2000).  
 
In another study Labropoulos et al reported that 70% of patients with GSV reflux complained of 
aching legs and this was more common with full-length GSV incompetence compared to above 
or below knee reflux alone.  Ankle swelling was also more likely with more prolonged (more 
severe) reflux (Labropoulos et al., 1994a).  A minority of patients (≤5%) with varicose veins 
develop complications including thrombophlebitis, varicose eczema, lipodermatosclerosis and 
ulceration (Tibbs, 1996).  
 
Although it has previously been suggested that an earlier deep venous thrombosis (DVT) was 
responsible for almost all cases of venous ulceration this view was proposed before ultrasound 
assessment of the venous system was widely available (Christopoulos, 1989). Subsequently it 
has become clear that both deep and superficial venous incompetence can result in the skin 
changes of advanced venous insufficiency either alone or in combination (Labropoulos et al., 
1996).  
 
1.6 Disease severity 
Based upon their appearance varicose veins are categorized as telangiectasia, venulectasia, 
reticular veins, and non-saphenous and saphenous varices, depending on their size and location 
(intradermal or subcutaneous). In this thesis “disease severity” associated with superficial 
venous incompetence was assessed using the methods described below. 
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1.6.1 CEAP classification 
In 1995 an international committee of the American Venous Forum produced a consensus 
document for the classification and grading of chronic venous disease, the CEAP classification 
(Porter and Moneta, 1995) which was formally endorsed by the American Venous Forum, the 
Joint Council of the Society for Vascular Surgery and the North American-International Society 
for Cardiovascular Surgery. Thus it is widely used as a clinical method of assessing the severity 
of venous disease. The basis for this classification is shown in Table 1.1 with limbs classified 
according to clinical signs (C), cause (E), anatomic distribution (A), and pathophysiology (P). In 
general, the most discriminatory information about disease severity in an individual patient is 
derived from the “C” grade (Table 1.2). 
 
 
 Definition 
C Clinical signs (grade 0-6), supplemented by (s) for symptomatic and (a) for 
asymptomatic presentation 
E Etiologic Classification (Congenital, Primary, Secondary) 
A Anatomic Distribution (Superficial, Deep, or Perforator, alone or in combination) 
P Pathophysiologic Dysfunction (Reflux or Obstruction, alone or in combination) 
Table 1.1: CEAP classification of chronic lower extremity venous disease  
(Porter & Moneta 1995) 
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“C” 
Class 
Clinical signs  
C0 No visible or palpable signs of venous disease 
C1 Telangiectasia, reticular veins, malleolar flare 
C2 Varicose veins 
C3 Oedema without skin changes 
C4 Skin changes ascribed to venous disease (pigmentation, venous eczema, 
lipodermatosclerosis) 
C5 Skin changes (as defined above) in conjunction with healed ulceration 
C6 Skin changes (as defined above) in conjunction with active ulceration 
Table 1.2: C of CEAP classification of venous disease in the lower limb  
(Porter & Moneta 1995) 
 
 
1.6.2 VCSS (Venous clinical severity score) 
The American Venous Forum Committee on Venous Outcomes Assessment developed a venous 
severity scoring system (VCSS) based on the most representative elements of the CEAP system 
(Rutherford et al., 2000). In the VCSS, 9 clinical characteristics of CVI are graded from 0 to 3 
using specific criteria to avoid overlap or arbitrary scoring. Finally 0-3 points are added 
depending upon the use or requirement for active conservative therapy (compression, elevation). 
This produces a 30-point scale (appendix: B2).  
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1.6.3 Aberdeen varicose vein severity score (AVVS) 
AVVS (Garratt et al., 1993) assesses the impact of the varicose veins on quality of life using a 
questionnaire comprising 13 validated questions. The assessment includes the extent of the 
varicosities, symptoms and the impact on quality of life (QOL). A full questionnaire and the 
methods for calculating the score are included in appendix B3.  
 
1.7 Investigations  
The aim of investigations in patients with a clinical diagnosis of varicose veins is to identify the 
site(s) of venous incompetence responsible for their development.  
 
A number of clinical tests have been described that will give an indication about the principle 
site of reflux. These have been superseded by more accurate investigations including hand-held 
Doppler and duplex ultrasound and will not be discussed further.  
 
Hand-held Doppler examination can be easily performed in an out-patient setting and is a useful 
screening test, particularly for identifying SFJ and GSV reflux where it performs well in 
comparison to duplex ultrasound (Darke et al., 1997). In contrast it is less reliable for assessing 
SPJ reflux and may be associated with a significant false positive rate (Kent and Weston, 1998)  
as a result of detecting reflux in other veins in the popliteal fossa (gastrocnemius veins, popliteal 
vein, and superficial tributaries of GSV crossing the back of the knee). Further, the location of 
the SPJ is much more variable than that of the SFJ which confounds the difficulty. Thus duplex 
ultrasound is the investigation of choice in patients where SPJ/SSV reflux is suspected.  
Similarly, hand-held Doppler is unreliable when assessing limbs with recurrent varicose veins 
for which duplex ultrasound is again required.  
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For the definitive identification of the source of reflux DUS is the investigation of choice (see 
below) and is mandatory when assessing patients who have, or are suspected to have had a 
previous deep vein thrombosis.  
 
Other investigations include ambulatory venous pressure measurements and air-
plethysmography. These are essentially research tools used to grade reflux severity and are 
rarely used clinically. Finally, contrast venography is now obsolete in respect of investigating 
patients with superficial venous incompetence although it may still be indicated in patients with 
secondary varicose veins, particularly if an iliac compression syndrome is suspected.  
 
1.7.1 Duplex ultrasound scan (DUS) 
DUS of the superficial and deep venous system has emerged as the most accurate and time 
efficient tool for assessing venous insufficiency. Several studies have demonstrated the 
effectiveness of DUS in accurately mapping patterns of venous reflux (Welch et al., 1992; 
Neglen and Raju, 1992; Vlentin et al., 1993; Baker et al., 1993). In addition to demonstrating 
abnormal venous anatomy/reflux DUS provides reliable and objective follow-up after 
intervention. Thus it can be used to document complete abolition of reflux in all treated venous 
segments and to detect and determine the causes of recurrences. Finally DUS is crucial to 
guiding treatment with the newer minimally invasive techniques. 
 
It should be noted however that colour Doppler imaging during DUS may underestimate the 
presence of reflux (Araki et al., 1993) and that this is best identified and documented using 
pulsed-wave Doppler imaging. Although most investigators use the criteria of reverse flow 
lasting for more than 1.0 second to define significant reflux (Labropoulos et al., 2006), there is 
no consensus on this. Further, some authors claim that the cut off for duration of reflux should 
be different for different veins; deep veins in calf: 0.5s, deep veins in thigh: 1s, iliac veins and 
IVC: 1.5s, perforating veins: 0.35s, superficial vein: 1s. (Sarin et al.,1994; Labropoulos et al., 
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2003; Min et al., 200; Neuhardt DL, 2008). In the studies reported in this thesis, reflux >1s in a 
superficial vein is considered significant. Even though, DUS is widely available and most 
commonly used to detect venous reflux it does not grade its severity.   
 
Some authors (Kalodiki et al., 1993, Neglen et al., 2004) suggest that a standardised calf 
compression using a rapid inflation / deflation pneumatic cuff could be used to assess reflux 
objectively. However, selecting cuff size in relation to different calf size is not practical. An 
alternative method could be to examine the patient in the 15° reverse Trendelenburg position 
with the Valsalva manoeuvre to elicit reflux, specifically for the examination of thigh veins 
(Masuda et al., 1994). The disadvantage is that the test is dependent on a cooperative patient 
who is able to perform the manoeuvre and the ability to perform the manoeuvre varies among 
patients.     
 
1.7.2 Objective assessment of reflux severity 
There are 3 principle methods that can be used to assess the severity of venous reflux. These 
are: 
i) measurement of the hydrostatic pressures in a dorsal vein on the foot  
ii) determination of the venous filling index using air-plethysmography   
iii) photoplethysmography  
 
Venous pressure measurements in pedal veins 
Although the static venous pressure in the pedal veins is of no use in discriminating venous 
insufficiency from healthy veins, measurement of ambulatory venous pressure in these veins is 
a useful tool for objective assessment of the severity of venous insufficiency and varicose veins 
(Nicolaides and Zukowski, 1986).  The ambulatory venous pressure (AVP) is defined as the 
lowest pressure reached during exercise (ten tip toe movements). Refill time (RT90) is the time 
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taken to reach the 90% of pre-exercise pedal venous pressure after the exercise (Figure 1.7). 
These two parameters have been shown to correlate with clinical severity of venous disease and 
the incidence of related complications (Nicolaides and Zukowski, 1986).  
 
Figure 1.7: Typical venous pressure recording of the effect of 10 tiptoe movements on 
venous pressure  
P = pressure; T = time; R = refilling; RT90 = time taken for 90% refilling; AVP = ambulatory 
venous pressure at the end of exercise 
 
Air-plethysmography (APG) 
Air-plethysmography provides quantitative information about various components of the calf 
muscle pump (Christopoulos et al., 1988 a; Christopoulos et al., 1988 b; Christopoulos et al., 
1989). These include the rate of venous filling of the reservoir (venous filling index) as a result 
of standing; the venous volume, which is the amount of blood in the venous reservoir; the 
ejected volume, and the ejection fraction as a result of a single tiptoe movement; and the 
residual volume and residual volume fraction as a result of 10 tiptoe movements. Although, 
ejection fraction and residual volume fraction were initially considered reproducible, this has 
been challenged by other authors (Yang et al., 1997; Asbeutah et al, 2005). Venous filling index 
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(VFI), a measurement of reflux severity has been found to be reproducible and has a good 
correlation with disease severity (Christopoulos et al., 1988 b).  
 
1.8 Treatment of varicose veins 
 
What is an ideal treatment for varicose veins? 
Beale et al described the ideal management for varicose veins as follows (Beale et al., 2005) 
“The optimum treatment of varicose veins requires accurate identification of the sources of 
superficial venous reflux. Subsequent treatment, specifically tailored to abolish venous reflux, 
should relieve any symptoms attributable to superficial venous incompetence, prevent 
complications, improve cosmesis, be associated with a low morbidity,  low recurrence rates, and 
if possible a short recovery time. The cost-effectiveness of potential therapies should also be 
considered”.  
 
Treatment options for varicose veins 
Treatment options for varicose veins range from non-operative compression hosiery to 
interventional surgical treatment. Although conventional surgical treatment has long been 
considered the standard option, the newer minimally invasive techniques are being studied as an 
alternative to this. The main treatment options are described in table 1.3. 
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Table1.3: Treatment modalities for varicose veins 
Conservative 
Treatment 
Compression hosiery Below knee grade II (20-30mmHg) compression stockings 
 
 
Minimally Invasive  
(Ablation) techniques 
Endovenous laser ablation (EVLA) Thermal ablation of truncal vein with diode laser (LA), May also 
require adjuvant phlebectomy or sclerotherapy (local anaesthesia) 
Radiofrequency ablation (VNUS
®
) / Closure Fast®  Thermal ablation of truncal vein with radiofrequency (LA),  May also 
require  adjuvant phlebectomy or sclerotherapy (local anaesthesia) 
Endovenous steam ablation (EVSA) Thermal ablation of truncal vein with water steam (LA),  May also 
require  adjuvant phlebectomy or sclerotherapy (local anaesthesia) 
Ultrasound guided foam sclerotherapy Chemical ablation of truncal vein under DUS guidance. May also 
require  adjuvant sclerotherapy for tributary varicosities 
 
 
Surgery  
SFJ ligation + GSV stripping / SPJ ligation ± SSV 
stripping and phlebectomies / perforator ligation 
GA day case or in-patient.  Widely available.  Variations include length 
of vein stripped and method of stripping 
Ambulatory conservative haemodynamic management 
(ACHM or CHIVA) 
Identification of sites of deep to superficial reflux and elimination of 
these sites only (GA) 
Trans-illuminated powered phlebectomy (TIPP, 
TriVex
®
) as an adjunct to truncal vein ligation /stripping 
Alternative treatment to phlebectomies resulting in fewer incisions. 
SFJ/SPJ ligation still required. (GA) 
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1.8.1 Conservative Treatment / Compression hosiery (CH) 
CH exerts pressure over the veins and tissue as defined by the law of Laplace: P=T/R; where the 
pressure (P) exerted by an elastic bandage or stocking is proportionate to its tension (T) and the 
inverse of the radius (R). Compression pressure is higher on more convex areas (ankle) than in 
less convex areas (thigh) provided the same tension is maintained. CH is designed to produce 
the same tension throughout the leg thus providing a pressure gradient from the ankle upwards. 
Different grades (class 1 to 4) of CH are used for different indications (table 1.4). 
Contraindications to CH include advanced peripheral arterial disease and septic phlebitis. 
Although different lengths of CH are available, ankle-knee stockings are more acceptable to 
many patients (Kiev et al., 1990). 
 
Grades Indications 
Class 1  
(18-21 mmHg) 
Mild varicose veins (C2) without oedema 
Early varicose veins in pregnancy 
Class 2 
(23-32 mmHg) 
Commonly used for symptomatic varicose veins and CVI (C3, C4, 
C5) and after other treatments (EVLA, foam sclerotherapy, surgery) 
Class 3 
(34-46 mmHg) 
Post thrombotic insufficiency, severe CVI (C6)  
Lymphoedema 
Class 4 
(>49 mmHg) 
Severe lymphoedema 
Elephantiasis 
 
Table 1.4: Different classes of compression stocking and their main indications (German 
Standard) 
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CH aims to reduce or control venous reflux and thus improve symptoms and reduce oedema 
among patients with varicose veins (Jones et al., 1980; Szendro et al., 1992; Ibegbuna et al., 
1997; Zajkowski et al., 2002; Hirai et al., 2002). However as expected, the benefit from CH is 
restricted to the period during which the stocking is worn (Labropoulos et al 1994b).   
 
A non-blinded randomised controlled trial of compression stockings (grades I and II) in 
pregnancy showed that the development of GSV reflux and symptoms were less common in the 
treated group (p=0.047) as compared to controls, but that there was no difference in the 
development of varicose veins (Thaler et al., 2001).   The study was not powered to assess 
differences between grade I and II stockings.  Compression therapy may also be facilitated by a 
variety of proprietary bandages although with the exception of Setopress® (half strength 
30mmHg; full strength 40mmHg) the pressure exerted by these is uncertain and difficult to 
control. 
 
Poor compliance (Kiev et al., 1990), a lack of patient education (Samson and Showalter, 1996) 
and poor cosmesis are drawbacks to the use of CH.   In general, grade II stockings are better 
tolerated than grade III stockings (Dale and Gibson, 1992) but compliance also varies 
depending on the manufacturer (Nelson et al., 2003). 
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1.8.2 Minimally invasive (ablation) techniques 
Several minimally invasive techniques are increasingly used to treat varicose veins. All of these 
avoid traditional surgical incisions, but may require 1-2mm wounds to facilitate cannulation of 
the target truncal vein. These techniques ablate the target vein in situ rather than removing it 
(stripping). These methods are summarised in table 1.5. 
 
Thermal ablation Chemical ablation 
Endovenous diathermy 
Endovenous radiofrequency (VNUS) 
Endovenous laser ablation (EVLA) 
Endovenous steam ablation (EVSA) 
Sclerotherapy (liquid) 
Foam sclerotherapy 
Table 1.5: Examples of different ablation types 
 
1.8.3  Thermal Ablation Techniques 
Endovenous administration of thermal energy is not new. Electrocoagulation was described by 
O‟Reilly in 1977 (O'Reilly, 1977) and endovenous monopolar diathermy was described again in 
1994 (Gradman, 1994). Use of endovenous radiofrequency and laser ablation has emerged in 
the new millennium and these techniques are being refined. Recently Milleret et al (Milleret, 
2006) have also described the endovenous steam ablation (EVSA) as an alternative method of 
delivering thermal energy. However, laser and radiofrequency ablation techniques are currently 
the most widely used thermal ablation techniques.  
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1.8.4 Endovenous Laser Ablation (EVLA) 
Endovenous laser ablation is a minimally invasive technique and this was initially described by 
Navarro and Min in 2001 (Navarro et al., 2001).  An important potential advantage of EVLA is 
that it is performed as an outpatient procedure under local anaesthesia. Different types of diode 
laser (810 - 1470nm wavelength) and a 1064nm Nd:YAG laser have been studied (Navarro et 
al., 2001; Proebstle et al., 2002;  Oh et al., 2003; Goldman et al., 2004). To date 810-940nm 
diode lasers are more commonly employed using 5-14 watts power (Beale and Gough, 2005).  
 
This lack of standardisation of the technique has attracted criticism although it should be 
considered that lasers of 810-940nm wavelength all work in the same way. The light produced 
by these lasers is preferentially absorbed by haemoglobin (fig 1.5) and their principle mode of 
action is believed to be via secondary injury to the vein wall after superheating of blood within 
the lumen of the treated vessel (Proebstle, 2002b). Nevertheless it is also possible that direct 
vein wall injury is promoted by the laser fibre given that ablation is performed with the patient 
in the Trendelenburg position with the target vein compressed by surrounding tumescent 
anaesthetic.  
 
More recently lasers of longer wavelength have become available and outcomes for a 1470nm 
laser have been published.  At this wavelength energy is preferentially absorbed by water (fig 
1.8) in the vein wall rather than by haemoglobin in erythrocytes. This, together with the use of a 
radial rather than bare tipped fibre has allowed a significant reduction in the power required to 
reliably achieve ablation of the target vein. Initial reports indicate that this has a major impact in 
reducing post-treatment discomfort without compromising efficacy (Pannier et al., 2009; 
Maurins et al. 2009). 
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Figure 1.8: Absorption coefficient of laser energy at different wavelength by H2O and 
HbO2 (source: Boilitec AG, Jena, Germany) 
 
A report by Min et al using an 810nm laser describes almost 500 patients followed for up to 3 
years
 
indicated GSV occlusion rates of 98% at 1 month and 93% at 2 years (n=121). No great 
saphenous veins regained patency after 2 years. The main complications were bruising (24%) 
and thrombophlebitis (5%) but there were no instances of DVT, burns or paraesthesia.  A 
separate study reports one instance of temporary paraesthesia following GSV EVLA (Min et al., 
2003). 
 
Fear of possible nerve injury, a potential adverse effect of the high temperature at the tip of the 
laser fibre delayed the use of this technique for the treatment of SP/SSV reflux. However, the 
protective (heat-sink) effect of perivenous tumescent anaesthesia was reported by Beale et al in 
2006 (Beale et al., 2006). Since then a number of studies have shown EVLA to be equally 
successful in treating varicosities that are secondary to this type of reflux. 
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The standard technique for EVLA (then called EVLT™) [endovenous laser treatment]) as 
described my Min et al requires percutaneous insertion of the laser fibre into the GSV at knee 
level. It is advanced to the SFJ under ultrasound control. Peri-venous tumescent local 
anaesthetic (0.1% lignocaine) is infiltrated around the GSV throughout its length to provide 
analgesia, to compress the vein and thus promote close contact between the vein wall and the tip 
of the laser fibre, and to prevent thermal damage to surrounding tissues.  
 
The laser fibre is fired as it is withdrawn from the truncal vein at a rate of 1cm/5sec at 12-14 
watts power. This delivers around 70J/cm energy. Although some authors have also advocated 
applying manual pressure over the vein to further assist vein wall apposition this might increase 
the risk of vein wall perforation and bruising. Post-treatment compression in the form of 
bandaging or class II compression hosiery is worn for 1-2 weeks following treatment and 
patients are encouraged to resume normal activities as soon as they feel able.  
 
To date there have been 5 randomised controlled trials comparing EVLA with conventional 
surgery. These suggest that abolition of reflux and improvements in quality of life are similar 
for both techniques. However EVLA appears to be associated with less post-treatment bruising 
and a more rapid return to normal activity. (de Medeiros et al., 2005; Ying et al., 2007; Beale et 
al., 2008; Rasmussen et al., 2008; Kalteis et al., 2008) 
 
At present EVLA shows considerable promise although long-term follow-up and more rigorous 
evaluation of outcomes is awaited. These were also the conclusions of a systematic review of 
the published outcomes for EVLA (Mundy et al., 2005). 
 
  
46 
 
  
EVLA: How does it work? 
Endovenous laser therapy causes thermal damage to the vein wall by the mechanisms described 
above. For those using a shorter wave-length (810-980nm) this results in focal coagulative 
necrosis, shrinkage and thrombotic occlusion of the vein (Proebstle et al., 2002b). Histological 
studies after in-vitro and in-vivo laser application have confirmed these findings together with 
instances of perforation, extravasation of blood around the vein, and a reduction in vein 
diameter 1 week following treatment [Weiss 2002; Proebstle et al., 2002b; Bush 2003).  
Comparison of the histological results of VNUS Closure
®
 and endovenous laser treatment found 
fewer vein wall perforations with VNUS Closure
®
, which the authors claimed correlated with a 
lower incidence of haematoma (Weiss 2002).  Interestingly however 2 recent studies, one of 
which was a randomised trial confirms that post-treatment pain and bruising is significantly 
reduced following ablation with a 1470nm diode laser compared to those of a shorter 
wavelength (Pannier et al 2010, Doganci &  Demirkilic, 2010). Thus the putative advantages of 
this newer laser discussed earlier appear seem to be reflected in clinical practice. 
 
EVLA: How effective? 
Observational studies report GSV closure rates of 88-100% (Mundy et al., 2005) with an 
improvement in the appearance of superficial varicosities and relief of symptoms. Ablation of 
the GSV is considered to provide a similar haemodynamic effect to that of high tie and GSV 
stripping. Unlike surgery, individual varicosities are not necessarily treated initially (although 
some surgeons do perform concomitant phlebectomy) and any residual varicosities that remain 
6 weeks or so after abolition of truncal vein reflux are typically treated by delayed 
sclerotherapy. Data from our own institution showed that some 40-50% of the patients require 
delayed sclerotherapy when EVLA is confined to the above-knee GSV but that this requirement 
is significantly reduced (17%) when ablation is performed to the lowest point of reflux (Chapter 
5) or following SSV ablation (18%; Chapter 6). 
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A potential criticism of any minimally invasive technique that avoids SFJ ligation is that the 
GSV tributaries may remain patent. Ligation of these has previously been considered pivotal to 
reducing recurrence rates (Browse 1999).  However Chandler et al have suggested that avoiding 
surgical disruption of the SFJ may reduce neovascularisation and thus recurrence rates may be 
lower (Chandler et al., 2000).   
 
Complications of EVLA 
Transient bruising and induration along the treated saphenous vein have been reported in 23- 
100% (Mundy et al. 2005) of patients with resolution within 3-4 weeks. Saphenous nerve 
paraesthesia has been documented in about 1% (Min et al., 2001; Proebstle et al, 2002 a) of 
limbs although this is usually temporary. Thrombophlebitis affects 3-8% (Proebstle et al, 2002 
a; Min et al., 2003) of patients and may occur both in the treated vein and its tributaries. Deep 
vein thrombosis (DVT) is a rare (1%) complication following EVLA (Marsh et al., 2010). These 
complications appear less frequent with a longer wave-length (1470nm) laser (Pannier et al 
2010, Doganci & Demirkilic, 2010). 
 
Finally an unusual complication of EVLA is the development of an arteriovenous fistula. This 
has been reported in 4 patients (Timperman, 2004; Theivacumar and Gough, 2009; Ziporin et 
al., 2010). It is uncertain whether these are the result of thermal injury from the laser fibre or 
whether they are secondary to a “needle-stick” injury during administration of the tumescent 
anaesthesia.  
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1.8.5 Radiofrequency ablation (RFA) 
Endovenous radio-frequency ablation (Closure system: VNUS® Medical Technologies Inc., 
Sunnyvale, CA) of the GSV was first described by Goldman (Goldman, 2000).  Initially it was 
usually performed under general or regional anaesthesia and combined with phlebectomy. In 
some centres sapheno-femoral ligation was also undertaken. More recently local anaesthesia has 
been adopted by many surgeons. After cannulation of the GSV at knee-level a 5 or 8 French 
gauge catheter is advanced to the SFJ under ultrasound control and then slowly withdrawn. 
Heating of the vein and surrounding tissue results in endothelial denudation, collagen 
denaturation and acute vein constriction (Weiss, 2002). A multi-centre study found that 85% of 
GSV were obliterated at 2 years (Merchant et al., 2002), with other series reporting occlusion 
rates of 88-100% after similar follow-up (Manfrini et al., 2000 ; Rautio et al., 2002; Sybrandy et 
al., 2002). There have also been a number of RCTs examining the efficacy of RFA against 
conventional surgery which show that RFA is effective and, like EVLA,  associated with a 
quicker post-treatment recovery (Lurie et al., 2005; Perälä et al., 2005; Luebke et al., 2008). 
However one study reported a DVT rate was up to 16% (Hingorani et al., 2004), the highest 
incidence following any endovenous ablation technique. This has not been substantiated by 
other studies. 
 
Recently the manufacturers of the VNUS Closure device have introduced VNUS Closure Fast. 
Although this is also based on radiofrequency energy the mode of action is somewhat different 
relying on a heating coil (of 7cm length) rather than bipolar electrode technology. The putative 
advantages of VNUS Fast are that procedure times are quicker (and similar to those of EVLA) 
with less post-treatment discomfort than after EVLA (Almeida et al., 2009; Shepherd et al., 
2010). Reported truncal vein ablation rates for VNUS Closure Fast is 99% which is generally 
superior to those for VNUS Closure (Proebstle et al., 2008). Nevertheless there is no 
comparative (RCT) data currently available for the newer device whilst a recent RCT 
comparing VNUS Closure with an 810nm diode laser has shown significantly better GSV 
ablation rates for the latter at 1 year (Gale et al., 2010). 
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Further, a meta-analysis of the outcomes for endovenous techniques for the treatment of 
varicose veins has indicated that successful GSV ablation is achieved significantly more often 
after EVLA than RFA (van den Bos et al., 2009) although the RFA data was derived from the 
results of studies for the original VNUS Closure device. These findings are summarised in 
figure 1.9.  
 
Figure 1.9: Anatomic success rate for different modalities of treatment  
(Stripping: surgical stripping, UGFS: ultrasound guided foam sclerotherapy, EVLA: 
endovenous laser ablation, RFA: radiofrequency ablation (van den Bos, 2009) 
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1.8.6 Chemical Ablation (Sclerotherapy) 
Sclerotherapy initiates a chemical thrombophlebitis that results in thrombotic occlusion of the 
target vein and subsequent vein fibrosis (chemical ablation) (Kern, 2002; Browse, 1999. 
Although sclerotherapy was introduced in the middle of the nineteenth century by Chassaignac 
(Browse, 1999), it was popularised by Fegan in 1960 (Fegan, 1960)] with the introduction of an 
injection-compression technique. Interest in sclerotherapy diminished when Hobbs (Hobbs, 
1968) published the results of a randomised study between sclerotherapy and surgery which 
showed a high failure rate following the former. Although various sclerosants [A: hypertonic 
solutions (hypertonic saline); B: emulsifying solutions (polidocanol, sodium tetradecyl sulphate 
(STD), ethanolamine oleate); C: corrosives (polyiodide iodine, chromated glycerine)] have been 
described (Browse et al., 1999), it would appear that sodium tetradecyl sulphate (STD) and 
polidocanol are most widely used (Partsch et al., 1997). STD is the only agent licensed for use 
in the UK.  
 
The use of ultrasound in the diagnosis and assessment of venous disease was introduced in late 
1980s. This in turn facilitated the concept of ultrasound guided sclerotherapy which was 
initially reported by Schadeck in 1991 (Schadeck and Allaert, 1991). Further, the idea of foam 
sclerotherapy originally described by Orbach (Orbach, 1950) using a “shaking method” was 
superseded by the two-syringe technique popularised by Tessari (Tessari, 2001).  Although 
sclerotherapy was mainly reserved for isolated varicosities that were not associated with GSV 
(or SSV) reflux (Galland, 1998), there is a large variation in practice in different countries 
(Partsch , 1997). Foam sclerotherapy appears to be more effective than liquid sclerotherapy 
(Belcaro et al. , 2003; Hamel-Desnos et al. 2003) and ultrasound guided foam sclerotherapy is 
now increasingly used to ablate both the GSV and SSV with success rates of 84-95% (Jia et al., 
2007; Darvall et al., 2010).  Although early truncal vein occlusion rates are acceptable re-
canalisation occurs in some 30-40% of treated veins within 2-3 years (Belcaro, 2003; Yamaki, 
2004). This is reflected in the meta-analysis summarised in fig 1.6 (van den Bos, 2009). 
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Although the complications of sclerotherapy are generally minor (symptomatic 
thrombophlebitis, skin staining, ulceration, matting) (Jia et al., 2007) more serious adverse 
events have also been described including DVT, anaphylaxis, visual disturbance and stroke 
(Goldman, 2000; Frullini and Cavezzi, 2002). These serious complications occur more 
frequently with foam than after liquid sclerosant presumably because of its increased use in the 
GSV and the risk of the foam entering the femoral vein. If this occurs then a paradoxical 
embolus through a patent foramen ovale is possible thus accounting for the cerebral 
complications. 
 
1.8.7 Surgical Treatment of Varicose veins 
Surgical treatment aims to abolish truncal vein reflux and to remove visible varicosities (truncal 
vein stripping and multiple phlebectomies).  Flush ligation of the superficial truncal vein to 
control the highest point of deep to superficial reflux is the basis of treatment. This remains the 
principal method of treatment offered to patients in the United Kingdom.  
 
1.9 Complications of varicose vein treatments 
Complications of varicose vein surgery are one of the commonest reasons for litigation, 
accounting for 17% of settled claims within the broad specialty of general surgery, 
including the highest Medical Defence Union (MDU) settlement for this specialty 
between 1990 and 1998 (MDU report, 2003). Cutaneous nerve injury is one of the 
commonest causes of litigation.  It is often temporary but may be permanent in around 
7% of patients (Holme et al., 1990).  More disabling nerve injuries can also occur with 
at least 12 cases of foot drop being recorded on the NHS Litigation Authority database 
after sapheno-popliteal ligation. Published complication rates for all of the treatment 
modalities described in this chapter are summarised in table 1.6.   
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 EVLA 
Bruising: 60-80% (Navarro et al., 2001; Min et al., 2001; Proebstle et al., 
2002; Almeida et al., 2009)  
Saphenous nerve injury: <1% (Min et al., 2001; Bush, 2003) 
Hyperpigmentation: <4% (Proebstle et al., 2002) 
Thrombophlebitis: 3-8% ( Mundy et al.,2005) 
DVT: 1% (Marsh et al. 2010) 
RFA  
Bruising:  <35% (Puggioni et al., 2005; Almeida et al., 2009) 
*Saphenous nerve injury: 3-49% 
*Thrombophlebitis: 2–20%  
*Skin burns: 2–7%   
*(Manfrini et al., 2000; Merchant et al., 2002; Rautio et al., 2002; 
Sybrandy et al., 2002; Lurie et al., 2003) 
DVT: 1-16%  (Hingorani et al., 2004; Marsh et al. 2010) 
Foot drop – 1 case reported (Kumar et al., 2010) 
Ultrasound-
guided foam 
sclerotherapy 
(GSV) 
Transient visual disturbances: occasional ( Frullini and Cavezzi , 2002; 
Forlee et al., 2006) 
Skin matting/staining/pigmentation: 8-55% (Kern,2002; Bountouroglou  
et al., 2006; Wright et al., 2006)  
Cutaneous neuro-sensory loss : <1%  (Guex et al., 2005; Jia  et al., 2007) 
Thrombophlebitis:4-10% (Kern,2002; Bountouroglou  et al., 2006) 
DVT: <1% (Kern,2002; Wright et al., 2006; Bountouroglou  et al., 2006) 
Surgery 
(Sapheno-
femoral 
ligation &GSV 
stripping to 
knee) 
Haematoma: up to 10% (Corder et al., 1991)
 
Cutaneous neurosensory loss : 5-7% (Holme et al., 1990) 
Wound infection: 2–15% (Corder et al., 1991)  
DVT : <1% (Critchley et al., 1997) 
Table 1.6: Complication rates following different methods of treatment for GSV 
incompetence  
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1.10 Recurrence rates following varicose vein treatment 
Although the RCTs of surgery and the newer endovenous therapies have shown that outcomes 
are similar in the short term it is also apparent that medium term follow-up of patients after 
surgery show that 25-37% of patients develop further varicose veins after 2-5 years (Munn et 
al., 1981; Dwerryhouse et al., 1999).  Further, late results suggest that recurrence occurs in the 
majority (>60%) after ≥ 10 years (Campbell et al., 2003, Winterborn et al. 2004a). Recurrence 
after surgery may be related to technical factors and in particular appear higher after sapheno-
femoral ligation without GSV stripping (Sarin et al. 1994, Jones et al. 1996).  Further, Egan et 
al. (Egan et al., 2006)  concluded that incomplete surgery was responsible for up to 80% of 
recurrences (17% intact GSV, 37% stump reflux, 44% incompetent thigh GSV) in a series of 
500 patients undergoing surgery for recurrent varicose veins following previous surgery for 
GSV-related varicosities. Similarly van Rij et al. (2003) reported recurrence rates of 50% 3 
years following SPJ ligation.  It is likely that this reflects both the lower rate of truncal vein 
stripping (fear of sural nerve injury) and the failure to perform a technically satisfactory 
sapheno-popliteal ligation due to the variable position of the junction in patients with small 
saphenous vein varicosities.  
 
Despite these publications many believe that the principle cause of recurrence following surgery 
is neovascularisation at the site of junctional ligation (Blomgren et al. 2005, de Maeseneer et al. 
2007) and Winterborn et al (2004a) showed that its incidence increased sequentially during 
follow-up (36%, 54%, 65%  at  2, 5, 11 yr). The mechanisms by which this phenomenon occurs 
will not be discussed further here. 
 
Overall some 20% of the patients requiring treatment for varicose veins do so because 
of recurrence (Darke, 1992; Ruckley, 1997).  Although the causes of recurrence include 
incompetent perforators, para-reflux, new sites of reflux and inadequate primary 
surgery, neo-vascularisation is thought to be the commonest cause for recurrence (Jones 
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et al., 1996). Histological evidence suggests that this is the result of angiogenesis at the 
site of truncal vein ligation (Nyamekye et al., 1998) although attempts to reduce this by 
technical modifications to the surgical technique (closing the cribriform fascia, over-
sewing the SFJ stump, interposition of a PTFE patch) are of unproven benefit 
(Earnshaw et al., 1998; Frings et al., 2004).  
 
Although the data on recurrence rates may appear confusing this largely reflects the 
different lengths of follow up and the definition of recurrence. Table 1.7 summarises the 
data reported in various studies for Duplex ultrasound detected and clinical recurrence 
after conventional surgery for varicose veins.  
 
Currently, the long term recurrence rates after minimally invasive therapies are 
unknown. Nevertheless since truncal vein ablation is performed under ultrasound 
control it is probable that “technically inadequate surgery” is less likely to be a factor in 
this. Work presented in this thesis will examine the possible impact of 
neovascularisation on the risk of recurrence following EVLA. In addition, the influence 
of “non-ligated tributaries” at the sapheno-femoral junction on recurrence will also be 
explored.   
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Table 1.7: Recurrence rates after treatment for varicose veins 
 Duplex Clinical Re-treatment rates 
Surgery  
(Sapheno femoral ligation 
and GSV stripping) 
15% [1yr] (Turton et al., 1993) 
13% [2yrs] (Jones et al., 1996) 
29% [5yrs] (Dwerryhouse et al., 1999) 
62-70%  [10 -11years] (Campbell et al., 
2003; Winterborn et al., 2004) 
25% [2yrs] (Jones et al., 1996) 
 37% [3yrs] (Munn et al., 1981) 
21% [5yrs] (Dwerryhouse et al., 1999)  
6% [2yrs] (Jones et 
al., 1996) 
  
Ultrasound guided GSV 
foam sclerotherapy  
27% [1yr] 
64% [5yrs] (Chapman-Smith and 
Browne, 2009) 
4% [10yrs]  
(Chapman-Smith and Browne, 2009) 
9% [1 yr] (Darvall et 
al., 2010) 
Radiofrequency ablation 
(VNUS
®
) 
10% [9mths] (Rautio et al., 2002) 5% [6mths] (Dauplaise and Weiss, 2001) 
3.8% [1yr] (Sybrandy and Wittens, 2002) 
14% [2yrs] (Whiteley et al., 2000) 
 
Not known 
Endovenous laser ablation 
(EVLA) 
1-2%[6mths] (Min et al., 2001) 
<7% [3yrs] (Min et al., 2003) 
Not known Not known 
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Chapter 2: 
2. General Methodology  
 
2.1 Assessment of patients with varicose veins 
All patients attending the venous clinic at The General Infirmary at Leeds between March 2005 and 
May 2007 were assessed (clinically and by using DUS) and provided that informed consent was 
obtained they were recruited for the studies that are presented in this thesis. This chapter describes 
the general methodology whilst methods for individual studies are described in each chapter. 
2.2 Clinical assessment  
Clinical History 
All patients were assessed clinically to identify symptoms and signs related to venous disease both 
before treatment and at every follow up visit. Relevant history including the duration of symptoms, 
the nature of these (aching, itching, heaviness of leg, ankle swelling), a previous history of 
superficial thrombophlebitis, deep vein thrombosis (DVT) or major limb trauma, and usage of 
anticoagulants (warfarin) or antiplatelet drugs (aspirin, clopidigrel) were recorded. Family history 
of varicosities and previous treatment details were also documented. 
Severity assessments 
The clinical severity of venous disease was established using CEAP [Clinical, etiology, anatomy 
and pathology] (Porter and Moneta, 1995) and Venous Clinical Severity Score (VCSS, Rutherford 
et al., 2000). Further the impact of disease specific quality of life was determined using the 
Aberdeen Varicose Vein Severity Score [AVVS] (Garratt et al., 1993). The questionnaire is 
reproduced in appendix B3. 
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The AVVS questionnaire is a 13-item disease-specific health-related quality of life measure for 
people with varicose veins.  The questions cover both symptoms and the cosmetic impact of 
varicose veins and includes a diagram on which patients indicate the distribution of their 
varicosities.  It was developed by Garratt and colleagues in 1993 and has been shown to have 
validity, reliability and reproducibility (Garratt et al., 1993; Smith et al., 1999).  It has also been 
shown to be responsive to change and an improvement in AVVS has previously been demonstrated 
in patients following varicose vein surgery (Garratt et al., 1993; Smith et al., 1999; Mackenzie et al., 
2002).  Questionnaires were completed before and at 6, 12 and 52 weeks following treatment.  
 
Changes in symptoms and signs, together with treatment-related complications and the presence of 
residual or recurrent varicosities were recorded at each post-treatment clinic visit together with any 
additional intervention that was required.  
 
Pain severity, patients‟ satisfaction and willingness to undergo the same treatment again were 
recorded in specific studies and these methods are described in the relevant chapters.  
 
2.3 Duplex ultrasound assessment  
All patients underwent routine DUS assessment according to the consensus document published by 
Coleridge-Smith et al (Coleridge-Smith et al., 2006; Cavezzi et al., 2006) using a portable TITAN 
ultrasound machine (TITAN®, Sonosite Inc, Bothell, USA) and a 5-10MHz probe both before and 
after treatment. The superficial, deep and perforating veins were assessed to identify all 
incompetent (or occluded) veins. The presence of retrograde flow lasting >1s was considered 
significant.  
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DUS examination was usually carried out with the patient standing and the distal calf muscle was 
compressed manually and released abruptly for assessment of reflux. However, examination of 
distal calf veins was performed with the patient sitting and foot compression was used to augment 
flow. Transverse and longitudinal views of the relevant veins, saphenous junctions and perforating 
veins were employed to identify the anatomy and presence of reflux more precisely.  
 
An angle of insonation of 45-60
0
 between the transducer and vein was used to achieve optimum 
colour or Doppler spectral signals. Patients with reflux in the superficial truncal veins associated 
with incompetent saphenous junctions were assessed for laser suitability and the criteria for this are 
given below.  
 
After treatment reflux at the saphenous junctions and the ablation status of the target truncal vein 
were recorded for all patients. Compressibility and detectable flow in the treated vein was 
considered ablation failure whilst absence of flow in a non-compressible vein represented 
successful ablation. SFJ tributaries and the patency and reflux status of the below-knee GSV (BK-
GSV) were assessed in detail for specific studies and these methods are described later.  
 
2.4 Training received 
Duplex ultrasound scanning skills were initially gained by attending an introductory course at Kings 
College, London followed by 6 months (from March 2005-Sep 2005) hands-on training by a senior 
ultrasonographer at the General Infirmary at Leeds. Data collection for most studies described in 
this thesis was dependent on DUS findings and thus the reliability of the information obtained has 
been assessed in two ways: 
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1. Consecutive varicose vein patients attending the venous clinic during a two-month period 
were scanned by the writer using the TITAN ® scanner and by a senior ultrasonographer 
with a Philips ® (iU22) ultrasound scanner (Andover, MA). Twenty-four limbs were 
studied. The accuracy was 100% in detecting reflux in the deep & superficial veins. 
 
2. The tributaries of the GSV at the SFJ were scanned and documented for comparison with 
the operative findings. Site marking of the perforating veins was also compared with 
operative findings. Identifying groin tributaries (≥2mm) that require ligation was accurate 
in 88% patients and perforator localisations (±1cm) in 96% patients.   
 
Hands-on EVLA training was received between May–September 2005 from the two senior 
consultant vascular surgeons (Professor MJ Gough and Mr AID Mavor) who, at that time, had the 
largest experience of EVLA in the UK. Experience in the treatment of residual varicose veins by 
foam sclerotherapy was also gained from these consultants. 
 
 
2.5 Suitability for standard EVLA 
Suitability for EVLA depended upon a ≥10cm relatively straight segment of GSV (or SSV, 
AAGSV in the appropriate studies) immediately distal to the SFJ / SPJ, an absence of significant 
varicosities arising within 10cm of the SFJ, and a GSV diameter of ≥3 mm at the intended site of 
cannulation (usually just above the knee). The main patterns of varicosities that are and are not 
suitable for EVLA are illustrated in figures 2.3 and 2.4.  The presence of two incompetent truncal 
vein joining at the SFJ did not preclude EVLA although these patients may only have been suitable 
for inclusion in some of the studies.  
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Figure 2.1: Illustrations showing varicose veins that are suitable for EVLA 
A- Adequate (>10cm) length of truncal vein (GSV) is present before varicosities join 
B- GSV tributaries (anterior accessory great saphenous vein (AAGSV) in this example) are usually 
relatively straight before becoming varicose  
Arrows indicate suitable cannulation sites 
  
B 
SFJ 
SFJ 
A 
Incompetent veins 
Competent / healthy veins 
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61 
 
   
 
 
 
 
              
 
 
 
 
 
                            
 
 
 
 
 
               
 
 
 
 
 
 
                      
 
 
Figure 2.2: Illustration showing some patterns of varicose veins that are not suitable for 
EVLA 
A- Only a short segment of truncal vein reflux  
B- Varicosities arising within a short distance of SFJ  
C- No truncal vein reflux, varicosities arising directly from SFJ 
D- Excessive GSV tortuosity  
C D 
SFJ 
A 
GSV 
SFJ 
GSV 
SFJ 
GSV 
SFJ 
B 
GSV 
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2.6 Patient selection 
Patients attending the venous clinic at The General Infirmary at Leeds were assessed clinically and 
by DUS in the outpatient clinic. Suitability for laser treatment was assessed and EVLA was offered 
as an alternative to surgery in appropriate patients. If suitable, patients were asked to take part in 
various clinical studies. Further, a prospective database was maintained of all patients undergoing 
EVLA. Two studies, namely “factors influencing effectiveness of EVLA” and “the reliability of a 
scoring system to assess the outcome of EVLA” were performed using information from this 
database.  
 
2.7 Pre-procedure preparations 
Patients were treated on an out-patient basis, initially in the surgical day unit but subsequently in a 
treatment room in the out-patient clinic. Written informed consent was obtained for both the 
procedure itself and for participation in any study for which consent had been given. All studies 
included in this thesis had the approval of the Leeds Teaching Hospitals NHS Trust Research Ethics 
Committee. Immediately prior to treatment a detailed DUS was repeated to identify and mark the 
truncal vein (GSV, SSV, or AAGSV) for treatment. When necessary, more than one truncal 
vein/limb was treated at a single visit. Similarly in patients with bilateral varicose veins both legs 
were usually treated on the same occasion.  
 
Any other variables that were recorded are described in the methodology for the individual studies.   
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2.8 The standard technique for EVLA 
Equipments 
The following equipment was used for EVLA: 
i. Seldinger needle, 5F 
ii. Double ended J/straight 120cm 0.035” guidewire  
iii. 70cm 5Fr sheath  
iv. Laser fibre, bare tipped, 600micron 
v. 810 nm diode laser power source (Boilitec AG, Jena, Germany) 
 
All the above were supplied by Synergyhealth® (EVLA Accessory pack 19042, Synergyhealth®, 
Chorley, UK). In selected patients when the truncal vein for treatment was particularly tortuous, or 
if the standard guidewire could not be passed along the full length of the vein for treatment a 0.035” 
J-tipped hydrophilic guidewire was used (Terumo Glidewire®, Terumo Medical Corporation, 
Somerset, USA). 
 
Other disposables 
i. 10ml, 20ml syringes 
ii. 3-way tap 
iii. 25G needle 
iv. 20G (152cm long) Spinal needle 
v. 0.9% saline 
vi. 2% lignocaine with adrenaline for dermal local anaesthesia 
vii. Tumescent local anaesthetic solution (20 ml of 2% lignocaine with  adrenaline 1:1000 
mixed with 480 ml of 0.9% saline) 
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viii. ultrasound probe cover 
ix. plastic receiver dish 
x. galipot 
xi. sterile swabs 
 
Summary of technique for EVLA 
The GSV was cannulated (using ultrasound guidance) at the level of knee or higher if there was 
only a relatively short straight segment of GSV. A guidewire was introduced proximally into the 
GSV & femoral vein and a 5FG catheter was positioned 1cm distal to the sapheno-femoral junction 
(SFJ) under ultrasound control. Perivenous tumescent local anaesthesia (0.1% lignocaine 150-
200ml) was infiltrated along the vein using ultrasound guidance. This provided anaesthesia, 
compressed the GSV, absorbed the heat generated by the laser, and separated surrounding tissues 
from the vein. A laser fibre connected to an 810 nm diode laser source was inserted through the 
catheter and then both were withdrawn so that 4-5 pulses of laser energy (12Watts power, 1 second 
pulses, 1 second intervals) were delivered to each cm of vein (48-60 Joules/cm).  
 
Following treatment a non-stretch compression bandage was applied from foot to groin for one 
week followed by a class 2 support stocking for a further week. Patients were prescribed 50 mg 
diclofenac sodium three times a day for 3 days to reduce inflammatory changes in the treated vein 
and encouraged to resume their normal daily activities (including work) as soon as possible.  
 
If required, residual varicosities were treated by foam sclerotherapy (sodium tetradecyl sulphate) 6 
weeks following initial treatment.   
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2.9 Detailed description of technique 
 
On-table preparation 
For GSV ablation the patient was positioned on a tilting table with the leg to be treated slightly 
flexed at the knee and hip with the latter externally rotated.  The patient lies prone for SSV 
treatment. The table is tilted into the reverse Trendelenburg position to fill the lower limb veins. 
 
After preparing the limb with povidone iodine a sterile towel was placed beneath it. Under 
ultrasound guidance, the vein was cannulated percutaneously after anaesthetising the overlying skin 
(1% lignocaine).    
 
Cannulation Techniques 
A 5 Fr needle connected to 10 cc syringe containing 5 ml of normal saline (0.9% NaCl) was used 
with the target vein imaged (DUS) transversely (Figure 2.5).  
 
The target site for cannulation was positioned in the middle of the screen and local anaesthetic 
(lignocaine 1%, 0.5 ml) injected 2-3cm distal to the probe in line with the vein. The vein was 
imaged proximally for 5cm to determine its direction. The needle was inserted towards the vein 
under ultrasound guidance. The needle tip was initially positioned just above the vein and then 
advanced into the vein. Aspiration of blood into the syringe confirmed the intravenous position of 
the needle. While stabilising the needle in the same position, the syringe was disconnected and a 
4Fr, J-tipped guidewire inserted into the vein through the needle.  
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a)                                                                                            b) 
 
 
 
 
 
 
Figure 2.3: a) Cannulation of a vein under transverse ultrasound guidance. The skin is 
punctured 2-3cm distal to the ultrasound probe and vein puncture site. b) Representation of 
ultrasound appearance; the white dot within the vein is the tip of the needle. 
 
a)                                                                                             b) 
 
 
 
 
Figure 2.4: a) Cannulation of a vein using longitudinal ultrasound imaging. Note that the skin 
is punctured just distal to the ultrasound probe: b) Representation of ultrasound appearance; 
the white lines indicate the walls of the needle. 
 
2-3cm 
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The other commonly used technique was to image the target segment of vein longitudinally and 
puncture the skin under local anaesthesia at the distal end of the probe (Figure 2.6). If the target 
vein was superficial it was sometimes useful to access the vein with a 16G intravenous catheter 
using a longitudinal view of the vein. The advantage of this technique is that the “flush-back” seen 
at the end of the catheter helps to prevent penetration of the back wall of the vein.  
 
Overcoming problems with cannulation 
Occasionally cannulation under ultrasound control was not possible. When this was the case then 
administration of a further aliquot of local anaesthetic into the subcutaneous tissues facilitated a 
small stab incision following which the target vein was delivered through the wound using a 
phlebectomy hook. This then allowed the operator to make a small venotomy and insert the 
guidewire under direct vision. 
 
Further problems may occasionally be experienced when passing the guidewire up the vein, 
particularly if it was tortuous. Most difficulties were overcome by using a hydrophilic coated 
guidewire with an angled tip (Terumo Glidewire®, Terumo Medical Corporation, Somerset, USA). 
This was generally introduced via the endovenous sheath if the standard guidewire had passed 
partly up the vein. 
 
The endovenous sheath 
A 5 Fr single lumen sheath of either 45cm or 70cm length (standard technique) was used. The 
sheath is marked at 1cm intervals to facilitate accurate withdrawal for optimum laser energy 
delivery (Figure2.7).  
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Figure 2.5: A 70cm length endovenous sheath marked at 1cm intervals 
 
 
The sheath was inserted over the guidewire and its tip positioned 1cm distal to the SFJ. When 
positioning the tip of the catheter, if not clearly visible on ultrasound, saline was injected through it 
and the jet emanating from the tip was easily identified with ultrasound. The length of the vein to be 
treated was recorded using the scale on the sheath.  
 
Tumescent anaesthesia (TA) 
Tumescent anaesthesia (lignocaine 0.1% [20 ml 2% lignocaine with 1:1000 adrenaline mixed with 
480ml normal saline]) was administered along the target vein under ultrasound guidance. The main 
purpose of the tumescent anaesthesia was to separate the vein from adjacent tissues and thus 
prevent inadvertent thermal damage to nerves and skin. The other purposes of the tumescent 
anaesthesia (TA) are summarised in table 2.1.  
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Function of tumescent anaesthesia Explanations 
Protects surrounding tissues (nerve, skin) 
from thermal injury 
Absorption of heat by the fluid around the 
vein 
Results in superior ablation rates TA compresses the target vein around the 
laser fibre and reduces the distance between 
vein wall and laser tip; it also reduces the 
amount of blood inside the vein and thus 
thrombus formation.  
Provides analgesia It reduces intra-procedure pain by absorption 
of heat and by its local anaesthetic effect. 
  Table 2.1: Functions of tumescent anaesthesia 
 
Technique for administration of tumescent anaesthesia  
TA was administered using 15cm long spinal needle under ultrasound guidance. After insertion of 
the sheath, the target vein usually vasoconstricts. The sheath itself is visualised as two white dots 
(the anterior and posterior walls of the sheath) on ultrasound. Keeping the two dots (cannulated 
vein) in the middle of the screen, the spinal needle connected to 20cc syringe was inserted 2-3cm 
from the probe after anaesthetising the skin with 1% lignocaine and advanced towards the vein. The 
needle tip was positioned deep to the saphenous fascia and superficial to the anterior wall of the 
vein (figures 2.8 & 2.9). An adequate amount of TA was injected until a 0.5-1cm radius of TA 
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surrounded the target vein to achieve the typical “doughnut” appearance on ultrasound (figure 
2.10). The needle is advanced proximally to deliver TA along the whole length of the vein requiring 
treatment with additional administration of local anaesthetic to the skin every 15cm or so. It is also 
important to inject adequate TA at both the SFJ and SPJ beyond the tip of the sheath. It is also 
crucial to administer adequate TA anterior to the vein to prevent skin burns in very superficial veins 
and to have adequate TA posterior to the vein particularly at the SF and SP junctions to protect the 
femoral and popliteal veins.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Technique for infiltration of tumescent anaesthesia: transverse view (left) shows 
the dough-nut appearance following administration 
 
 
 
 
 
        Scan probe               TA needle 
 
 
 
             
               
      
 
      
 
 
 
 
 
 
 
 
 
 
 
Needle tip 
TA 
Endovenous sheath within the vein 
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Figure 2.7: a) adequate tumescent anaesthesia around the vein: b) Insufficient TA anterior to 
vein (arrow) 
 
Figure 2.8: Ultrasound image showing “doughnut” appearance of TA 
 
Saphenous fascia     
Tumescent anaesthesia 
Collapsed vein over the sheath       
Deep fascia 
a 
 
 
 
 
 
 
 
  
   b 
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Delivery of laser energy 
The bare tipped laser fibre was inserted into the endovenous sheath and advanced to the tip of the 
sheath (a mark on the laser fibre indicates the length for insertion) and the latter was then 
withdrawn by 1cm to position the tip of the laser fibre in the same place as the sheath was 
previously located, but with 1cm of the fibre extending beyond the sheath. The laser fibre was 
subsequently connected to the power source (figures 2.11 & 2.12) that delivered laser energy at 
12W power with 1s laser pulses at 1s interval. Both laser fibre and the endovenous sheath are 
withdrawn together (locked together by a luer-lock system) whilst pulses of laser energy are 
delivered to the target vein. In the standard technique 4-5 laser pulses at 12W power were delivered 
per cm of vein as recommended by the manufactures (energy density: 48-60J/cm). 
 
     
  Figure 2.9: Bare-tipped laser fibre connected to laser power source 
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Figure 2.10: 810nm diode laser power source set at 12W and 1s pulses with a 0.1s interval 
 
Completion of laser treatment 
On completion of treatment a steristrip was applied to the cannulation site. A Panelast® (Panelast, 
Lohmann-Rauscher, Austria) bandage was then applied from foot to groin but with a strip of foam 
laid over the treated vein to apply compression for 1 week.  This was then replaced with a Grade 2 
compression stocking (Mediven stocking, medi-UK, Hereford, UK) which was worn during the day 
for the second week.  
 
It should be noted that since the studies that are described in this thesis were performed patients 
now wear a Class 2 compression stocking from the time of treatment (continuously for the first 
week) and that the foam strip is no longer used.   
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2.10 Post treatment  
Instructions 
Patients were advised to resume their normal activities, including work, as soon as possible. 
Diclofenac sodium 50 mg three time a day was prescribed for 3 days (unless there were 
contraindications to this: peptic ulcer, oesophagitis, asthma) to reduce post-laser discomfort. 
Patients were routinely reviewed at 6 and 12 weeks and any residual varicosities treated with foam 
sclerotherapy if requested.   
Follow up assessments 
All patients were seen at 6, 12 and 52 weeks following treatment and all limbs were assessed 
clinically and by using DUS. A prospective log of complications was maintained. Nerve damage 
(sensory) was assessed objectively using a Neurotip (Owen Mumford Ltd, Woodstock, England) on 
patients who reported subjective numbness.  
 
If residual varicosities were present at the 6 week follow up visit they were treated with 1-3% STD 
foam sclerotherapy (if requested by the patient). Foam was prepared according to the Tessari 
method (Tessari et al., 2000) and sclerotherapy performed using either a 25G hypodermic needle or 
butterfly needle (Abbott, Maidenhead, UK). A compression bandage (Panelast®) was applied with 
local re-enforcement using cotton wool balls over the treated vein. This compression bandage was 
left in-situ for 1 week and patient advised to walk 2-3 mile per day. Patients were followed up after 
a further 6 weeks to reassess the legs. Any complications were documented and further 
sclerotherapy was given if required.  
Summary of follow up schedule 
As indicated above patients were reviewed at 6, 12 and 52 weeks unless stated otherwise in 
individual studies. All patients were assessed clinically for residual or recurrent veins and for 
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improvements in symptomatology. This was assessed both verbally and objectively using the 
methods described in Table 2.2. Data analysis and statistical methods for each study are described 
in the individual chapters.  
 
 Pre-op 6 weeks 3 months 1 year 
Clinical assessment     
Duplex ultrasound scan     
AVVS     
CEAP     
VCSS     
Requirement for injection 
sclerotherapy 
    
Satisfaction (VAS)     
Complications     
Table 2.2: Summary of follow-up protocol 
AVVS: Aberdeen varicose vein severity score 
VCSS: Venous clinical severity score 
CEAP: clinical sign, etiology, anatomy, pathophysiology 
VAS: visual analogue scale 
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Chapter 3: 
3. Factors influencing the effectiveness of EVLA 
 
Successful ablation of the target truncal vein could be influenced by several factors. Two studies 
were conducted to analyse these factors. 
3.1 Study 1: Technical Factors influencing the effectiveness of EVLA  
3.1.1 Introduction 
A successful long-term outcome depends upon elimination of the highest point of “deep to 
superficial” incompetence and ablation of the incompetent truncal vein. (Trendelenburg, 1891; 
Rivlin, 1975; Tibbs and Fletcher, 1983; Koyano and Sakaguchi, 1988; Corbett et al., 1988; Goren 
and Yellin, 1991).  This chapter examines factors that might determine the efficacy of EVLA using 
data derived from patients undergoing treatment for GSV incompetence and SFJ reflux. Successful 
ablation of the treated vein is crucial in determining the long-term success of EVLA and a previous 
meta-analysis indicates that this is achieved in 88-100% of limbs
 
(Mundy et al., 2005). 
 
Similar success rates are reported for radiofrequency ablation [RFA] (Manfrini et al., 2000; 
Merchant et al., 2002; Rautio et al., 2002; Sybrandy and Wittens, 2002), 
 
although the potential 
mechanisms of injury may be different for the two techniques. RFA (VNUS Closure) delivers 
thermal energy to the GSV resulting in controlled heating to 85
0
C for a set period of time. This is a 
lower temperature than that achieved by EVLA but it is maintained for longer. It is believed that 
RFA causes endothelial denudation, collagen denaturation and acute vein constriction (Weiss, 
2002). Whilst RFA relies on a standard protocol for the treatment of all patients this is not the case 
for EVLA. The power of the laser, the total energy delivery and the amount of energy delivered/cm 
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of vein (energy density) are all under the control of the operator. Nevertheless when EVLA was 
first introduced into clinical practice the manufacturer (Diomed Inc, Andover, MA) advised the use 
of 12W power delivering around 48J/cm vein. However, since not all studies report 100% occlusion 
rates success may depend on a number of factors. These have been examined in this observational 
study with the aim of developing a standardised protocol to ensure successful ablation in as many 
patients as possible.    
3.1.2 Methods 
Patients 
All patients attending the venous clinics at the General Infirmary at Leeds and the BUPA Hospital, 
Leeds between January 2002-April 2006 with SFJ and GSV reflux were evaluated by duplex 
ultrasound scanning to assess their suitability for EVLA. If appropriate, this was offered as an 
alternative to surgery and patients were treated according to their preference. Those who required 
ablation of an additional truncal vein (anterior accessory saphenous vein or SSV) or who were 
taking warfarin were excluded from the study. (Of the 582 patients included in this study, 312 
patients‟ data was collected by my predecessor Rosie Beale and the remaning data is collected by 
me). 
 
EVLA suitability  
Suitability for EVLA depended upon a ≥10cm relatively straight segment of GSV immediately 
distal to the SFJ, an absence of significant varicosities arising within 10cm of the SFJ, and a GSV 
diameter of ≥3 mm at the intended cannulation site (usually just above the knee).  
Standard laser technique 
This was described in Chapter 2. A bare-tipped laser fibre connected to an 810 nm diode laser 
source (Diomed Inc, Andover, MA) was used to deliver 4-5 pulses of laser energy (12W power, 1s 
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pulses, 0.1s intervals) per cm vein. Neither concomitant phlebectomy nor foam sclerotherapy was 
performed at the time of primary treatment. Post-EVLA care was as described in Chapter 2.  
 
Follow-up 
Patients were reviewed at 6 and 12 weeks. Treated limbs were assessed clinically and by duplex 
ultrasound scanning.  Those who had residual varicosities with controlled truncal reflux (occluded 
GSV) were offered foam sclerotherapy (as per Chapter 2) at the 6 week visit. Patients with 
persisting significant GSV reflux (>1s) at any follow-up appointment were offered the choice of 
conventional surgery or repeat EVLA. 
 
Criteria for successful GSV ablation on ultrasound were non-compressibility or non-visualisation of 
the treated segment of vein together with an absence of flow on colour-flow duplex ultrasound and 
a competent SFJ. Treatment failures were defined as veins demonstrating flow and/or reflux in all 
or part of the treated segment of the GSV.  
 
Data collection and analysis 
The following data were collected and stored on a prospectively maintained database (Microsoft 
Office Access, 2003) by 3 research fellows and 2 consultant vascular surgeons trained in venous 
duplex ultrasound: 
 Patient height and weight (without footwear) and calculated body mass index (BMI). 
 Maximum GSV diameter on ultrasound (avoiding focal dilatations) whilst standing. 
 Length (L) of GSV treated.  
 The total laser energy (TLE) delivered to the GSV (obtained [Joules] from laser power source)  
 The energy density (ED, J/cm) administered: TLE/L. 
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 Data on whether the GSV had been successfully ablated (see above) either throughout the 
“treated” length or partially if this was applicable. 
 
A prospective log of all complications that occurred after EVLA was also maintained.  
Examination of the database identified two groups of patients:  
 a) Those with full-length occlusion of the treated GSV and a competent SFJ (Group A)  
 b) Those with a fully or partially patent GSV, irrespective of any clinical  improvement or    
    the reflux status of the SFJ (Group B). 
 
Statistical analysis 
Variables between the two groups were compared using a student-t test (unpaired) and a chi-square 
test employed to compare complication rates between the groups. A “p” value of <0.05 was 
considered statistically significant.  Data are presented as median (±inter-quartile range) unless 
stated otherwise.  All analysis were performed using the statistical package SPSS® for Windows 
(SPSS (14), Chicago, Illinois, USA).   
 
 
3.1.3 Results 
582 patients (644 legs) were reviewed at 6 weeks and 3 months. Demographic data, including the 
severity of the venous disease (C of CEAP) are shown in Table 3.1. In 599/644 (93%) the 3-month 
ultrasound scan confirmed full-length ablation of the treated GSV. Of the remainder the GSV was 
partially occluded in 19/644 (2.9%) legs and patent in 26/644 (4%). The median energy density 
delivered during ablation was 48 (±(IQR 37-59) J/cm in group A and 37 (±(IQR 30-46) J/cm in 
group B. This difference was statistically significant (p<0.01). There was also a difference in the 
total laser energy used (Group A: 1877J versus Group B: 1191J, P<0.05) although this is not 
reflected by a difference in the median length of GSV treated in the two groups (Group A: 33cm 
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versus Group B: 29cm).  The median GSV diameter was similar in the groups (A: 7.2 mm versus B: 
6.9 mm, ns) as was the BMI (A: 25.2 versus B: 25.1, ns).  These results are summarised in table 3.2. 
 
 Total Group A Group B 
Number patients 582 538 44 
Median age (range) 50 years (16-86) 50 (16-86) 48 (24-72) 
Female 378 (65%) 349 (65%) 29 (66%) 
Male 204 (35%) 188 (35%) 16 (34%) 
Number of treated legs 644 599 45 
Primary varicose veins 534/644 (83%) 491/599 (82%) 43/45 (96%) 
Recurrent varicose veins 110/644 (17%) 108/599 (18%) 2/45 (4%) 
C2 Varicose veins 361/644 (56%) 321/599 (54%) 40/45 (89%) 
C3 Oedema 59/644 (9.2%) 56/599 (9%) 3/45 (7%) 
C4 Skin changes 172/644 (26.7%) 170/599 (28%) 2/45 (4%) 
C5 healed ulcer 33/644 (5.1%) 35/599 (6%) 0 
C6 active ulcer  19/644 (2.9%) 19/599 (3%) 0 
 
C of CEAP score : Clinical, Etiology, Anatomy, Pathology (EAP is similar in all patients) 
Table 3.1: Patient demography and disease severity assessment 
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Variables Group A (n=599) Group B (n=45) “P” value 
Total laser energy (J) 1877   (IQR 997-2350) 1191    (IQR 1032-1406) <0.05 
Energy Density (J/cm) 48      (IQR 37-59) 37       (IQR 30-46) <0.01 
Diameter of the vein* (mm) 7.2      (IQR 5.6-9.2) 6.9       (IQR 5.5-7.7) 0.28 
BMI (Kg/m
2
)  25.2    (IQR 23.0-28.5) 25.1     (IQR 24.3-26.2) 0.36 
Length of treated vein (cm) 33       (IQR 27-39) 29       (IQR 24-35)    0.06 
Table 3.2: Comparison of variables in the groups (IQR- inter-quartile range) 
* Maximum diameter measured while patient is standing 
Group A: Limbs with complete occlusion of the treated GSV 
Group B: Limbs with either a patent or partially occluded GSV  
 
 
The ED administered to individual limbs ranged from 22-82 J/cm and this was used to sub-group 
the treated limbs (table 3.3). The frequency of successful ablation was greater with increasing ED 
and when this was ≥60 J/cm GSV ablation was achieved in all limbs (100%).  Importantly, a higher 
ED did not appear to influence complication rates and the frequency of „phlebitis‟ in veins that 
received ≥60J/cm or <60J/cm was 7.4% (7/95) and 10.7% (59/549) respectively. This difference 
was not statistically significant (p=0.316).  
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Energy 
density 
(J/cm) 
Number 
of limbs 
treated 
Complete 
occlusion  
% success  Phlebitis Transient 
cutaneous 
numbness 
DVT 
<30 82 71 86.6% 9 (10.9%) 1 0 
30 – 39.9 168 149 88.7% 16 (9.5%) 2 0 
40 – 49.9 176 164 93.2% 19 (10.8%) 2 0 
50 – 59.9 123 120 97.6% 15 (12.2%) 1 1 
60 – 69.9 79 79 100% 7 (8.8%) 1 0 
≥70 16 16 100% 0 (0%) 0 0 
Total 644 599 93% 66 (10.2%) 7 (1.1%) 1 (0.2%) 
Table 3.3: Success and complication rates according to energy density at 3 months  
 
3.1.4 Discussion  
The findings of this study form the basis for developing a standardised protocol for successful 
EVLA. It is clear that an ED of energy density ≥60J/cm is central to achieving complete GSV 
occlusion. This equates to 5 pulses/cm vein when using 12W power, 1s pulses and 1s intervals for 
laser fibre withdrawal i.e. 2mm pull-back during each 1s interval. Continuous withdrawal of the 
fibre using 14W power has subsequently been adopted in our unit as this has the benefit of reducing 
treatment times. Delivery of 60J/cm with this technique requires pull-back of 1cm of the laser fibre 
in 4.3s. For practical purposes a policy of withdrawing 1cm of fibre over 5s (70J/cm) has been 
adopted. That this is both efficacious and safe is confirmed by this study, and in particular 
complication rates were not influenced by delivery of higher levels of laser energy within the range 
used. 
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Other authors have also assessed the efficacy of different levels of energy delivery. Timperman 
reported similar data to that presented here, with a significant difference in laser energy delivery 
between “successes” and “failures” (63.4J/cm versus 46.6J/cm, p<0.0001). In that study there were 
no treatment failures with an ED of >80J/cm (Timperman et al., 2004) although in a subsequent 
study the same author treated 100 GSV with 95J/cm achieving successful ablation in 95% of limbs 
(Timperman et al., 2005).  In contrast Kim et al achieved 100% technical success in 34 patients 
using a 980nm diode laser at 11W power, delivering 35.16J/cm (Kim et al., 2006). It is likely that a 
small study such as this reflects reporting bias rather than a real finding.  
 
It has been suggested that reporting energy delivery as J/cm is an oversimplification and does not 
take vein diameter into account. Thus Proebstle found that laser fluence (laser energy per cm
2
 vein) 
was a risk factor for non-occlusion (Proebstle et al., 2004) and that treatment regimes should be 
based upon this type of calculation. Such an argument may be flawed since vein diameter at the 
time of ablation is significantly reduced due to catheter-induced spasm following cannulation 
together with the effect of the tumescent anaesthesia. Further, the vein may not be of a uniform 
diameter and thus both calculation of fluence and the delivery of the appropriate laser energy to 
individual segments of vein are more difficult. A protocol based on J/cm seems more practical and 
despite the author‟s apparent enthusiasm for calculating laser fluence Proebstle has also reported 
results that are similar to those presented here (Proebstle 2006) in a study assessing the difference 
between a 15- or 30-W power supply at 3- and 12-month follow-up ablation with a 940-nm laser. In 
this study the average energy densities were 23.6 J/cm (15-W) and 69.9 J/cm (30-W). They reported 
significantly more failures in the 15W group at 3 months and concluded that higher energy delivery 
leads to fewer failures. They proposed an energy density threshold of ≈60 J/cm of vein (Proebstle et 
al., 2006). Although another study has shown that energy density levels of up to 160J/cm can be 
used without an adverse outcome (Carradice et al., 2010).  Prince at al. have shown that an energy 
density beyond 80J/cm is not associated with an increase occlusion rate. (Prince el al., 2008). 
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Interestingly, similar energy density levels (60-70J/cm) are delivered by the Closure FAST device 
(Proebstle et al., 2008; Almeidia et al., 2009). That the energy required to achieve irreversible vein 
wall damage regardless of the mechanism of delivery seems logical. 
  
Although the protocol described above is straightforward it may not be suitable for all interventions. 
If the vein for ablation is particularly superficial (within 1cm of skin surface) a reduction in energy 
density (50J/cm) might be considered to prevent skin burns although this is unnecessary if the vein 
is separated from the skin by ≥1cm following administration of TA. The basis for this is a previous 
study by Beale et al which showed that the maximum perivenous temperature 10mm from the vein 
was 36
0
C (Beale et al., 2006) thus ensuring that skin burns will not occur. Nevertheless, in the 
popliteal fossa nerve injury could be critical but should be avoided by not exceeding 60J/cm. 
Conversely, in the proximal GSV, particularly in a large vein, the vein is usually deeper and up to 
100J/cm can be safely used to ensure proximal occlusion. 
 
This study has also shown that neither vein diameter nor the length of vein ablated had any 
influence upon success rates and these findings are not particularly surprising. The impact of BMI 
upon outcome was also examined since the efficacy of post-EVLA compression might have been 
reduced in obese patients. Although this did not seem to be an important factor conflicting data has 
been reported by Timperman
 
who found a statistically significant difference in body mass index 
(BMI) between successes and failures [30 versus 46, p=0.0009] (Timperman et al., 2004). This 
difference could be explained by the absence of super-obese patients in our study.  
 
Laser energy inflicts thermal injury to the venous endothelium and sub-endothelial collagen leading 
to fibrous sclerosis of the vein (Proebstle  et al., 2002; Corcos et al., 2005; Bush et al., 2005)  
Although different wave length diode lasers (808-1470 nm) have been used for GSV ablation 
(Navarro et al., 2001;Min et al., 2001 ; Proebstle  et al., 2002; Bush et al., 2005)  this study 
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employed an 810 nm diode laser which proved to be safe, and effective (provided sufficient energy 
was used). 
 
Successful EVLA depends upon inflicting sufficient vein wall damage to cause initial contraction 
and subsequent fibrosis of the treated vein rather than thrombosis which could lead to re-
canalisation and treatment failure. In order to achieve this factors other than the quantum of thermal 
energy delivered to the vein are likely to be important. Adequate volumes of tumescent anaesthesia 
and treatment in the Trendelenburg position should ensure that the vein is empty and that the laser 
fibre is in close proximity to the vein wall. This should increase the certainty of achieving 
irreversible damage to the vein wall. Further, it ensures that the distribution of energy is more 
predictable and not dependent upon vein diameter or the volume of blood within the vein at the time 
of treatment.  
 
In conclusion this study has shown that the ED (J/cm) of laser delivery is the main determinant of 
successful GSV ablation during EVLA and that delivery of ≥60J/cm is required for optimum 
results. Neither GSV diameter nor BMI appeared to influence outcome. Finally, the frequency with 
which phlebitis occurred did not appear to be influenced by an energy density within the study 
range.  
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3.2 Study 2: Influence of Warfarin upon the efficacy of EVLA  
3.2.1 Introduction 
Endovenous laser ablation (EVLA) employs thermal energy to cause irreversible vein wall 
injury and thus occlusion of an incompetent truncal vein. The work described above has 
shown that laser energy density is the single most important factor that determines the 
efficacy of laser ablation and this is also confirmed by others (Mordon et al., 2006).   
 
In the short term it is possible that thrombotic occlusion of the treated vein occurs in some 
veins (although it should be avoided provided the recommendations described above are 
followed) before vein contraction and fibrosis ensue. Thus it is possible that factors that 
inhibit thrombus formation such as anticoagulants may influence the success of EVLA.  
 
Unlike surgery, EVLA may be particularly suitable for older patients and those with 
significant medical co-morbidities in whom the treatment of superficial venous reflux and 
varicose veins is indicated because of complications such as varicose eczema, 
lipodermatosclerosis and ulceration. A proportion of these patients may be prescribed long 
term anticoagulation with warfarin for their co-existent medical conditions. This would 
usually be stopped prior to conventional varicose vein surgery because of the risk of intra-
operative bleeding. Further, in-patient as opposed to day-case surgery is usually required 
with the duration of admission prolonged if pre-operative conversion to heparin therapy is 
required or post-operative stabilisation of anticoagulant therapy necessary. A potential 
advantage of EVLA, given the absence of surgical incisions, is that anticoagulant therapy 
may not need to be stopped before treatment. It is unknown however whether continuing 
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warfarin therapy influences the success of truncal vein ablation. This study therefore 
examines this issue.    
 
3.2.2 Methods 
Patients 
Of 393 patients who underwent EVLA for varicose veins between May 2005 and January 2007 at 
the General Infirmary at Leeds, 22 patients (median age 62 (51-77), 12 female, 10 male; 24 limbs) 
continued taking warfarin at the time of treatment (“warfarin group”) for isolated sapheno-femoral 
junction (SFJ) and GSV reflux. Outcomes in these patients were compared with those in 24 age/sex 
and disease-severity (CEAP) matched control patients who were not taking warfarin (“no-warfarin 
group”). The control patient for each study patient was the next patient who underwent EVLA in 
our department and fulfilled the inclusion criteria. Patients with concomitant reflux in both the SSV 
and GSV and those with deep vein reflux from a previous deep vein thrombosis (DVT) were 
excluded from the study. The indication for warfarin therapy in the study group was atrial 
fibrillation (n=14) or a metallic heart valve (n=8). Informed consent was obtained for the procedure 
and for data collection from all patients who received EVLA for varicose veins  
 
Data collection  
Prior to laser treatment all patients underwent DUS [TITAN®, Sonosite Inc, Bothell, USA, 5-10 
MHz linear probe] to confirm the site of superficial venous incompetence. In addition the diameter 
of the GSV was measured 10cm distal to the SFJ, avoiding any localised dilatation. Suitability for 
GSV EVLA was established using criteria that have been described earlier in this thesis. Patients‟ 
past medical history and drug history were documented. Disease severity was assessed using “C” of 
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the CEAP clinical classification
4
 (“EAP” of CEAP were the same for all patients). Disease specific 
quality of life was assessed using AVVS scores before and 1 year after treatment.  
 
EVLA was performed using an 810nm diode laser (12W power, 1s pulses, 0.1s intervals) and 
tumescent local anaesthesia (0.1% lignocaine with adrenaline) as described earlier. Neither 
concomitant phlebectomies nor foam sclerotherapy were undertaken although the latter was 
performed at the first follow-up visit (6 weeks) for residual varicosities if requested by the patient. 
Treatment details including the laser energy density (J/cm) were documented.  
 
During follow up patients were assessed at 6, 12 and 52 weeks for successful GSV ablation (DUS), 
the presence of residual or recurrent varicosities and changes in AVVS scores. The criteria for 
successful ablation have been described earlier. Patient satisfaction was assessed at 1 year using a 
10cm VAS which was then calculated as a percentage.  A log of complications was maintained 
throughout the study. This included the development of a deep vein thrombosis (DVT), phlebitis, 
nerve damage (sensory or motor), chronic pain, and pigmentation. All these were assessed clinically 
apart from DVT which was assessed both clinically and by DUS (at each visit). This is a 
prospective observational cohort study with two groups.  
 
Statistical analysis 
All data were tested for normal distribution and are presented as median (±inter-quartile range) 
unless stated otherwise.  The AVVS before and after laser ablation were compared within a group 
using a Wilcoxon test and the improvements in AVVS between groups were compared with a 
Mann-Whitney U test.  All analysis were performed using the statistical package SPSS® for 
Windows (SPSS (14), Chicago, Illinois, USA). 
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3.2.3 Results 
Disease severity and the demographic data for the two groups are summarised in table 3.4. Pre and 
post treatment vein diameters were similar in both groups (table 3.5). Successful occlusion of the 
full length of the treated GSV was observed in 20/24 (83%) limbs in the “warfarin group” compared 
to 23/24 (96%) limbs in “no-warfarin group” (p=0.347). Although the overall laser ED was similar 
in the two groups, of the 4 patients in whom ablation was not achieved in the “warfarin group”, 3 
patients received suboptimal laser energy densities (46, 44, and 52J/cm). In these patients the GSV 
was patent and compressible on DUS at 6 weeks suggesting primary treatment failure. This is 
endorsed by an unchanged maximal vein diameter in these patients (table 3.5). In the remaining 
patient who received 62J/cm laser energy the GSV was partially occluded at 6 weeks GSV but fully 
patent with reflux at 12 weeks. This is more likely to represent re-canalisation. Similarly, the patient 
in whom treatment failed in the “no-warfarin group” received 58J/cm laser energy and had a 
partially occluded vein at 6 weeks which had recanalised at 12 weeks. Interestingly, both of these 
patients showed a reduction in vein diameter during follow-up.  These data are summarised in table 
3.5. There were no treatment failures in either group between 3 and 12 months. 
  
90 
 
   
Characteristics Warfarin              (%) No warfarin                (%) 
Male 10                         (45%) 10                          (45%) 
Female 12                         (55%) 12                          (55%) 
Age, median (range) 62 (51-77) years 62 (51-77) years 
Number of limbs treated 24 24 
CEAP: C2  13                         (54%) 13                           (54%) 
            C3 4                          (17%) 4                            (17%) 
            C4 4                          (17%) 4                            (17%) 
            C5 2                          (8%) 2                             (8%) 
            C6 1                          (4%) 1                             (4%) 
Table 3.4: Demography and CEAP classification of patients undergoing EVLA  
 
A significant improvement in AVVS occurred in both groups: “warfarin group”: 14.6 (8.9-19.1) to 
3.8 (1.9-6.2), “no-warfarin group”: 13.9 (7.6-20.1) to 3.5 (2.2-6.4); p<0.001. However, there was no 
difference in either the improvement between the groups (p=0.446) or in patient satisfaction with 
their treatment and outcome (”warfarin”=92% versus “no warfarin”=90%, p=0.391).  
 
There were no instances of DVT in either group and only one patient in the “no-warfarin group” 
reported marked post-EVLA discomfort (“phlebitis”). None of the patients described either 
extensive bruising or haematoma formation in either group. 
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Patient/ 
Group 
Laser energy 
(J/cm) 
Total laser energy 
(J) 
DUS findings (ablation status, reflux status and diameter)  
Pre-EVLA 6 weeks 12 weeks 52 weeks 
“warfarin” (1) 46* 1380 Patent, Reflux 
7.6 mm 
Patent, reflux 
7.4 mm 
Patent, reflux 
7.6mm 
Patient had successful  
re-do EVLA 
“warfarin” (2) 44* 1408 Patent, Reflux 
8.2 mm 
Patent, reflux 
8.3mm 
Patent, reflux 
8.1mm 
Patient had successful  
re-do EVLA 
“warfarin” (3) 52* 1456 Patent, Reflux 
7.7 mm 
Patent, reflux 
7.9 mm 
Patent, reflux 
7.6 mm 
Patent, reflux 
7.5mm 
“warfarin” (4) 62 2260 Patent, Reflux 
8.4 mm 
Partially occluded 
7.8 mm 
Patent, reflux 
5.1 mm 
Patent, reflux 
4.9 mm 
“no warfarin” (1) 58 2320 Patent, Reflux 
7.3 mm 
Partially occluded 
7.0mm 
Patent, reflux 
4.3 mm 
Patent, reflux 
3.2 mm 
Warfarin Group: 
Median (IQR) 
64 (54-72) 1997   (1686-2350) Patent, Reflux 
7.9 ±2.1 
Fully occluded 
5.0±1.4 
Fully occluded 
3.1±1.3 
Fully ablated 
not visible 
No-warfarin Group: 
Median (IQR) 
66 (55-74) 2016 (1640-2460) Patent, Reflux 
7.6 ±2.2 
Fully occluded 
5.2±1.5 
Fully occluded 
3.0±1.4 
Fully ablated 
Not visible 
P (warfarin vs no-
warfarin) 
0.09 0.15 0.19 0.21 0.24 - 
Table 3.5: Treatment details, ablation status, vein diameter and presence of significant reflux (>1s) in patients with treatment failure at 6, 12 and 52 
week follow-up compared to patients who had successful treatment in groups A and B  
 3 patients in ”warfarin” group received suboptimal laser energy density(<60 J/cm)1,2,3 
 Warfarin patients 1, 2, 3 and 4 – subsequently had successful re-do EVLA at 6, 7, 13 and 18 months respectively 
 No-warfarin patient 1 had US guided foam sclerotherapy at 12 months 
92 
 
   
3.2.4 Discussion  
Unlike conventional surgery, EVLA ablates the incompetent truncal vein in-situ without the 
need for surgical incisions. When varicose vein surgery is performed on patients who are taking 
warfarin it is common practise to discontinue therapy 3 days prior to operation. Although 
conversion to peri-operative anti-coagulation is not usually required for patients with atrial 
fibrillation this would have been necessary for the 8 patients with a metallic heart valve who 
were included in this study.  
 
It is important to note that the small sample size is a weakness of this study. Further, patients‟ 
warfarin therapeutic level was not assessed from blood on the day of the EVLA treatment but 
checked from the warfarin yellow book. This may potentially be another weakness of this study.  
 
The results of this study show that EVLA is effective in most patients who continue to take 
warfarin throughout the treatment period.  Although there were more treatment failures in these 
patients it seems likely that sub-optimal laser energy delivery at least contributed to this in most 
instances. Nevertheless it is probable that warfarin therapy also contributed to these failures and 
thus it is reasonable to conclude that a laser energy density of ≥60J/cm is required in these 
patients.  Conversely, the temptation to use significantly higher energy densities in patients 
taking warfarin should probably be avoided since this is likely to be associated with a greater 
frequency of vein wall perforation and bruising. This did not seem to be the case in the present 
study delivering a median energy density of 64J/cm. Although the extent of bruising was not 
quantified patient satisfaction was no different to that in patients who were not on warfarin. 
 
Even if warfarin therapy was the primary reason for these treatment failures successful ablation 
occurred in the majority of patients thus justifying both the adoption of this technique in these 
patients and the continuation of anticoagulant therapy. Further, all 4 failures subsequently 
underwent successful re-do EVLA. 
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A diode laser of 810 nm wavelength produces temperatures above 700 
0
C at the tip of the laser 
fibre (Weiss et al., 2002). Nevertheless the temperature recorded 3mm from the vein wall
 
in the 
surrounding tumescent anaesthesia is only 43 
0
C (Beale et al., 2006).  It is therefore clear that 
the vein wall absorbs a significant proportion of the thermal energy that is delivered. Although 
Probstle et al suggested that heat conduction from the laser fibre to the vein wall is the result of 
steam bubble formation in blood  (Proebstle  et al., 2002), a more recent study suggests that 
direct contact between the fibre and the vein is the most likely mechanism of action
 
(Fan et al., 
2008). These high temperatures result in a range of injuries to the vein including denaturation of 
protein, tissue desiccation, necrosis, and possibly carbonisation with charring depending on the 
temperature to which it exposed. (Goldman, 1991; Fan et al., 2008). This type of transmural 
damage results in a progressive fibrosis and permanent occlusion of the vein rather than a 
temporary thrombotic occlusion (Proebstle et al., 2002; Fan et al., 2008) and previous studies 
have provided ultrasound-based evidence for this (Weiss et al., 2002). Data from the present 
study confirms that these same changes occur in patients who undergo EVLA whilst taking 
warfarin (figure 3.1). Thus anticoagulants do not appear to interfere with the process of fibrotic 
occlusion following EVLA.  
 
It might be argued that foam sclerotherapy would be a satisfactory alternative to surgery and 
EVLA in patients taking warfarin. However a recent study suggests that this technique only 
results in patchy endothelial damage and minimal subendothelial injury (Ikponmwosa et al., 
2008). Thus thrombotic occlusion is likely to be a major component of its (initial) success and 
anticoagulants could prevent this. Further studies are required to assess the impact of warfarin 
on the efficacy of foam sclerotherapy. 
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Figure 3.1: Sequential ultrasound appearance of GSV in a patient from the “warfarin 
group” after successful EVLA. These changes are identical to those occurring in patients 
who are not anticoagulated (Figure 4.1)  
A): GSV pre-EVLA (9.2 mm, hypo-echoic, compressible) 
B): GSV 6 weeks post-EVLA (8.5 mm, hypo-echoic, non-compressible, vein occluded). Note 
that this is a more magnified view than the pre-operative image. 
C): GSV 12 weeks post-EVLA (3.6 mm, iso-echoic, not compressible, vein ablated) 
D): GSV 1 year post-EVLA (non-visible - arrow shows empty saphenous space) 
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Given that EVLA appears an effective therapy for superficial venous incompetence in patients 
taking warfarin the risks of conventional surgery and the longer hospital stay associated with 
this in anticoagulated patients can be avoided. This will inevitably improve the cost 
effectiveness of treatment in these patients. Further, since patients who are taking warfarin are 
generally older and less fit than the majority of those requesting treatment for varicose veins the 
risks of intervention should be reduced. This may be particularly important given that these 
patients are more likely to require treatment for complications of their venous disease. That this 
is the case is reflected by a relatively high proportion of patients classified as C3-C6 in this 
study.   
 
In conclusion, EVLA in patients who continue to take warfarin is safe and effective.  Although 
warfarin can be continued during EVLA, adequate laser energy density or fluence should be 
administered to ensure a satisfactory outcome.  
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Chapter 4: 
4. Structural changes and haemodynamic impact after EVLA  
 
Using the standard technique for GSV EVLA the vein is ablated from 1cm distal to the SFJ to 
the level of knee leaving the below-knee GSV intact. This mirrors the current technique for 
GSV stripping during conventional surgery which is aimed at reducing the risk of saphenous 
nerve injury. However, unlike surgery, EVLA does not specifically treat the GSV tributaries at 
the SFJ and concomitant treatment of the superficial varicosities is not undertaken when 
following the original description of the technique. This chapter assesses the impact of EVLA 
on the following: 
 
1)  What happens to the ablated GSV?  
2) What happens to the SFJ tributaries? 
3) What happens to the distal (below-knee) GSV? 
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4.1 What happens to the ablated GSV?  
4.1.1 Introduction 
The majority [70%] (Labropoulos et al., 1994)
 
of varicose veins are the result of SFJ and GSV 
incompetence. Although EVLA is initially effective (88-100%) in ablating the GSV, (Min et al., 
2001; Min et al., 2003; Mundy et al., 2005) critics of the technique suggested that it induced 
thrombotic occlusion of the vein and was thus likely to be associated with a significant risk of 
re-canalisation rather than permanent occlusion. Further it was suggested that re-canalisation 
would result in a loss of any therapeutic benefit. This observational cohort study has 
investigated these two issues. 
 
4.1.2 Methods 
Patients 
Seventy-three consecutive patients (84 limbs) underwent above-knee GSV EVLA for primary 
varicose veins due to SFJ/GSV reflux between March 2005 and November 2005 and completed 
1 year follow up (Group A). A further group of 27 patients (Group B) with re-canalisation of a 
previously treated GSV were identified from a prospectively maintained database of patients 
undergoing EVLA during the previous 3 years. Group A assessed the current frequency of re-
canalisation in our centre and acted as a control group for comparison with group B, all of 
whom had a re-canalised GSV.  
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Data collection 
Pre-treatment disease severity was assessed using the CEAP classification, AVVS scores and 
VCSS. The maximum GSV diameter was measured whilst standing. All patients underwent 
EVLA using the stepwise withdrawal technique (810nm diode laser, 12W power) described 
earlier. The vein was ablated from the groin (SFJ) to the level of the knee. Following EVLA a 
duplex ultrasound scan (TITAN®, Sonosite Inc, Bothell, USA, 5-10 MHz linear probe) was 
performed at 6, 12 and 52 weeks to assess echogenicity, compressibility, diameter and flow 
status of the treated GSV. Absence of flow in a non-compressible vein or a non-visible GSV 
represented successful ablation. Re-canalisation was considered to have occurred when either 
antegrade or retrograde blood flow was observed in a compressible vein (segmental or full 
length). Compressibility and flow in the femoral and popliteal veins was assessed at each visit 
to exclude a deep vein thrombosis. The calf veins were not scanned unless the patient reported 
possible symptoms of a DVT. Foam sclerotherapy was used to treat any residual varicosities in 
the study limbs at 6 week follow up. AVVS and VCSS were reassessed at 1 year and clinical 
recurrence of varicose veins documented. All data were recorded prospectively in both groups 
of patients. For the purpose of disease severity comparison, patients with a re-canalised GSV in 
group A were analysed with group B in order to fully assess the impact of successful ablation.  
 
Statistical analysis 
Symptom improvement (AVVS, VCSS) was assessed using a Wilcoxon paired test within each 
group. Comparison between groups was performed using a Mann-Whitney U test and a student-
t test employed to assess the metric data (vein diameter).  All data are presented as median 
(±inter-quartile range) or as mean ±standard deviation. All analyses were performed using 
SPSS® for Windows (SPSS, Chicago, Illinois, USA).   
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4.1.3 Results 
Demographic data, the CEAP grading for the study limbs and the pre-treatment GSV diameters 
are shown in table 4.1.  There was no difference in the maximum pre-treatment diameters in 
patients with an occluded or re-canalised vein. The treated length of vein was similar in both 
groups: 33±8cm in group A and 31±6cm in group B (table 4.2). 
 
 
Characteristics Group A              (%) Group B                (%) 
Male 31                         (42%) 10                          (37%) 
Female 42                         (58%) 17                          (63%) 
Age, median (range) 50 (26-76) years 51 (33-72) years 
Number of limbs studied 84 27 
CEAP-C2  46                       (54.8%) 18                         (66.6%) 
           C3 11                      (13.1%) 4                           (14.8%) 
           C4 19                      (22.6%) 3                           (11.1%) 
           C5 6                         (7.1%) 2                            (7.4%) 
           C6 2                         (2.4%) 0 
Table 4.1: Patients demographic details and the CEAP classification before EVLA 
 
 
 Group A Group B p 
Diameter of the vein (mm) 7.7±2.0 7.9±1.6 0.23 
Length of vein treated (cm) 33±8 31±6 0.34 
Table 4.2:  Comparison of pre-treatment diameter of the vein and the length of vein 
treated between groups 
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Group A 
The length of vein ablated was 33±8cm and the GSV was occluded in all 84 limbs (no flow, 
non-compressible vein) at 6 weeks. Subsequently 3/84 (3.5%) veins showed evidence of re-
canalisation without significant reflux at 12 weeks. These veins remained patent with only flash 
reflux (<1s) at one year with no evidence of recurrent varicosities. There were no new instances 
of re-canalisation after 3 months. None of the post-EVLA scans showed any signs of deep vein 
thrombosis. In all patients the GSV diameter became progressively smaller during follow-up 
(table 3), with 70/82 (85%) being non-visible at 12 months. In 9 limbs a small (≈2mm diameter) 
iso-echoic or hyper-echoic nidus remained visible within the saphenous space without a 
demonstrable lumen or flow. These veins were considered to be occluded. The ultrasound 
findings are summarised in table 4.3. Limbs in group A received a median of 66 (55-74) J/cm 
laser energy. 
 
DUS findings Pre-treatment 
 
(N=84) 
6 weeks  
 
(n=84) 
12 weeks 
 
(n=84) 
1 year  
 
(n=82) 
Diameter 7.7 ±2.0  5.1±1.3 
 
*P<0.01 
3.2±1.2 
 
**P<0.01 
2.6±0.7  
 
(for the visible 
veins, n=12) 
Hypo-echoic GSV 84    (100%) 62      (73.8%)  
 
 12   (14.2%)  
 
 
0 
Iso-echoic  
GSV 
0 19      (22.6%)  
 
 
60   (71.4%)  
 
 
5          (6%) 
Hyper-echoic 
GSV 
0 3          (3.6%)  
 
 
9     (10.7%)  
 
4       (4.7%) 
 
 
GSV non-visible 0 0 0 70   (85.4%) 
 
GSV 
re-canalisation 
N/A 0 3       (3.6%) 
 
 
3      (3.7 %)  
 
Table 4.3: Comparison of the ultrasound findings of the treated segment of GSV before 
and after EVLA in group A 
  *  pre-EVLA versus 6 weeks 
** 6 weeks versus 12 weeks  
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Group B 
Of the 27 patients in group B (31±6cm vein ablated), 3 had significant GSV reflux (>1s) and 
persisting varicosities on their 6 weeks post-EVLA scan suggesting primary treatment failure. 
All were successfully re-treated with EVLA. Although 1 patient was taking warfarin and 
another had removed the compression bandage early, all had received low dose laser energy (44, 
48, 38 J/cm) during treatment. The median laser energy for group B as a whole was 42 (37-55) 
J/cm. Primary failure of EVLA is suggested by the persisting large diameter (5.2, 6.4, 7.3 mm) 
of the GSV at 6 weeks compared to that of the other patients in group B who did not require re-
treatment (3.0±0.5mm), including 6 patients with patent, small diameter veins and no or flash 
reflux at 6 weeks. The remaining 18 patients who received  44 (39-55) J/cm laser energy, had 
evidence of re-canalisation at 12 weeks following a satisfactory 6 week scan. During subsequent 
follow up these GSVs remained unchanged in size (2.9±0.8 at 12 weeks v 3.0 ±0.7 at 1-year; 
p=0.33) with no clinical evidence of recurrent varicosities. Finally, of 16/24 patients in group B 
who did not undergo repeat EVLA, DUS showed no reflux at 52 weeks (group BNR) whilst 8 
(group BTR) had evidence of trickle reflux (reflux >1s but only detectable on low-gain settings). 
The AVVS improved from 13.4 (8.2-19.4) to 2.5 (0.7-3.6), p<0.001 in group BNR and from 14.8 
(6.3-17.5) to 4.2 (2.2-8.1), p<0.001 in group BTR. In both groups the GSV was significantly 
smaller at 1 year than before treatment (BNR: 7.3±2.5mm v 3.1±0.8mm [p=0.006]; BTR: 
7.2±2.3mm v 3.0±0.7mm [p=0.009]). 
 
Comparison of successful ablation and re-canalisation 
At 1 year, the AVVS score improved from 15.1 (7.3-21.2) to 2.4 (1.1-4.2), p<0.001 and the 
VCSS from 4 (2-6) to 0 (0-2), p<0.05 in patients who had successful GSV ablation. Similar 
improvements were recorded in patients with GSV re-canalisation, excluding the 3 primary 
treatment failures: [AVVS: 14.2 (7.4-18.1) v 3.3 (2.1-5.5), p<0.001 and VCSS: 4 (2-5) v 0 (0-
2), p<0.05)]. There was no difference in the percentage improvement in the AVVS score 
between the groups (group A: 82.4% (60.1-98.2) v group B: 78.2% (55.3-92.3), p=0.24).   
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4.1.4 Discussion 
Laser energy causes thermal injury to the endothelial and sub-endothelial layers of the treated 
vein leading to fibro-thrombosis (Proebstle et al., 2002 a; Proebstle et al., 2002b) of the vein. 
The relative lack of fibrosis during the initial post-treatment period results in the typical hypo-
echoic appearance on ultrasound, similar to that of an acute thrombosis. With increasing fibrous 
tissue formation over time, the ablated GSV becomes iso-echoic or sometimes hyper-echoic 
before becoming non-visible by 1 year (Figure 4.1).  Progressive development of fibrosis and 
contraction explains the gradual diminution in vein diameter following treatment. Further, re-
canalisation of the GSV did not occur >3 months after EVLA, a finding confirmed by others 
(Min et al., 2003). 
 
The results of this study suggest that when GSV re-canalisation occurs 6-12 weeks after 
treatment it is accompanied by vein shrinkage and continuing symptom relief, at least in the 
short term.  Thus the symptomatic improvement was maintained at 1 year. Nevertheless longer 
follow-up is required to determine whether recurrent varicosities or symptoms subsequently 
develop.  
 
Interestingly conversion of a large diameter GSV to a small, competent vein was the original 
aim of the radiofrequency RESTORE
TM
 system (VNUS Medical Technologies, Inc, Sunnyvale, 
California) which was subsequently replaced by the CLOSURE device which aims to ablate the 
GSV permanently. Unlike the present data for group B, both symptoms and varicosities recurred 
in most patients following treatment with RESTORE (Manfrini et al., 2000). 
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Figure 4.1: Ultrasound appearance of GSV after successful EVLA showing changes over 
time 
A: GSV before EVLA (8.6 mm, hypo-echoic, compressible) 
B: GSV 6 weeks after EVLA (7.8 mm, hypo-echoic, non-compressible: vein occluded) 
C: GSV 12 weeks after EVLA (2.2 mm, iso-echoic, not compressible: vein ablated) 
D: GSV invisible 1 year after EVLA (arrow shows empty saphenous space) 
 
 
 
A 
D C 
B 
Pre-EVLA 6-weeks 
12-weeks 1-year 
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In 3/27 group B patients the GSV diameter remained unchanged from the pre-treatment value 
with significant reflux at the first follow up visit (6 weeks). It seems likely that these patients 
represent primary treatment failures. Such a conclusion is based on the low laser energy used in 
these patients, 2 of whom also had other possible reasons for non occlusion (warfarin, early 
removal of compression bandage). It is also possible that these veins had been temporarily 
occluded but underwent early thrombus dissolution allowing preservation of the pre-treatment 
vein diameter. Regardless of the cause of these early failures further treatment (repeat EVLA or 
surgery) is likely to be required for this small subgroup.  Whilst other authors (Labropoulos et 
al., 2006) have suggested the use of ultrasound guided foam sclerotherapy following GSV re-
canalisation this technique was not used in patients with a primary treatment failure because of 
the relatively high risk of further re-canalisation with this technique (Belcaro et al., 2003). 
Nevertheless it may have a role in patients with segmental re-canalisation. Although one of 
these patients was taking warfarin experience in other patients does not suggest that this, or 
antiplatelet drugs need to be discontinued prior to EVLA provided that >60J/cm energy is 
delivered to the vein (Chapter 3).  
 
The mechanism for re-canalisation between 6-12 weeks (the majority of “failures”) is also open 
to debate. Whilst thrombus dissolution is considered the most important factor intra-luminal 
neovascularisation may also play a role (Labropoulos et al., 2006). If this occurs it is believed 
that a patent vaso vasorum of the target vein continues to supply blood to the fibrothrombus in 
the vein lumen bringing growth factors that promote new vessel formation. Such 
neovascularisation may communicate with the patent vaso vasorum forming an intra-luminal 
arterio-venous fistula. Regardless of the mechanism re-canalised veins show evidence of a 
significant diameter reduction (Figure 4.2), with no or trickle reflux and resolution of 
symptoms. These patients do not require further treatment, at least within the first year. Further 
follow up of these patients is required to determine the medium / long term prognosis.  
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Figure 4.2: Ultrasound appearance of a re-canalised GSV at 3-months. Note the re-
canalised GSV is small (2.5mm) compared to its pre-EVLA size (5.9mm) 
 
In conclusion, the GSV diameter diminishes over a period of months following EVLA and most 
successfully ablated veins (85%) are not visible by 1 year. Using current treatment parameters 
(≥60J/cm laser energy) GSV re-canalisation is uncommon (4%) and occurs within 3 months of 
treatment. In most cases re-canalisation does not lead to clinical recurrence or return of 
symptoms and does not require further intervention. In patients with early re-canalisation 
(primary treatment failure) repeat EVLA has proved successful. 
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4.2 Fate of GSV tributaries at the saphenofemoral junction 
 
4.2.1 Introduction 
The role of EVLA in the management of varicose veins secondary to SFJ and GSV reflux has 
already been discussed. One potentially important difference between this (and other minimally 
invasive therapies for varicose veins) and conventional surgical treatment is that the latter 
generally includes ligation of all SFJ/GSV tributaries in the groin in addition to GSV stripping 
and multiple avulsions. Since non-ligation of these tributaries is suggested as one of the causes 
of recurrent varicosities after surgery (Rivlin, 1975; Campbell, 1990; Redwood et al., 1994; 
Sarin et al., 1994) critics of EVLA have suggested that the durability of the technique might be 
compromised by failing to interrupt these veins. The fate of the untreated SFJ/GSV tributaries 
and their clinical significance following EVLA has therefore been investigated in this study.  
 
4.2.2 Patients and Methods 
Preliminary-study 
Prior to undertaking this study, our ability to identify first generation SFJ/GSV tributaries using 
a portable high resolution duplex ultrasound scanner (TITAN®, Sonosite Inc, Bothell, USA) 
was assessed. 
  
Twenty-four SFJs in 20 patients aged 33-61 years (12 females and 8 males) undergoing primary 
sapheno-femoral ligation were scanned (DUS). The number and configuration of first 
generation GSV tributaries within 5cm of the SFJ were drawn on a diagram. The diagrams were 
compared with the operative findings recorded on a similar diagram that was completed by a 
consultant vascular surgeon performing surgery.  Only tributaries requiring ligation, rather than 
diathermy, were included. 
107 
 
   
Analysis of the DUS accuracy 
A scoring system was developed to grade the accuracy of the DUS findings. On the operative 
drawing, which was considered the gold standard, each tributary requiring ligation was given a 
score of 2. Thus the maximum score was the number of the GSV tributaries X 2. The DUS 
drawing was then scored giving one point for identification of a tributary and another for 
determining its correct configuration. The maximum DUS score therefore equalled the operative 
score only if all the tributaries and their correct configurations were identified. The sensitivity 
was calculated as the total DUS score X 100%/ total maximum (operative) score.  
 
Main study 
Patients 
Seventy patients who underwent GSV EVLA to treat primary symptomatic varicose veins due 
to isolated SFJ/GSV reflux between January 2005 and October 2005 were reassessed at one 
year. Patients who had reflux in more than one truncal vein who underwent EVLA, and those 
who had treatment for recurrent varicose veins were excluded from the study. Demographic 
details and the clinical severity of the varicosities are shown in table 4.4. 
 
Demographic data Number (%) 
Male 28 (40%) 
Female 42 (60%) 
Age, median (range) 49 (29-72) years 
Number of Limbs studied 81 
CEAP: C2 (Symptomatic) 42 (52%) 
            C3 12 (15%) 
            C4 19 (23%) 
            C5 6 (7.5%) 
            C6 2 (2.5%) 
Table 4.4: Patient demographic details and their CEAP classification 
108 
 
   
Data collection 
In addition to the usual clinical assessments, pre-EVLA symptom severity was assessed using 
AVVS scores and VCSS. Data were recorded prospectively. Following EVLA, patients 
underwent serial duplex ultrasound assessment (TITAN®, Sonosite Inc, Bothell, USA, 5-10 
MHz linear probe) of the GSV, the SFJ and the deep veins at 6, 12 and 26 weeks.   
 
At 1 year follow up the limbs were examined to identify any residual or recurrent varicose 
veins, and the AVVS and VCSS re-assessed.  Further, a detailed DUS was conducted to assess 
the SFJ and any tributaries. The GSV was examined from the knee (site of cannulation) to the 
SFJ and if visible checked for compressibility and flow status. Non visibility of the GSV or non-
compressibility with absent flow in a visible GSV represented successful ablation. Careful DUS 
assessment of the SFJ was conducted by holding the probe longitudinally, horizontally and at 
different angles to identify any patent tributaries. The reflux status in these tributaries and the 
SFJ were assessed using colour flow. Patient satisfaction with the results of treatment was 
recorded using a visual analogue scale. 
 
Statistical analysis 
The changes in AVVS and VCSS after laser ablation were compared using a Wilcoxon test.  
Patients‟ satisfaction scores were compared using a two tailed unpaired student t-test. A “p” 
value of <0.05 was considered statistically significant.   
Data are presented as median (± inter-quartile range) unless otherwise stated.  All analyses were 
performed using the statistical package SPSS® for Windows, version 12 (SPSS, Chicago, 
Illinois, USA).   
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4.2.3 Results 
Results of the preliminary study 
In all patients DUS (TITAN®, Sonosite Inc, Bothell, USA) identified at least 2 first generation 
tributaries (Table 4.5). The overall score for DUS was 108 points compared to a maximum 
score of 122 points. The presence of 2 first generation tributaries was correctly identified in all 
limbs. When more tributaries were present it was more difficult to identify them all. However, 
the overall accuracy in identifying first generation tributaries of the GSV/SFJ was 88.5%.  
 
 
No. 1
st
 generation 
tributaries 
Operative findings     
(No. limbs) 
No. limbs with 
correct DUS 
findings  
No. with inaccurate 
DUS findings  
(No. tributaries 
identified) 
 
2 
 
 
14 
 
14 
 
none 
 
3 
 
 
7 
 
4 
 
   3 (2,2,2) 
 
4 
 
3 
 
1 
 
2 (2,2) 
 
Table 4.5: The number of tributaries identified by DUS compared to operative findings 
 
Results of the main study 
At 1 year the treated segment of GSV was non visible on DUS in 77/81 (95%) limbs, iso-echoic 
(occluded) in 2/81 (2.5%) limbs and was patent in 2/81 (2.5%) limbs. There was no significant 
reflux in the 2 re-canalised GSVs, one of which was competent whilst the other demonstrated 
flash reflux (<1s). Thus 79/81 (98%) treated GSVs were successfully ablated resulting in a 
competent SFJ. None of the post-treatment duplex scans showed evidence of deep vein 
thrombosis. One or more patent tributaries were seen in continuity with the SFJ in 48/81 (59%) 
limbs - Group A. None of these tributaries demonstrated reflux. In 32/81 (40%) limbs (Group 
B) there was flush occlusion of the GSV with the SFJ and no tributaries were identified in 
110 
 
   
continuity with it. There was evidence of neovascularisation (with reflux) at the SFJ in one 
limb. In both patients who had a re-canalised GSV patent non-refluxing tributaries were 
identified.  
 
 
Figure 4.3: Box-plot graph comparing the pre-treatment & 1 year post-EVLA AVVS in 
patients with patent GSV/SFJ tributaries (Group A) and patients with no visible 
tributaries (Group B)  
 
The AVVS were similar in both groups (Figure 4.3): Group A: pre-EVLA 13.9 (7.6-19.2), 1 
year-follow-up 2.9 (0.6-4.8), p<0.001; Group B: pre-EVLA 14.9 (9.2-20.2), 1 year follow-up 
3.1 (0.8-5.1), p<0.001, and there was no significant difference in the improvement in AVVS 
between the groups [Group A 9.8 (5.8-13.2); Group B 9.6 (6.1-13.6), p=0.27; Figure 4.4]. 
Similarly, VCSS confirmed that the treatment effect was the same regardless of the presence of 
A  B Groups 
0 
5 
10 
15 
20 
25 
30 
AVVS 
  
     P<0.001             P <0.001 
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patent tributaries [Group A: pre-EVLA 4 (2-5), follow-up 0 (0-3), p<0.01; Group B: pre-EVLA 
4 (2-6), follow-up 0 (0-3), p<0.01; Pre-post reduction in score: Group A 4 (1-5), Group B 4 (1-
6), p=0.36].  
 
Figure 4.4: Improvements in AVVS in patients with patent GSV/SFJ tributaries (Group 
A) and in patients with no visible tributaries (Group B) 
 
80/81 (99%) limbs had no residual or recurrent varicosities. In one limb, with no visible SFJ 
tributaries recurrence had developed due to an incompetent mid thigh perforator. Patient 
satisfaction was similar in both groups: Group A 92% and Group B 93% (p=0.31).  
  
Groups 
 A   B 
0 
5 
10 
15 
20 
AVVS 
Change 
p=0.27 
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4.2.4 Discussion 
Ultrasound is operator dependant and detecting GSV tributaries at the SFJ may be difficult. 
However, comparison with surgical findings has shown that high resolution DUS can be used to 
identify these with an acceptably high sensitivity. Although defining the precise anatomy of a 
complex junction may be a challenge, two or more tributaries were identified in all patients.  
EVLA was very effective in ablating the GSV resulting in a competent SFJ in all patients.  
Further, in 40% of the treated limbs, there was flush ablation with the femoral vein leaving no 
tributaries in continuity with the SFJ. Although, one or more tributaries were seen in continuity 
with SFJ in the remainder, these tributaries were all competent. Symptom improvement or 
recurrence was not influenced by the presence of patent tributaries that were in continuity with 
SFJ.   
 
Reflux from an incompetent SFJ may be distributed into the GSV and/or one of the other main 
tributaries such as the anterior accessory great saphenous vein (AAGSV). Reflux into more than 
one tributary is uncommon. Although there is little published data about this our experience of 
screening patients as to their suitability for EVLA suggests that it occurs in <5% patients. 
During the treatment of varicose veins all of the tributaries of the SFJ or proximal GSV that 
demonstrate reflux require ablation in order to achieve a successful outcome, and this concept is 
as important when endovenous treatments are performed as it is when surgery is undertaken. At 
operation, it is generally believed that the competent tributaries of the proximal GSV should 
also be ligated to reduce the risk of recurrence. However some authors argue that ligation of 
competent tributaries is unnecessary and it may promote neo-vascularisation (Chandler et al., 
2000). 
 
During EVLA, only the main trunk that has reflux, commonly the GSV is treated with no 
specific attempt being made to treat other tributaries. However, when the tip of the laser fibre is 
positioned 0.5-1.0cm from the SFJ (Min et al., 2001) the proximal extent of ablation may be 
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influenced by several factors.  These include the anatomical configuration of the tributaries, the 
quantum of laser energy delivered and the efficacy of post-EVLA compression.  
 
The initial concept of EVLA was that vein wall injury, leading to occlusion, was the result of 
heat transmission to the vessel by blood (Proebstle et al., 2002a). Distal to the groin this seems 
unlikely because of vein spasm around the catheter, venous compression (both manual and from 
tumescent anaesthesia) and because patients are treated in the Trendelenburg position. However, 
at the proximal end of the GSV it is more likely that some blood remains within the lumen and 
conducts thermal energy more proximally. This is a potential mechanism for flush occlusion of 
the GSV and occlusion of the tributaries (Figure 4.5). Support for such a mechanism is 
suggested by the ultrasound visualisation of steam bubbles in the proximal GSV during EVLA 
(Figure 4.6).  
 
                                Patent tributary 
                                     
 
 
 
                                      Ablated GSV 
 
 
 
                                Ablated GSV & tributary 
 
Figure 4.5: Non-flush and flush laser ablation of GSV  
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Figure 4.6: Ultrasonic appearance of steam bubbles in the proximal GSV during EVLA   
 
 
That flush occlusion of the GSV does not occur in all patients presumably reflects variable 
transfer of heat into the proximal GSV. It may also be related to the efficacy of post-operative 
compression bandaging although it is unlikely that this is particularly effective in the groin, 
even in patients in whom flush ablation is achieved.  
 
The results of this study indicate that the GSV/SFJ tributaries at the groin may or may not be 
ablated following EVLA. If they remain patent reflux into an untreated tributary (AAGSV, 
duplex saphenous system) is possible and could lead to recurrent varicose veins (Figure 4.7) but 
this seems rare.   
  
Tip of laser fibre in GSV 
SFJ 
Spreading steam bubbles 
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        Incompetent SFJ with GSV reflux                           Incompetent SFJ with AAGSV reflux 
 
Figure 4.7: Possible para-reflux following ablation of GSV that had reflux 
 
In summary this study does not suggest that leaving non-refluxing tributaries in the sapheno-
femoral junction is detrimental to the patient. At one-year follow up clinical examination for 
recurrence, the improvement in AVVS or VCSS scores and the degree of patient satisfaction 
were the same regardless of tributary patency. In one patient with recurrent varicosities this was 
the result of an incompetent thigh perforator. In addition only 1/81 limbs showed evidence of 
neo-vascularisation which is believed to be the commonest cause of recurrence following 
surgery (Jones et al., 1996; van Rij et al., 2004).  
  
SFJ 
FV 
AAGSV 
GSV reflux 
Ablated GSV 
AAGSV reflux 
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4.3 Fate of untreated below-knee GSV 
 
4.3.1 Introduction 
The original technique for EVLA as described by Min et al. comprised treatment of the above-
knee GSV [AK-GSV] (Min et al., 2001), thus mimicking stripping of the AK-GSV during 
surgery. The subsequent reflux status of the below-knee GSV (BK-GSV) and its clinical 
significance following proximal GSV ablation have not been assessed previously and this issue 
has been addressed in this study.  
 
4.3.2 Methods 
Patients 
All patients attending the venous clinic at The General Infirmary at Leeds between March 2005-
Deceber 2005 following standard endovenous laser ablation of the AK-GSV for varicose veins 
due to SFJ/GSV reflux were included in the study. Sixty nine limbs in 64 consecutive patients 
(24 males, 40 females; median age 51 [IQR 40-61]) with diverse disease severity (C2:40, C3:9, 
C4:10, C5:7 and C6:3) were studied.   
 
Data collection and Follow-up 
Before treatment patients were assessed clinically and the AVVS score measured. Standard 
EVLA of the AK-GSV was performed using an 810 nm diode laser under tumescent anaesthesia 
as an out-patient procedure as described in Chapter 2
. 
 Patients were reviewed at 6 weeks to 
assess the presence of residual varicosities which were treated with foam sclerotherapy if 
required. A duplex ultrasound scan (DUS) was performed at 6 and 12 weeks to confirm ablation 
or otherwise of the AK-GSV. Absence of flow in a non-compressible vein represented 
successful ablation. In addition the patency and reflux status of the BK-GSV (knee-ankle) were 
determined. Limbs were allocated to one of 3 groups depending on the findings: group A: no 
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reflux; group B: flash reflux <1s duration; group C: significant reflux >1s. The AVVS was re-
measured at 6 weeks.  
 
Statistical analysis 
The AVVS scores before and after laser ablation were compared within a group using a 
Wilcoxon test. The improvement in AVVS between groups was compared by a Mann-Whitney 
U test. Sclerotherapy requirements were compared between groups using a Fisher‟s exact  test. 
A p value of <0.05 was considered significant. Data are presented as median (±inter-quartile 
range) unless stated otherwise.  All analysis were performed by the statistical package SPSS® 
for Windows (SPSS (14), Chicago, Illinois, USA). 
 
4.3.3 Results 
Complete occlusion of the treated length of AK-GSV and SFJ competence were confirmed in 
all (69/69) limbs. Conversely, the distal untreated BK-GSV was compressible and patent in all 
limbs (69/69). Of these 34/69 (49%) had normal forward flow without reflux (Group A), 7/69 
(10%) had flash reflux (Group B), and 28/69 (41%) had significant (>1s) reflux (Group C) in 
the untreated BK-GSV (Figure 4.8). No incompetent calf perforators were identified in these 
patients. All three groups showed a significant improvement in AVVS at 6 weeks, Group A: 
14.6 (8.4-19-3) v 2.8 (0.5-4.4), Group B: 13.9 (7.5-20.1) v 3.7 (2.1-6.8), group C: 15.1 (8.9-
22.5) v 8.1 (5.3-12.6); p<0.001 for all three groups. Percentage improvement in AVVS was 
86.2%, 82.1% and 59.1% in groups A, B and C respectively (Figure 4.9). The improvement in 
AVVS was significantly (p<0.001) lower in group C compared to the other two groups. 
 
 
Delayed foam sclerotherapy was required in 44% (30/69) of treated limbs. In group C this was 
necessary in 25/28 (89%) patients compared to 4/34 (12%) in group A and 1/7 (14%) in group 
B. The sclerotherapy requirement for group C was significantly higher than that for groups A 
and B (p<0.001).  
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Knee level 
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No reflux (49%) 
 
Flash reflux (10%) 
 
Significant reflux (41%) 
 
Figure 4.8: Reflux status of the patent below-knee GSV after above knee laser ablation 
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Figure 4.9: Percentage improvement in AVVS scores for groups A, B and C  
(* p<0.001 versus groups A and B) 
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4.3.4 Discussion 
The original concept of EVLA, as described by Min et al was that laser ablation of the AK-GSV 
would eliminate sapheno-femoral and GSV reflux in the same way as sapheno-femoral ligation 
and GSV stripping during conventional varicose vein surgery. Following EVLA the BK-GSV 
remains patent in most patients. Rarely, it may become occluded secondary to thrombophlebitis. 
Thus, in the majority of patients blood from the BK-GSV will drain into the deep veins via calf 
perforators or other competent tributaries. Persisting reflux in the BK-GSV will occur in the 
presence of incompetent perforating veins in the proximal calf, although this was not evident in 
any of the patients included in this study. Duplex scanning however showed that in patients with 
persisting BK-GSV reflux a patent tributary was in continuity with the untreated GSV and that 
ante-grade flow in this tributary appeared to promote continuing GSV reflux (Figure 4.10).  
 
Varicosities arising from the GSV may have several communications. Following ablation of the 
AK-GSV all the varicosities that are directly connected to this segment of vein tend to diminish 
in size, and may disappear. In contrast, varicosities that are in direct continuity with an 
incompetent BK-GSV will continue to receive blood from this and will persist following 
successful ablation of the proximal AK-GSV. Although, surgical phlebectomy or foam 
sclerotherapy will obliterate these residual varicosities it is logical to assume that the 
requirement for additional treatment may be reduced if the incompetent GSV from the SFJ to 
the lowermost point of reflux is ablated. 
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                      FV 
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                                                                                            probably maintain the reflux in  
                                                                                             BK-GSV  
 
 
 
 
Figure 4.10: The potential mechanism for persisting BK-GSV reflux following successful 
EVLA of the AK-GSV 
 
Some 44% of limbs in this study required delayed sclerotherapy for residual varicosities after 
laser ablation of the AK-GSV. The majority of these patients had persistent reflux in the BK-
GSV in whom 89% underwent delayed foam sclerotherapy. The optimum treatment for residual 
varicosities after EVLA has been debated with both delayed sclerotherapy and concomitant 
phlebectomies (Mekako et al., 2007) having their proponents. The latter policy, even on the 
basis of the results presented here would mean that 56% of the whole group would undergo 
unnecessary phlebectomy, as well as requiring the use of an operating theatre for their 
treatment, thus increasing treatment cost. Abolition of reflux throughout the incompetent GSV 
should significantly reduce the need for adjuvant therapy for the superficial varicosities.   
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The results of this study confirm that ablation of AK-GSV results in symptom improvement 
regardless of the reflux status of the BK-GSV, although the benefit was significantly reduced in 
the presence of persistent BK-GSV reflux. This finding is not entirely surprising since previous 
studies have shown that the anatomic extent of reflux correlates with the symptoms and signs of 
venous disease (Labropoulos
 
et al., 1996). Further, a recent study has shown that persisting BK-
GSV is responsible for symptoms following surgical stripping of the AK-GSV (van Neer et al., 
2006). This lends further support to the concept that ablation of a longer length of an 
incompetent truncal vein might result in a better clinical outcome.  
 
Although these results suggest that persistent reflux in the BK-GSV is responsible for residual 
symptoms and more residual varicosities, it is not possible to comment upon the pre-treatment 
reflux status of the below-knee GSV since this was not recorded. Nevertheless, it is tempting to 
suggest that ablation of the BK-GSV, when reflux is present prior to EVLA, will provide 
improved symptom relief and reduce the requirement of subsequent sclerotherapy.  
 
Minimally invasive options for ablation of an incompetent BK-GSV include EVLA and 
ultrasound guided foam sclerotherapy. Although laser ablation might be associated with the risk 
of thermal injury to the saphenous nerve below the knee this seems unlikely on the basis of 
previous temperature studies (Beale et al., 2006) and the safe use of laser therapy for small 
saphenous vein ablation in the popliteal fossa (Proebstle et al., 2003). 
 
In conclusion, the presence of persisting reflux in the below-knee GSV appears responsible for 
both persisting symptoms of venous disease and residual varicosities following AK- GSV 
EVLA. Ablation of the below-knee GSV at the initial treatment may prove more effective in 
both respects and further studies are required to assess this hypothesis.  
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Chapter 5: 
 
5. Randomised controlled trial: Does standard above-knee great 
saphenous vein EVLA provide optimum results in patients with 
both above and below-knee reflux?   
 
5.1 Introduction: 
The data presented in Chapter 4 showed that 44% patients required treatment for residual 
varicosities after routine AK-GSV EVLA. Further, symptom relief was less and the requirement 
for delayed sclerotherapy was greatest when there was persistent reflux in the BK-GSV.  It 
therefore seemed logical to perform a randomised controlled trial to compare the efficacy of two 
different techniques for correcting both above and below-knee GSV reflux against the standard 
above-knee EVLA technique. The hypothesis for the study was that ablation of a longer 
segment of incompetent GSV would reduce the requirement for treating residual varicosities 
and provide additional symptom improvement.  
 
5.2 Methods 
The study was approved by our institutional ethics committee (appendix C) and was registered 
as a Current Controlled Trial (ISRCTN 31316759). It was conducted between October 2005 and 
June 2007 at The General Infirmary at Leeds. Patients with below-knee varicosities associated 
with both above and below-knee GSV reflux were invited to participate provided that they 
wished to undergo EVLA and were suitable for this technique. Patients were excluded from the 
study if they had: recurrent varicose veins, concomitant reflux in another truncal vein or 
perforator, allergy to sodium tetradecyl sulphate (STD), BK-GSV tortuosity precluding EVLA, 
a competent BK-GSV, age <18 years, or did not give informed consent. Participants were 
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recruited from 114 consecutive patients with varicose veins due to isolated sapheno-femoral and 
GSV reflux. They were randomised (block randomisation) to one of three treatment groups 
(figure 5.1).  A sealed envelope method was used for randomisation and this was opened just 
before the treatment.   
 
Power Calculation  
This study planned to compare the follow-up sclerotherapy requirement across groups, to see if 
one modified treatment technique is significantly better than the other technique. From our pilot 
study we found that following standard EVLA 48% require follow-up sclerotherapy and the 
mean number of required sclerotherapy sessions was 0.66 (standard deviation 0.812). For this 
study we are expecting the sclerotherapy requirement to be halved with the modified technique. 
Analysis will be performed using two sample t-tests of equal proportions. Calculations are for 
80% power at a 5% level of significance with 32 subjects required per group." 
 
Inclusion Criteria 
 Primary varicosities due to SFJ/GSV reflux 
 Below knee varicosities due to reflux in both the above and below-knee segments of 
the GSV   
 
Exclusion criteria  
 Recurrent varicose veins 
 Concomitant reflux in another truncal vein 
 Patients with known allergy to STD 
 No reflux in below-knee GSV 
 Age under 18 years 
 Not willing to take part in the study 
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Figure 5.1: Details of randomisation and RCT protocol  
28/95 (29%) excluded: 
BK-GSV too tortuous 
for EVLA 
114 patients with 
isolated GSV reflux 
screened for study 
19 patients excluded: 
BK-GSV competent 
67/95 (70%) patients suitable for 
modified EVLA technique 
2/67 patients declined 
participation in study 
65/67 patients randomised  
Group B 
 
EVLA of AK & BK-
GSV 
(21 patients, 23 limbs) 
Group A 
Standard EVLA  
AK-GSV  
(BK-GSV not treated) 
(22 patients, 23 limbs) 
Group C 
EVLA of AK-GSV + 
foam sclerotherapy to  
BK-GSV 
(22 patients, 22 limbs) 
Follow up at 1 week    clinical, DUS, pain score 
 
Follow-up at 6 weeks    clinical, DUS, AVVS, assessment of saphenous nerve  
integrity, Incompetent BK-GSV ± residual varicosities 
treated by foam sclerotherapy 
 
Follow-up at 12 weeks  clinical, DUS, AVVS, patient satisfaction scores 
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5.2.1 Treatment  
Group A underwent standard AK-GSV EVLA whilst in group B, EVLA was used to ablate the 
incompetent GSV from mid-calf to groin. Patients in group C underwent A-K EVLA with 
concomitant catheter-delivered foam sclerotherapy for their BK-GSV reflux.  No patients were 
given synchronous sclerotherapy to their superficial varicosities at the time of EVLA. As EVLA 
was performed using local anaesthesia with immediate mobilisation DVT prophylaxis was not 
used.  
Group A: standard above-knee EVLA  
The GSV was cannulated at or just above (<5cm) the knee joint and a 5F (1.67mm) endovenous 
catheter (ELVeS™ Plus Katheter; Biolitec Group, Bonn, Germany) was passed over a 
guidewire. The catheter tip was positioned 1cm distal to the sapheno-femoral junction (SFJ) and 
EVLA performed as described in Chapter 2 using an 810 nm diode laser (12W power) 
delivering energy at a density of 60-70 J/cm. Post –treatment management was also as detailed 
above. 
 
Group B: above and below-knee EVLA  
The technique was identical to that for group A except that the GSV was cannulated in the calf, 
either below the lowest incompetent tributary or 70cm from the sapheno-femoral junction if 
GSV reflux persisted beyond this point (catheter length 70cm). Laser energy was again 
delivered at 60-70 J/cm. 
 
Group C: AK-GSV EVLA and concomitant BK-GSV foam sclerotherapy  
The GSV was cannulated as in group B and the catheter positioned 1cm distal to the SFJ. 
Tumescent anaesthesia was infiltrated only from the knee upwards and EVLA performed from 
groin to knee. The laser fibre was then removed and the catheter gradually pulled back towards 
the cannulation site in the calf whilst administering 2.5-3 ml of 1% STD foam (Fibrovein , 
STD Pharmaceutical Products Ltd, Hereford, UK) to the below-knee GSV. The foam was 
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prepared according to Tessari‟s method (Tessari et al., 2001). A compression bandage was 
applied to the leg following treatment.  
 
Group C was included in the study to assess the combined effect of AK-EVLA and BK-GSV 
sclerotherapy as this technique would be appropriate in patients in whom BK-GSV tortuosity 
precludes laser ablation. This technique might also provide optimum treatment if group B 
patients report significant rates of saphenous nerve injury. 
 
5.2.2 Data collection and follow-up 
Pre-treatment clinical severity was assessed using CEAP grading (Porter & Moneta 1995) and 
AVVS scores (Garratt et al., 1993). The GSV diameters in mid-thigh and mid-calf were 
recorded whilst standing as were the length of vein treated, details of laser energy delivery and 
the time taken to complete the procedure (skin preparation to off-table time). Following 
treatment patients completed a daily (for 1 week) visual analogue scale (1-100) to assess pain, 
and were reviewed at 1, 6 and 12 weeks. At each visit the study limbs were assessed clinically 
and by duplex ultrasound (DUS) to ascertain the reflux status (significant reflux = >1s measured 
by spectral trace analysis) of the SFJ and both the AK and BK-GSV. Absence of flow in a non 
compressible vein represented successful ablation. GSV diameters were recorded at each visit 
(The follow-up proformas are given as appendix).  
 
At 6 weeks patients were assessed for the presence of residual varicose veins (visible, palpable 
superficial varicosities ≥3mm diameter) and varicosities associated with BK-GSV reflux were 
treated by foam sclerotherapy of this vein. For isolated varicosities without truncal vein reflux 
foam sclerotherapy was administered to the varicosities themselves. Sclerotherapy was not 
performed for BK-GSV reflux (ultrasound) in the absence of visible varicosities. The AVVS 
was repeated at the 6 week visit.  
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At 12 weeks, limbs were again assessed for the presence of residual varicosities and AVVs was 
recorded. In addition, ablation or patency of the treated truncal vein was confirmed by DUS and 
patient satisfaction with treatment determined using a visual analogue scale (1-100). A log of 
complications was maintained throughout the study and all data were collected and recorded 
prospectively. Patients were specifically questioned about neurological symptoms which were 
objectively assessed if present.  
 
Study end points 
The primary end-points were the presence of residual varicosities requiring sclerotherapy and an 
improvement in the AVVS scores, a disease specific quality of life measure. The secondary end-
points were pain scores, patient satisfaction and complication rates.  
 
 
5.2.3 Statistical analysis 
The sclerotherapy requirement for each group was compared using a Fisher‟s exact  test. AVVS 
improvement within a group was tested using the Wilcoxon test and compared between groups 
by a Mann-Whiteney U test. Pain scores and patient satisfaction were compared using a student-
t test (unpaired).  . A “p” value of <0.05 was considered significant.  Data are presented as 
medians (±inter-quartile range) unless stated otherwise.  All analyses were performed with the 
statistical package SPSS® for Windows (SPSS-14, Chicago, Illinois, USA).   
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5.3  Results 
Demographic details are given in table 5.1 and treatment details in table 5.2. At both 1 and 6 
weeks DUS showed no retrograde SFJ flow and no groin tributary reflux in any of the treated 
limbs. Similarly, the AK-GSV was ablated (non-compressible, no flow) in all limbs of all 3 
groups.  
 
In group A the BK-GSV remained patent in all instances and 15/23 (65%) showed persistent 
reflux (>1s) at 1 week. Examination at 6 weeks confirmed that reflux (>1s) was still present in 
12/23 (52%) limbs. For these, ultrasound guided foam sclerotherapy was administered to the 
BK-GSV.  
 
 Group A Group B Group C 
Age (range) years 40 (30-69) 42 (27-70) 46 (31-68) 
Male 9 8 10 
Female 13 13 12 
Number of limbs treated 23 (22 patients) 23 (21 patients) 22 (22 patients) 
CEAP:  
C2 
 
16 
 
15 
 
14 
C3 3 3 3 
C4 3 4 4 
C5 1 0 1 
C6 0 1 0 
 
Table 5.1: Patient demography and disease severity scores (C of CEAP) 
CEAP score : C of Clinical, Etiology, Anatomy, Pathology 
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 Group A Group B Group C 
Length of vein treated by EVLA (cm) 31 (29-34) 52 (49-60) 30 (28-33) 
Length of vein treated by FS at primary 
treatment 
Nil Nil 19 (17-22) 
Laser energy density (J/cm) 64 (60-71) 61 (59-70) 62 (58-71) 
Duration of the procedure (min) 39 (32-47) 45 (40-56) 44 (40-56) 
Table 5.2: Treatment details (FS: catheter delivered foam sclerotherapy) 
 
In group B the BK-GSV was ablated in all cases (23/23) compared to 19/22 (86%) in group C. 
The 3 patent BK-GSVs in group C had persistent reflux and these were re-treated (ultrasound 
guided foam sclerotherapy) at 6 weeks.  
 
At 12 weeks, the SFJ remained competent and the AK-GSV ablated (non-compressible 
shrunken vein with no flow) in all limbs. Similarly, the BK-GSV remained occluded in all 
group B and C patients but 2 limbs in group A showed significant (>1s) below-knee reflux 
despite previous foam sclerotherapy. A further 11 BK segments showed flash (<1s) reflux. 
Sequential DUS showed that following laser ablation (AK-GSV in all groups, BK-GSV in 
group B) there was a progressive, significant, reduction in vein diameter. After BK-GSV 
sclerotherapy (groups A and C) this had not occurred by 12 weeks. The results are summarised 
in tables 5.3 and 5.4. 
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Table 5.3: GSV diameter (mm ±IQR) before and after EVLA: p values relate to comparison with previous measurement  
within the same group (1 week v pre-EVLA; 6-weeks v 1 week; 12 weeks v 6 weeks) 
 
 
 
Group A Group B Group C 
AK-GSV BK-GSV AK-GSV BK-GSV AK-GSV BK-GSV 
Pre-EVLA 7.9 (5.9-9.2) 5.4(4.8-6.0) 7.8 (6.0-8.9) 5.9 (4.7-6.3) 7.7 (6.1-9.1) 5.5 (4.7-6.1) 
At 1 week  7.4 (5.9-8.9) 
p = 0.46 
5.5 (4.9-6.1) 
p = 0.36 
7.6 (6.0-8.7) 
p = 0.38 
5.7 (4.6-6.2) 
p = 0.47 
7.5 (6.1-9.0) 
p = 0.37 
5.4 (4.5-6.1) 
 p = 0.32 
At 6 week 5.2 (3.6-6.4) 
p = 0.04 
5.4 (4.8-6.1) 
p = 0.32 
5.2 (3.5-6.4) 
p = 0.03 
4.0 (3.1-4.8) 
p = 0.03 
5.3 (3.6-6.5) 
p = 0.02 
5.4 (4.3-6.0) 
p = 0.49 
At 12 week 3.2 (2.1-4.0) 
p = 0.03 
5.3 (4.6-6.0) 
p = 0.34 
3.1 (2.2-3.9) 
p = 0.02 
2.8 (2.1-3.3) 
p = 0.01 
3.2 (2.2-4.1) 
p = 0.04 
5.0 (4.0-5.9) 
p = 0.09 
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Table 5.4: Reflux status of vein segments after EVLA (data for 12 weeks represent the combined effect of EVLA and delayed foam 
sclerotherapy)   
* 2 limbs in group A required further DUS guided foam sclerotherapy at 12 weeks  
 Group A (n=23) Group B (n=23) Group C (n=22) 
 AK-GSV BK-GSV AK-GSV BK-GSV AK-GSV BK-GSV 
 
 
At 1 week  
Ablated/occluded 23 (100%) 0 23 (100%) 23 (100%) 22 (100%) 19 (86%) 
Patent, no or flash reflux 0 8 (35%) 0 0 0 0 
Patent, reflux >1s 0 15 (65%) 0 0 0 3 (14%) 
 
 
At 6 week 
Ablated/occluded 
 
23 (100%) 0 23 (100%) 23 (100%) 22 (100%) 19 (86%) 
Patent, no or flash reflux 0 11 (48%) 0 0 0 0 
Patent, reflux >1s 0 12 (52%) 0 0 0 3 (14%) 
 
 
At 12 week 
Ablated/occluded 
 
23 (100%) 10 (43%) 23 (100%) 23 (100%) 22 (100%) 22 (100%) 
Patent, no or flash reflux 0 11 (48%) 0 0 0 0 
Patent, reflux >1s 0 2* (9%) 0 0 0 0 
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The overall sclerotherapy requirements (to the BK-GSV or directly into superficial varicosities) 
by 12 weeks were 61% (14/23) in group A, 17% (4/23) in group B, and 36% (8/22) in group C. 
These difference were highly significant (2=9.39 (2 df), p=0.01 for overall data). The 
difference between groups A and B was also significant (p=0.006) but not that between B and C 
(p=0.19) or A and C (p=0.14).  
 
Compared to pre-EVLA there was a significant improvement (p<0.001) in the AVVS score in 
all groups at 6 weeks (before sclerotherapy). These results are shown in table 5.5. The % 
improvement in AVVS at 6 weeks was 55.4%, 84.2% and 72.8% for groups A, B and C 
respectively and this was greater in groups B and C compared to group A (PA-B=0.011, PA-
C=0.015). Following foam sclerotherapy at 6 weeks all groups showed a further improvement in 
AVVS at 12 weeks which was greater in group A (Table 5.5).  
 
 Pre-EVLA 6 weeks 12 weeks 
Group A 14.8 (9.3-22.6) 6.4 (3.2-9.1) 
p (pre-6wk) < 0.001 
3.2 (0.5-4.9) 
p (6-12 wk) = 0.023 
Group B 15.8 (10.2-24.5) 2.5 (1.1-3.7) 
p (pre-6wk) < 0.001 
1.9 (0.5-2.4) 
p (6-12 wk) = 0.073 
Group C 15.1 (9.0-23.1) 4.1 (2.3-6.8) 
p (pre-6wk) < 0.001 
2.4 (0.6-3.9) 
p (6-12 wk) = 0.064 
Table 5.5: Aberdeen varicose vein scores (AVVS) before and after EVLA 
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The significant improvement in AVVS in group A could have been the result of either a 
reduction in the number of residual varicosities or occlusion of the incompetent BK GSV (or 
indeed both). In order to assess this, the AVVS was recalculated after excluding the question 
relating to the appearance of the varicosities. Following this adjustment the significant 
improvement in AVVS remained indicating that ablation of the BK GSV following foam 
sclerotherapy had made an important contribution to the reduction in symptom severity score 
(Table 5.6). 
 
Group A Pre-EVLA 6 weeks 12 weeks 
Overall AVVS 
 
14.8 (9.3-22.6) 6.4 (3.2-9.1) 
p (pre-6wk) < 0.001 
3.2 (0.5-4.9) 
p (6-12 wk) = 0.023 
AVVS except for 
Q1 
10.6 (8.1-19.3) 5.2 (2.9-7.2) 
p (pre-6wk) < 0.001 
2.2 (0.3-3.8) 
p (6-12 wk) = 0.012 
Table 5.6: Recalculation of AVVS excluding first question in group A before and after 
EVLA 
 
Median pain scores (out of 100) at 1 week were 32 (12-45), 34 (10-40) and 36 (12-50) in groups 
A, B, and C respectively, with no difference between the groups [p=0.12 (A-B), 0.16 (B-C), 
0.11 (A-C)]. Although some tenderness was recorded along the treated GSV in most limbs at 1 
week, only 2 patients in group C reported persistent pain due to BK-GSV thrombophlebitis for 
which diclofenac sodium was prescribed.  
 
Skin staining over the BK-GSV was visible in 2/22 (9%) limbs at 6 weeks in group C. This had 
faded significantly at 12 weeks but was still visible. No skin staining occurred after BK-GSV 
EVLA. Of the 26 limbs requiring foam sclerotherapy at 6 weeks (15 BK-GSV; 11 isolated 
varicosities) 4 (15%) developed marked tenderness of the treated vein and 6 (23%) skin 
staining.  
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Patient satisfaction rates at 12 weeks were 90% (A), 94% (B) and 90% (C) with no difference 
between the groups. Complications other than “phlebitis” were uncommon with 1 patient in 
Group C reporting transient numbness in the distribution of saphenous nerve. There were no 
instances of DVT (common or superficial femoral veins, popliteal vein) on DUS performed at 1 
week. 
 
5.4 Discussion 
Compared to standard above-knee EVLA concomitant ablation (laser or sclerotherapy) of an 
incompetent below-knee GSV resulted in fewer residual varicosities and superior symptom 
relief at 6 weeks. Further, these techniques reduced the subsequent requirement for delayed 
foam sclerotherapy. This study also confirms that both below-knee GSV EVLA and foam 
sclerotherapy are safe. Although randomisation of more patients might have resulted in 
significant differences in symptom improvement (AVVS) and sclerotherapy requirements 
between groups B and C this was considered unnecessary once it became apparent that EVLA 
of the BK-GSV was not associated with saphenous nerve injury. 
 
Previous experience with EVLA indicated that some 44% of patients require delayed foam 
sclerotherapy for residual varicosities following ablation of the above-knee GSV. The greater 
proportion (61%) of limbs requiring sclerotherapy following standard EVLA in this study is 
explained by the presence of both above and below-knee GSV reflux in all limbs and mirrors 
the findings of Monahan
 
who reported a similar rate of residual varicosities following GSV 
radiofrequency ablation (Monahan. 2005). Clearly, although ablation of the above-knee GSV 
will abolish SFJ and proximal GSV reflux, it only abolished reflux in the below-knee GSV in 
half of the limbs. In the presence of persistent reflux varicosities that connect directly to the 
below-knee GSV will almost certainly remain. Conversely, ablation of both the above and 
below-knee GSV should disconnect most if not all of the varicosities from the truncal vein and 
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thus ablation of the GSV from mid calf to groin is more likely control the varicose veins. In 
limbs where this was achieved by EVLA only 17% required subsequent sclerotherapy.  
 
Group C received catheter directed foam sclerotherapy to the BK-GSV while Group A received 
delayed foam sclerotherapy at 6 weeks under ultrasound guidance via a cannula for their 
residual incompetent BK-GSV. The effectiveness of such ultrasound guided foam sclerotherapy 
is therefore not comparable to that of catheter directed foam sclerotherapy treatment.   
 
This study has also shown that concomitant catheter guided below-knee GSV foam 
sclerotherapy following above-knee laser ablation was successful in abolishing GSV reflux 
19/22 (86%) and reduced the requirement for subsequent sclerotherapy (36%) although this 
technique was not as effective as full length EVLA. The failure of chemical ablation in 3 
patients in this group might be explained by the use of 1% STD rather than 3% STD. 
Nevertheless previous reports indicate that GSV ablation with STD foam is unsuccessful in 
about 10% of patients (Frullini et al. 2002; Jia et al., 2007). Although 2 patients in group C 
developed symptomatic phlebitis, the combination of sclerotherapy and thermal ablation is 
otherwise safe and more effective than standard above-knee EVLA alone. In addition to 
reducing the subsequent requirement for treating residual varicosities it was also accompanied 
by a greater improvement in the AVVS.  
 
The frequency of skin staining following sclerotherapy to either the BK-GSV or to residual 
varicosities was relatively high. Although this has only been assessed at 12 weeks, and may 
have subsequently improved, it provides further justification for laser ablation of both the above 
and below-knee GSV when this is incompetent and technically feasible.    
 
Although some 85% of limbs with primary varicose veins due to SFJ/GSV reflux are suitable 
for standard above-knee EVLA (Theivacumar et al., 2007), only 70% (67/95) with below-knee 
GSV reflux were suitable for longer length EVLA from mid-calf to groin because of below-
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knee GSV tortuosity (fig 5.1). In these patients concomitant above-knee EVLA and below-knee 
foam sclerotherapy would seem to offer the most effective initial therapy.  
 
Following above-knee EVLA persistent reflux in the below-knee GSV was successfully treated 
by DUS guided foam sclerotherapy and this explains the greater improvement in AVVS in 
group A between 6 and 12 weeks. Although this might be partly explained on the basis that 
these patients had more residual varicosities that were subsequently ablated by foam 
sclerotherapy they also had persisting BK-GSV reflux prior to further treatment. Recalculation 
of AVVS for group A at 6 and 12 weeks after excluding the scores representing the extent of the 
residual varicosities confirms that the improvement during this period remained significant and 
thus reflects the symptomatic benefit of abolishing BK-GSV reflux (Table 5.6).   
 
The impact of persistent below-knee reflux upon symptoms has been described earlier and was 
the rationale for designing this trial. However, we have also shown that foam sclerotherapy 
directed only at the residual varicosities did not provide additional symptom relief following 
successful ablation of above-knee EVLA (Theivacumar et al., 2006). The findings of these 
studies suggest that when residual varicosities are associated with below-knee GSV reflux 
following standard EVLA further treatment should be directed at the below-knee GSV rather 
than the varicosities themselves. More importantly, this would suggest that above-knee EVLA 
combined with multiple phlebectomies may not be as effective as some suggest (Mekako et al., 
2006)
 
when below-knee GSV reflux is present. Further this technique may require the use of an 
operating theatre and perhaps general anaesthesia, thus reducing the cost-effectiveness of 
EVLA.  
 
It is also clear that concomitant phlebectomy results in the excision of some varicosities that 
would have resolved spontaneously following abolition of GSV reflux, particularly in Group B 
patients, only 17% of whom required delayed sclerotherapy. Such a policy of delayed 
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intervention for persistent varicose veins is also promoted by Welch following RFA (Welch. 
2006).  
 
Although the presence of residual varicosities has been used as one of the end-points of this 
study it should be considered that following abolition of below-knee GSV reflux, the residual 
varicosities are unlikely to be responsible for symptoms. Thus their further treatment with 
sclerotherapy is only of cosmetic value. When such intervention is offered the risk of 
pigmentation, the frequency of which has been reported as 0-67% (Jia et al., 2007), must be 
discussed with the patient. Nevertheless pigmentation diminishes with time and Georgiev has 
reported that it persists in only 1% of patients at 1 year (Georgiev, 1990).   
 
Although pigmentation may be cited as a reason for preferring phlebectomy over delayed 
sclerotherapy de Roos et al compared outcomes for the two techniques in a randomised 
controlled trial and reported that phlebectomies take longer and are associated with more 
complications [blisters, bruising, phlebitis, matting, scarring] (de Roos et al., 2003). Similarly, 
Brethauer et al who compared a policy of concomitant phlebectomy or delayed sclerotherapy 
described equivalent outcomes in terms of patient satisfaction but with a greater incidence of 
phlebitis in the phlebectomy patients (Brethauer et al., 2001).  Finally Darwood et al
 
have 
reported that there were no differences between the two techniques in terms of cosmesis with 
95-98% of patients being satisfied with the outcome (Darwood et al., 2008).   
 
This last point is important since it is often suggested that sclerotherapy is more likely to result 
in an unsatisfactory outcome because of associated pigmentation. However this complication 
also occurs after phlebectomy. Table 5.7 summarises data from a number of studies reporting 
the adverse events associated with these two therapies (Ramelet, 1997; de Roos et al., 2002; 
Frullini et al., 2002). For post-sclerotherapy pigmentation the data has been published by 
Georgiev who reviewed patients one year after their initial treatment (Georgiev, 1990).  
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 Phlebectomy Sclerotherapy 
Major haematoma 0.1-2-4% N/A 
Post-op haemorrhage 0.3-4.3% N/A 
Pigmentation 0.4-17.5% 5-25% (1%)* 
Scars/skin necrosis 3-5% 0.2-1.0% 
Phlebitis 0.4-20% 1.1-3.3% 
Matting 0.5-9% 3-10% 
Lymphocele 0.1-2.3% N/A 
DVT 0-0.5% 0.1-0.2% 
 
Table 5.7:  Complications of phlebectomy and sclerotherapy (N/A = not applicable)  
 * proportion of patients with pigmentation at 1 year 
 
 
 A potential drawback to performing EVLA from mid-calf to groin is the greater time required 
for the procedure. This largely relates to the administration of the tumescent anaesthesia.  
Compared to the standard technique treatment times for patients in groups B and C were an 
average of 5-10 minutes longer. It might also be considered that the risk of thermal injury to the 
saphenous nerve might be greater following below-knee EVLA because of the more intimate 
relationship of the nerve to the vein. This study provides no evidence to support this hypothesis.   
 
Given that this study supports the concept that varicosities that are directly connected to a 
refluxing truncal vein will improve after ablation of the truncal vein, provided that the point of 
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communication is interrupted, it is logical to suggest that an incompetent truncal vein should be 
ablated from a point at or below the lowest point of branch reflux (Figure 5.2). This will require 
cannulation of a segment of competent truncal vein that will be of smaller diameter than the 
incompetent proximal vein. Whilst more experienced clinicians may find this relatively easy, 
this procedure can be facilitated by cannulating the vein with an 18G intravenous catheter which 
is smaller than the 5F needle supplied with the laser fibre, but still allows insertion of the 
guidewire. Similarly, most of the manufacturers of laser equipment include micro-puncture kits 
amongst their products. Alternatively the vein can be hooked to the skin surface through a small 
stab incision and cannulated under direct vision.   
 
Although patients in group B had a higher satisfaction rate compared to the other 2 groups, this 
difference was not statistically significant. Similarly there was no difference in mean pain scores 
during the first week indicating that the 3 treatment methods are equally acceptable to patients.  
 
In conclusion, longer length laser ablation of the great saphenous vein from mid-calf (or below 
the lowest point of reflux) to groin is safe and more effective than standard AK-GSV ablation 
when treating patients with below-knee varicose veins due to reflux in both the above and 
below-knee segments of the GSV. Although the follow-up in this study is short and does not 
provide any new data on the long-term efficacy of EVLA it seems logical that this technique 
should be adopted whenever possible. Alternatively, standard EVLA can be combined with 
catheter guided foam sclerotherapy to the below-knee GSV and this method would seem to 
offer the optimum therapy when tortuosity of the below-knee GSV makes it unsuitable for 
EVLA. 
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Figure 5.2: Shows the fate of varicosities following ablation from different points 
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Chapter 6: 
 
6. Other applications for EVLA 
 
EVLA was initially described as a method of treating GSV related varicosities (Min et al. 2001) 
and surgeons were reluctant to apply this technique to patients with SPJ/SSV reflux because of 
the close proximity between the high temperature laser fibre and the tibial nerve in popliteal 
fossa and the sural nerve in calf. However, previous work in our unit showed that the maximum 
temperature reached adjacent to the GSV during EVLA
 
was 43.3
o
C, with a median maximum 
temperature of 34.5
o
C 3mm from the GSV (Beale et al., 2006).   This is lower than the 
temperature that would be expected to cause permanent thermal neuronal injury (either by direct 
neuronal injury or by thrombosis of vasa nervorum causing neuronal ischaemia). Thus adjacent 
nerves should be safe during EVLA provided adequate tumescent anaesthesia is given to 
separate the nerves from the target vein. This chapter analyses the wider use of EVLA in the 
following situations:   
 
1. Small saphenous vein (SSV) reflux 
2. Anterior accessory great saphenous vein (AAGSV) reflux 
3. Recurrent varicose veins  
4. Paradoxical reflux 
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6.1  EVLA for small saphenous vein reflux 
 
6.1.1  Introduction 
The standard treatment for varicose veins associated with short saphenous reflux is ligation of 
the sapheno-popliteal junction (SPJ) with or without stripping of the small saphenous vein 
(SSV) under general anaesthesia. However recurrence rate following surgery may be as high as 
50%
 
at 3 years (van Rij et al., 2003). In many instances this is the result of inaccurate ligation of 
the SPJ. In addition neovascularisation, which is the commonest cause for recurrence following 
sapheno-femoral ligation and stripping, may have a role (Jones et al., 1996; van Rij et al., 2004).  
The frequency with which this occurs following SSV surgery has not been investigated but 
when present it allows further reflux into the SSV, which is often still present.  
 
It has been suggested that the laser energy creates steam bubbles from blood which cause 
thermal injury to the vein wall resulting in damage to the endothelial and sub-endothelial tissues 
(Proebstle et al., 2002). Alternatively direct contact between the laser fibre and the vein wall 
may be responsible for the thermal injury. Aside from its anaesthetic function the tumescent 
anaesthesia absorbs heat and prevents injury to the surrounding tissues. Further it compresses 
the vein around the laser fibre. Although the temperature at the laser fibre tip exceeds 720
0
 C the 
impact of this on reducing peri-venous temperature has been described above. That EVLA may 
provide a more effective treatment for SPJ and SSV reflux is suggested by the poor results from 
surgery, the accurate visualisation of the SPJ with ultrasound during EVLA, allowing ablation 
of the SSV from this point distally, and the possibility that laser ablation reduces the risk of neo-
vascularisation.  
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6.1.2  Methods 
Patients 
Of the 91 patients attending the venous clinics at the General Infirmary at Leeds between 
November 2004 and January 2006 with symptomatic varicosities due to SPJ/SSV reflux 65 
patients (68 limbs) were found to be suitable for EVLA and underwent SSV EVLA. Suitability 
for the procedure depended upon a ≥10 cm relatively straight segment of SSV immediately 
distal to the SPJ, an absence of significant varicose tributaries arising within 5 cm of the SPJ 
and a distal SSV of ≥3 mm diameter at the intended cannulation site. Demographic details are 
shown in table 6.1. Primary varicose veins were present in 52 limbs whilst previous SPJ ligation 
had been performed in 16 limbs. Using the CEAP classification, determined by a consultant 
vascular surgeon or an experienced surgical trainee, the maximum grading was C2 in 46 
patients, C3 in 8, C4 in 12 and C5 in 2. All C2 patients complained of aching and/or pruritus.  
 
Laser technique 
In these studies the SSV was cannulated in mid-calf or a little higher if there was a relatively 
short segment of straight SSV under ultrasound guidance. Current practice however is to gain 
access to the SSV at or below the lowest incompetent tributary wherever possible. A guidewire 
was passed proximally into the popliteal vein and a 5F catheter was positioned under ultrasound 
control 1 cm distal to the SPJ. Relatively larger volumes (compared to greater saphenous vein 
EVLA) of perivenous tumescent local anaesthesia (0.1% lignocaine, 150-200ml) were 
infiltrated along the vein under ultrasound guidance with a greater proportion (50-60 ml) of this 
used in the popliteal fossa to eliminate the possibility of thermal nerve injury. A bare tipped 
fibre was inserted via the catheter and gradually withdrawn so that 5-6 pulses of laser energy 
(810 nm diode laser, 12Watts power, 1 second pulses at 0.1 second intervals) were delivered / 
cm vein (60-72 Joules/cm). 
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Number patients (n) 65 (68 limbs) 
Median age (range) 48 years (28-82) 
Male: Female  22: 43   
BMI, median (±IQR)  25.1 (22.4-28.3) 
Vein diameter
*
, median (±IQR) 6.2 mm (5.1-7.6) 
C2 Varicose veins  n=46 (68%) 
C3 Oedema  n=8 (11.7%) 
C4 Skin changes n=12 (17.6%) 
C5 Healed ulcer n=2 (2.9%) 
C6 Active ulcer  n=0 
Ep Primary  n=68 (100%) 
Ad Deep veins n=0 
As Superficial veins n=68 (100%) 
Pr Reflux n=68 (100%) 
 
Table 6.1: Patient demography and disease severity scores (maximum “C” score for each 
patient) 
* : maximum diameter measured with patient standing 
CEAP score : Clinical, Etiology, Anatomy, Pathology 
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Following treatment a non-stretch compression bandage was applied to the limb for 1 week 
followed by a class 2 support stocking for a further week. Patients were prescribed 50 mg 
diclofenac sodium tds for 3 days to reduce inflammatory changes in the SSV. Patients were 
encouraged to resume their normal daily activities (including work) as soon as possible.  
 
Data collection and Follow-up 
Pre-treatment data collection included clinical assessment of the varicose veins (CEAP clinical 
stage), completion of the AVVS questionnaire and measurement of maximum SSV diameter on 
standing. Details of the laser energy used and the length of vein treated were also recorded. 
Following treatment patients were asked to keep an analgesic diary for one week and underwent 
clinical and duplex scan assessments at 6 weeks, 3 months and 6 months to determine whether 
the SSV had been successfully ablated.  
 
Specifically, ultrasound examination determined if the SSV remained visible and if it did its 
patency was assessed on the basis of compressibility and visible colour flow following a calf 
squeeze. If SSV flow was present reflux was assessed using both Doppler waveform analysis 
and colour flow imaging. Finally, the deep veins were examined for evidence of deep vein 
thrombosis.  
 
Clinical examination at 6 weeks was used to assess the extent of any residual varicose veins. If 
these were of cosmetic concern they were treated by foam sclerotherapy (1.0% sodium 
tetradecyl sulphate, mixed 1:3 with air using a 3-way tap). At subsequent clinical review the 
development of recurrent varicosities was determined.  
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The AVVS questionnaire was repeated at 3 months. All data including the ultrasound findings 
were collected by a team of 2 consultant vascular surgeons and 2 research fellows who had 
appropriate ultrasound training.  
 
A prospective log of complications (thrombophlebitis, bruising, pigmentation, skin burn, DVT) 
was maintained and the presence of cutaneous numbness determined by direct questioning. If 
present this was mapped by clinical examination. Finally patients were asked whether they 
would undergo EVLA again and if they would recommend the procedure to a friend.   
 
The AVVS before and after laser ablation were compared using a Wilcoxon test. A p value of 
<0.05 was considered significant.   
 
 
6.1.3 Results 
A median of 17cm (IQR: 12-20) of SSV was ablated using a total energy of 1131 J (IQR: 928-
1364) delivered at an energy density of 66.3 Joules/cm (IQR 54.2-71.6). 
 
The time taken return to normal daily activity was a median (IQR) of 0 (0-4) days with 42/65 
(65%) patients doing so straightaway. The overall duration of analgesic use was 3 (0-14) days 
which may reflect the provision of a 3 day supply of diclofenac sodium (50mg tds). However 
15/65 (23%) patients did not take any painkillers. 12/68 (18%) limbs received delayed foam 
sclerotherapy at 6 weeks for residual varicosities.  
 
The median (IQR) pre-treatment AVVS was 15.4 (11.8-19.7) compared to 4.6 (3.2-6.7) 3-
months post treatment (Figure 6.1). This improvement was highly significant (p<0.001). Finally 
64/65 (98%) patients would choose laser treatment again if they required it. 
148 
 
   
 
Figure 6.1: Pre and post treatment Aberdeen Varicose Vein Severity Scores (AVVS) in 
patients undergoing small saphenous vein laser ablation. Thick and thin horizontal lines 
indicate the median and range. The boxes represent inter quartile range  
 
Although not specifically recorded, minor bruising along the line of the SSV was reported by 
most patients. However this had disappeared by the time of the 6-week assessment. Although 
some minor pigmentation was present in a minority of limbs at this time this had resolved in all 
patients by 3 months. No skin burns occurred.  
 
Symptomatic superficial “phlebitis” of the SSV was documented in 3/68 (4.4%) limbs and was 
treated with a further course of diclofenac sodium 50 mg tds for as long as required. There was 
no evidence of deep vein thrombosis on either clinical or ultrasound examination in any patient. 
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Transient numbness in the distribution of the sural nerve was reported in 3/68 (4.4%) limbs at 
initial follow-up and this was confirmed by objective neurological examination. It resolved by 6 
months in all patients. No other neurological symptoms or signs were documented.   
 
Ultrasound examination confirmed complete occlusion of the small saphenous vein to the level 
of sapheno-popliteal junction in all limbs (68/68, 100%) at 6 and 12 weeks. Forty-eight limbs 
(46 patients) have completed at least six months follow up. The SSV was no longer visible in 42 
limbs (87.5%), iso-echoic in 4 (representing simple occlusion) and hyperechoic 
(obliteration/fibrosis) in 2.  
 
In the 12 limbs receiving sclerotherapy no further varicosities developed by 6 month follow-up 
and none of the patients (56 limbs) who did not require adjuvant sclerotherapy at 6 weeks have 
requested it to date.  
 
6.1.4 Discussion 
Successful treatment of small saphenous varicosities depends upon abolition of sapheno-
popliteal and small saphenous vein reflux. The former is traditionally achieved by sapheno-
popliteal ligation although stripping of the small saphenous vein is more controversial as it may 
be associated with sural nerve injury. Accurate ligation of the sapheno-popliteal junction can be 
technically demanding because of variability in its anatomical location and the relatively poor 
exposure of the popliteal vein and its branches afforded by a cosmetically acceptable incision. 
Although accurate ligation is facilitated by pre-operative ultrasound marking of the junction 
more than 50% of patients may develop recurrent varicose veins, often as a result of inadequate 
surgery
 
(van Rij et al., 2003).   
 
Conventional varicose vein surgery may also be associated with significant morbidity. Although 
usually minor (wound problems, cutaneous neuro-sensory loss) it may delay return to normal 
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activity and employment. Further, more serious complications may occur during sapheno-
popliteal ligation with 12 cases of foot drop due to nerve injury being recorded in the NHS 
Litigation Authority database in the period 1995-2003. Nevertheless one case of foot drop has 
now been descried following SSV EVLA (Kumar and Gipinath, 2010).  
 
In view of these drawbacks the newer minimally invasive methods of treating superficial venous 
incompetence in the SSV are of interest. The outcomes for both EVLA and RFA for GSV 
incompetence have been discussed earlier and thus the use of EVLA for SPJ and SSV reflux 
seems logical. Although efficacy for EVLA and RFA appear similar the UK cost of disposables 
for the latter is greater. Initially, a further advantage of EVLA was the shorter treatment times 
required compared to VNUS Closure (Covidien, Mansfield, USA) although this is no longer a 
factor following the introduction of VNUS ClosureFast.   
 
Foam sclerotherapy of truncal veins is also gaining popularity and has the advantage of 
significantly lower cost. However there is some concern about the durability of the technique 
with GSV occlusion rates of 90% at 28 days but only 81% at 3 years (van den Bos, 2009). 
However, Darvall et al have recently reported a 91%success rate for SSV at 1 year (Darvall  et 
al., 2009; Darvall et al., 2010). A further problem with the data for foam sclerotherapy is the 
lack of randomised controlled trials and thus the probability of reporting bias. 
 
Unlike above-knee GSV ablation there was initial concern about the possible risk of nerve 
injury in the popliteal fossa during laser therapy for small saphenous vein reflux. However, 
despite the high temperature at the tip of the laser fibre a previous study from our unit which 
measured temperatures adjacent to the GSV confirmed that following adequate administration 
of tumescent anaesthesia the perivenous temperature reached a median of 34.5
0
C and thus nerve 
injury should be avoided (Beal et al., 2006).  
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The present study has confirmed that laser ablation of the small saphenous vein is both effective 
and safe. Although 3 patients developed temporary paraesthesia in the distribution of the sural 
nerve this resolved within 6 months. There was no evidence of other motor or sensory nerve 
injury. Similarly there were no instances of skin burns or other serious complications such as 
deep vein thrombosis. Further, the small saphenous vein was successfully ablated from the 
sapheno-popliteal junction in all patients with spontaneous regression of associated varicosities 
in the majority of patients (52/68 [76%]) limbs. In the 16 limbs with residual varicosities 
delayed (6 weeks) foam sclerotherapy was performed in 12 (18%). No further treatment was 
required in 4 limbs in which symptoms had resolved and any remaining varicose veins were of 
no concern. Successful ablation of the small saphenous vein was associated with a significant 
reduction in symptom severity scores and a rapid return to normal activity (65% of patients 
doing so immediately).  
 
Although not the primary focus of this study the proportion of patients who were suitable for 
SSV EVLA was also assessed. Thus 50/69 (72%) and 15/22 (69%) of patients with either 
primary or recurrent varicose veins were suitable for EVLA.  
 
Two other small studies have also reported similar results for SSV ablation (occlusion rates 
95%, 97%) using EVLA (Proebstle et al., 2003; Perkowski et al., 2004), although neither 
reported the impact of this on symptom relief or the need for subsequent ambulatory 
phlebectomy or sclerotherapy. Similarly, post treatment morbidity was not described.  
 
In summary, this study was the first to confirm the safety and efficacy of endovenous laser 
ablation in the treatment of small saphenous varicosities. Given the variable results of sapheno-
popliteal ligation ultrasound guided laser treatment is likely to prove more successful than 
conventional surgery provided that the durability of the procedure is similar to that reported for 
GSV laser therapy.  
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6.2 EVLA of the anterior accessory great saphenous vein (AAGSV) 
6.2.1  Introduction 
Incompetence at the sapheno-femoral junction (SFJ) is the commonest cause [70%] 
(Labropoulos et al., 1994; Myers et al., 1995) of varicose veins and SFJ ligation and GSV 
stripping is the standard treatment for varicose veins associated with GSV reflux. In some 
patients reflux may occur in the anterior accessory great saphenous vein (AAGSV) rather than 
the GSV although many surgeons strip the latter when performing surgery for this type of 
incompetence. This study assesses the safety and short-term efficacy of AAGSV EVLA with 
preservation of a competent GSV in patients with isolated SFJ/AAGSV reflux.  
 
6.2.2  Methods 
Patients 
Of the 474 patients who underwent laser treatment for their varicose veins between March 2004 
and Jan 2007 at The General Infirmary at Leeds, 33 patients (median age of 43 (32-65), 21 
female, 12 male) with isolated SFJ/AAGSV reflux (type A in figure 6.2) underwent AAGSV 
EVLA alone (group A). Twelve of these patients had undergone previous treatment for varicose 
veins [GSV EVLA (n=3); surgical stripping of GSV (n=9)]. Outcomes for patients in group A 
were compared with those for 33 age/sex matched controls who had GSV EVLA alone during 
the same time period (Group B: isolated SFJ/GSV reflux), 13 of whom had had previous 
treatment for varicose veins. Demographic data and the disease severity (CEAP classification) 
for the two groups are compared in table 6.2. Patients who had varicosities (primary or 
recurrent) arising from an incompetent SFJ with reflux in either the AAGSV (Group A) or GSV 
(group B) were included in the study but patients who had previous deep vein thrombosis 
(DVT) and those who with reflux in more than one truncal vein (AAGSV and GSV) were 
excluded. Further, limbs that had intra-saphenous reflux with a competent SFJ were also 
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excluded. Although types B and D in the figure 6.2 are also suitable for EVLA, they were not 
included in this study. 
 
 
Characteristics Group A Group B 
Number of patients (limbs) 33 (33) 33 (33) 
Age  43 (32-65) 43 (32-65) 
Male : Female 21:12 21:12 
Primary: recurrent varicose veins 21:12 20:13 
C2 28   (85%) 26    (79%) 
C3 4     (12%) 5      (15%) 
C4 1     (3%) 1       (3%) 
C5/6 0 1       (3%) 
 
Table 6.2: Patient demography and “C”: of CEAP classification for Group A (AAGSV 
reflux) and Group B (GSV reflux) 
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Figure 6.2: Laser suitability of different anatomical patterns of AAGSV reflux 
 
EVLA technique 
For group A, the AAGSV was cannulated as far distally as possible in the straight segment of 
vein under ultrasound guidance and a guidewire was passed proximally.  A 5F catheter was 
positioned with the tip located at least 1 cm from SFJ to protect the competent GSV. In all other 
respects EVLA was performed as described in chapters 2 and 3 as it was for patients in group B.  
 
Data collection and Follow-up 
Prior to EVLA all patients underwent a duplex ultrasound scan (DUS) [TITAN®, Sonosite Inc, 
Bothell, USA, 5-10 MHz linear probe] to determine the site of superficial venous incompetence. 
Previous treatment for varicose veins was documented. Ultrasound examination was performed 
with the patient standing. Following calf compression and release retrograde flow in the truncal 
vein lasting >1 s represented significant reflux. The diameter of the GSV (10 cm distal to SFJ 
whilst standing, avoiding focal dilatations) was measured in both groups, as was the AAGSV 
diameter in group A. Suitability for GSV EVLA was established using criteria that have been 
described previously (chapters 2, 3). Similarly suitability for AAGSV EVLA depended upon a 
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≥10 cm relatively straight segment of AAGSV immediately distal to the SFJ, an absence of 
significant varicosities arising within 10 cm of the SFJ, and an AAGSV diameter of ≥3 mm at 
the intended cannulation site (Figure 6.3). Disease severity was assessed using “C” of the CEAP 
clinical classification
4
 prior to treatment (“EAP” of CEAP were the same for all patients) and 
the Aberdeen varicose vein severity score (AVVS) was determined before and 1 year after 
EVLA. All data were collected prospectively by a consultant vascular surgeon or vascular 
research fellow.  
 
Figure 6.3: Suitability for EVLA in AAGSV in patients (Group A)  
 
 
FV: Femoral vein 
SFJ:  Sapheno-femoral Junction 
GSV: Great saphenous vein 
AAGSV: Anterior accessory GSV 
Incompetent 
AAGSV≥10cm 
Diameter≥3mm 
Competent/  
absent GSV 
FV 
SFJ 
Line represents a competent vein 
Line represents an incompetent vein 
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EVLA was performed using tumescent local anaesthesia and an 810nm diode laser at 12W 
power delivering 60-80J/cm. Neither concomitant phlebectomies nor foam sclerotherapy were 
undertaken. Following treatment a compression bandage was applied for one week followed by 
a class II support stocking for a further week. Patients were reviewed at 6, 12 and 52 weeks. All 
patients with visible residual varicosities were treated with foam sclerotherapy at 6 weeks (if 
required) using 1% sodium tetradecyl sulphate (STD) foam (Fibro-vein®, STD Pharmaceutical 
Products Ltd, Hereford, England) prepared by the Tessari method (Tessari et al., 2001). A non-
stretch compression bandage was applied for 1 week following foam sclerotherapy of residual 
varicosities. 
 
During follow up, in addition to clinical examination for residual varicosities, assessment of 
symptom improvement (AVVS) and a record of complications DUS was also performed at 6, 12 
and 52 weeks to assess SFJ and tributary competence and ablation or otherwise of the AAGSV. 
Patency of the deep veins was assessed at 6 and 12 weeks and the diameters of visible veins 
were re-measured at 1 year. Absence of flow in a non-compressible vein or a non-visible GSV 
or AAGSV vein on DUS represented successful ablation. The primary outcomes were DUS 
confirmed ablation rates and the improvement in AVVS in both groups at 1 year. Patient 
satisfaction was assessed at 1 year using a visual analogue scale of 1 to 10 on a 10 cm scale. 
Patients were asked to locate their satisfaction point on this scale which was then calculated as a 
percentage.  A log of complications was maintained throughout the study. Secondary outcomes 
included patients‟ satisfaction, sclerotherapy requirement and complication rates. All data were 
collected prospectively. 
 
 
Statistical analysis 
AVVS scores before and after laser ablation were compared within a group using a Wilcoxon 
test and the improvements in AVVS between groups were compared by a Mann-Whitney U test. 
Sclerotherapy requirements were compared using a chi-square test. A p value of <0.05 was 
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considered significant. Data are presented as median (inter-quartile range) unless stated 
otherwise.  All analysis were performed using the statistical package SPSS® for Windows 
(SPSS (14), Chicago, Illinois, USA). 
 
6.2.3  Results 
The treatment details for both groups are summarised in table 6.3. All treated anterior and great 
saphenous veins were completely ablated and SFJ reflux abolished in all patients of both groups 
at one year. Foam sclerotherapy for residual varicosities was required in 20/33 (61%) of group 
A and 14/33 (42%) of group B (χ2 = 2.2 (1 df) p=0.218). Patient satisfaction scores were similar 
(Group A: 84%, Group B: 90%, p=0.23) and the AVVS had improved at 1 year when compared 
to pre-treatment scores (A: 4.1 (2.1-5.2) v 11.6 (6.9-15.1); group B: 3.3(1.1-4.5) v 14.5 (7.6-
20.2); p<0.001 for both groups. Percentage improvement in AVVS was 64.6% (Group A), and 
77.2% (Group B) with no significant difference between the groups (p=0.18).  
 
Parameters Group A (AAGSV) Group B (GSV) p-value 
Diameter of treated vein (mm) 7.1 (5.2-8.0) 7.8 (5.2-8.8) 0.12 
Length of vein ablated (cm) 19 (14-24) 32 (24-42) cm <0.001 
Total laser energy (J) 1178 (912-1488) 2012 (1460-2466) <0.001 
Laser energy density (J/cm) 61  (56-68) 63 (57-68) 0.34 
Table 6.3: Treatment details for Group A (AAGSV reflux) and Group B (GSV reflux) 
 
None of the participants developed a DVT or signs of sensory nerve damage although 2 patients 
in group A and 1 in group B had symptoms of phlebitis in the EVLA–treated vein before 
sclerotherapy was performed. In addition, of 34 patients (from both groups) who received 
delayed foam sclerotherapy 5 (3 in group A and 2 in group B) developed symptomatic phlebitis. 
Although skin staining was not documented at 6 weeks, it was present in 11 patients following 
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foam sclerotherapy at 12 weeks. This had faded in all patients by 1 year but was still visible in 
3/34 (9%) patients. No other complications occurred.  
 
Twelve patients in group A had undergone previous GSV stripping or EVLA. In the remaining 
21 patients the GSV was preserved following AAGSV ablation and all were in continuity with 
the SFJ with no evidence of reflux at 1 year. Similarly, the GSV diameter remained unchanged 
(3.2±0.9 (pre-treatment) versus 3.3±0.6 (1 year); p=0.32). A similar improvement in AVVS 
scores was also observed in this sub-group (4.4 (2.0-5.4) v 11.4 (6.0-14.1), p=0.002) Finally, the 
AAGSV was non-visible on DUS at 1 year in any patient in Group A and no clinical 
recurrences were visible in patients from either group at this review 
 
6.2.4  Discussion 
Abolition of SFJ reflux requires ablation of all incompetent truncal veins arising from the 
junction. Thus AAGSV ablation abolishes reflux at the SFJ when associated with isolated reflux 
in this vein. Figure 6.4 illustrates the fate of the SFJ, GSV and AAGSV following successful 
AAGSV ablation. The subsequent improvement in symptom scores was similar to that achieved 
after GSV ablation.   
 
Although SFJ reflux can be associated with incompetence in one or more of its tributaries, most 
patients (85%) only have GSV reflux (Theivacumar et al., 2007) and GSV ablation abolishes 
SFJ reflux with persisting competence of its tributaries at 1 year (chapter 4.2). Equally, when 
SFJ incompetence is associated with reflux in more than one truncal vein (5%; Theivacumar et 
al., 2007), all incompetent veins require either ablation (EVLA) or stripping (surgery) to restore 
SFJ competency. 
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Figure 6.4: Diagrammatic representation of GSV-sparing AAGSV laser ablation 
 
FV: Femoral vein     GSV: Great saphenous vein 
SFJ:  Sapheno-femoral junction    ASSV: Anterior accessory saphenous vein 
 
 
Isolated AAGSV/SFJ reflux occurs in around 10% of the patients (Theivacumar et al., 2007). 
During conventional surgery many surgeons also strip the competent GSV because of the 
possibility that post-SFJ ligation neo-vascularisation may subsequently promote GSV reflux and 
recurrent varicose veins. Although stripping of incompetent truncal veins is required to reduce 
recurrence rates there is no evidence to support this for competent veins. During EVLA 
selective ablation of the incompetent truncal vein can be achieved without the need to ablate 
competent truncal veins. Thus a healthy GSV may be preserved. Subsequently it will still be 
available if required for vascular or coronary artery reconstruction. That such a policy is likely 
to be successful is further supported by the finding that EVLA is believed to be associated with 
Line represents a competent vein 
Line represents an incompetent vein 
Pre-EVLA (Incompetent SFJ) Post-EVLA (competent SFJ at 1-year) 
 Incompetent      
   AAGSV 
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FV 
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SFJ 
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  AAGSV 
GSV still  
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a lower risk of neovascularisation (Chapter 7) presumably because there is less trauma to the 
surrounding tissue.   
 
Ideally, AAGSV EVLA should have been compared with surgery for AAGSV reflux. The issue 
of routine practice for this type of reflux (in the UK) made this difficult. Further, most patients 
with varicose veins now chose EVLA over surgery if their truncal veins are suitable for 
ablation. Nevertheless, comparing AAGSV and GSV EVLA in this study suggests that 
symptom improvement is similar. Further, previous studies show that EVLA and surgery in 
patients with SFJ/GSV reflux
 
(Mekako et al., 2006; Darwood et al., 2008; Carradice et al., 2011) 
 
are equally effective in improving symptom scores. 
 
Despite these results, EVLA is unlikely to replace surgery for all patients with SFJ/AAGSV 
reflux as anatomical considerations (figure 6.2) mean that it is only feasible in 70% of cases 
(unpublished data). Although not statistically significant (small sample size), the sclerotherapy 
requirement was higher following AAGSV EVLA compared to GSV EVLA. This reflects the 
shorter segment of AAGSV that can be ablated, and the extensive varicosities that may be 
present distal to the site of vein cannulation. This is consistent with previous findings that the 
need for adjuvant sclerotherapy is minimised by commencing ablation at the lowest point of 
reflux (chapter 5). 
 
Following GSV EVLA some 40% of patients do not have any branch tributaries in continuity 
with the SFJ (chapter 4.2).  In contrast following AAGSV EVLA the GSV remains in continuity 
with the SFJ in all patients allowing normal GSV function. In conclusion, GSV sparing EVLA 
of the AAGSV abolishes SFJ reflux associated with isolated SFJ/AAGSV incompetence, and 
improves symptom scores to a similar degree as GSV EVLA with no evidence of GSV neo-
reflux, or recurrent varicosities at 1 year. This treatment option preserves the healthy GSV for 
future use if required. Although long-term results are required, the technique appears both safe 
and effective.  
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6.3 EVLA for recurrent varicose veins 
 
6.3.1 Introduction 
Recurrence following surgical treatment of varicose veins is common particularly when follow-
up is extended to 10 years or more (Campbell et al., 2003, Winterborn et al. 2004a). Thus some 
20% of the patients requiring treatment for varicose veins have recurrent varicosities
 
(Dark, 
1992) following surgery for either SFJ/GSV or SPJ/SSV reflux.  Whilst many authors have 
associated recurrence with the development of either junctional or strip-tract neo-vascularisation 
(Jones et al., 1996) others believe that technically inadequate surgery may have an important 
role, particularly following sapheno-popliteal ligation. Other reasons for the development of 
recurrent varicose veins also include perforator incompetence and undiagnosed pelvic vein 
reflux (Egan et al 2006, van Rij et al., 2005; Blomgren et al., 2005).   
 
Re-do surgical treatment is time consuming and technically challenging and is associated with 
more complications (Loeprecht, 1997; Earnshaw et al., 1999; Perrin et al., 2000). 
 
It therefore 
seems logical to consider the safety and effectiveness of endovenous laser ablation (EVLA) in 
the treatment of these where it is appropriate. This may particularly be the case when the 
incompetent truncal vein remains in-situ (not stripped, incomplete stripping) at the previous 
surgery. Further information is provided below in respect of the suitability of patients for EVLA 
for recurrent varicose veins arising from an incompetent GSV, AAGSV or SSV.    
 
 
6.3.2 Methods 
Patients 
Patients attending the venous clinic at The General Infirmary at Leeds with a history of 
recurrent varicose veins were assessed both clinically using the CEAP classification and by 
duplex ultrasound scan (DUS), (TITAN®, Sonosite Inc, Bothell, USA). This was performed to 
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assess the suitability for EVLA. When confirmed patients were offered EVLA in preference to 
conventional surgery. Consecutive patients who have undergone EVLA for their recurrent 
varicose veins between March 2005 and March 2007 were included in this study. Varicosities 
due to at the sapheno-popliteal reflux following previous groin surgery and those due to 
sapheno-femoral incompetence after sapheno-popliteal ligation were not included in this study.   
 
During the study period 106 limbs in 91 consecutive patients (male: 31 female: 60, median age 
56 [iqr 42-74]) who underwent EVLA for their recurrent varicose veins and completed at least 
12-weeks follow up by August 2007 were included in the study. Those who had recurrence 
secondary to isolated GSV incompetence (Group Gr: 51 limbs in 47 patients) were compared 
with an age and sex matched group of patient undergoing EVLA for primary SFJ/GSV reflux 
(Group Gp). The controls were identified from the prospectively maintained database with same 
age (±2 years), sex and disease severity matched individuals.  Similarly those who had 
recurrence arising from an isolated incompetent residual SSV (Group Sr: 24 limbs in 23 
patients) were compared with a matched group of patients who had EVLA for primary SPJ/SSV 
reflux (Group Sp).  
 
Suitability of recurrent varicose veins for EVLA 
All recurrent varicose veins that are associated with an incompetent relatively straight segment 
of truncal vein (GSV/AAGSV/SSV) which measures >10 cm in length and >3mm in diameter at 
the intended cannulation site were considered as potentially suitable for EVLA provided that the 
varicosities were arising from this vein. The presence of junctional neovascularisation did not 
precluded EVLA. Conversely, varicosities that connected directly to the neo-vessels, or that 
were secondary to either perforating or pelvic vein reflux without an interim truncal vein were 
considered unsuitable for EVLA. Figure 6.5 illustrates types of recurrences and their suitability 
for EVLA.  
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Figure 6.5: Patterns of recurrent varicose veins and their laser suitability (upper row veins are suitable for EVLA while the lower row veins are not)
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EVLA technique 
The target truncal vein (residual GSV or SSV) was treated by endovenous application of laser 
energy using an 810 nm diode laser at 12W power under tumescent local anaesthesia (0.1% 
Lignocaine) as an out-patient procedure. Full detail of the EVLA technique is described earlier 
in this thesis (chapter 2).  The guidewire usually (but not always) failed to enter the common 
femoral or popliteal veins after previous GSV/SSV ligation and thus the sheath was advanced as 
far as possible without piercing the vein wall. The tip of the sheath was visualised by DUS to 
confirm its position within the appropriate superficial vein. In patients in whom  the truncal vein 
was connected to a deep vein via neovascularisation, these were filled with 1-2 ml of sclerosant 
foamed (3% sodium tetradecyl sulphate [STD], [Fibro-vein®, STD Pharmaceutical Products 
Ltd, Hereford, England]) prepared according to Tessari‟s method. The foam was administered 
via the endovenous catheter (ELVeS™ Plus Katheter; Biolitec Group, Bonn, Germany) prior to 
the introduction of the laser fibre. However as routine foam sclerotherapy was not used to treat 
other superficial varicosities at the initial treatment. Following EVLA a compression bandage 
was applied for 1 week followed by a grade 2 compression stocking for a further week. Residual 
varicosities were treated by delayed foam sclerotherapy at 6-12 weeks.  
 
Data collection 
In all patients, disease severity was assessed using CEAP, VCSS and AVVS. Treatment details 
including the length of vein ablated, the laser energy delivered, and the requirement for 
junctional sclerotherapy to neo-vessels were all recorded prospectively. The control group was 
obtained from the Leeds EVLA database.  
 
Following treatment patients were reviewed at 6, 12 and 52 weeks with a median [iqr] follow up 
of 12 months (3-18 months). The abolition or persistence of deep to superficial reflux and 
truncal vein incompetence were recorded together with the requirement for sclerotherapy for 
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persistent residual superficial varicosities. Post treatment clinical severity was determined using 
VCSS and AVVS.  Finally a log of complications was maintained throughout the study.  
Statistical analysis 
The VCSS and AVVS before and after laser ablation were compared within a group using a 
Wilcoxon test and the improvements in AVVS between groups were compared by a Mann-
Whitney U test. A p value of <0.05 was considered significant. Data are presented as median (± 
inter-quartile range) unless stated otherwise.  All analysis were performed using the statistical 
package SPSS® for Windows (SPSS (14), Chicago, Illinois, USA). 
 
6.3.3 Results 
The type of recurrence is shown in table 6.4 and patients‟ demographic details for each of the 
groups are given in table 6.5. 
 
 
 
Table 6.4: Anatomical causes of recurrent varicose veins treated by EVLA  
Reason for recurrence Group n % 
Recurrent GSV ± groin neovascularisation Gr 51 48% 
Para-reflux into AAGSV ± groin neovascularisation  11 10% 
Residual GSV supported by reflux from pudendal vein  4 4% 
Incompetent thigh perforator with distal GSV reflux  6 6% 
Recurrent SSV reflux ± popliteal neovascularisation Sr 24 23% 
> 1 source of reflux (combinations of above)  10 9% 
Total  106 100% 
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Group Gr 
(Recurrent 
GSV) 
Group Gp 
(Primary  
GSV) 
Group Sr 
(Recurrent 
SSV) 
Group Sp 
(Primary 
SSV) 
Number of patients 
(limbs) 
47   (51) 47   (51) 23  (24) 23  (24) 
Age median (iqr) 
52 (42-68) 52 (42-68) 49 (33-65) 49 (33-65) 
Male : Female 
20:27 20:27 9:14 9:14 
C2 of CEAP 
27        (53%) 30        (59%) 10       (42%) 11      (46%) 
C3 of CEAP 
9         (17.6%) 7          (14%) 7         (29%) 8        (33%) 
C4 of CEAP 
10       (19.6%) 11       (21%) 5         (21%) 4       (17%) 
C5/6 of CEAP 
5          (9.8%) 3           (6%) 2         (8%) 1       (4%) 
VCSS 
4 (3-5) 
 
4 (3-5) 4 (3-5) 4 (3-5) 
 
Table 6.5: Patients’ demography and CEAP/VCSS scores of the age and sex matched 
study groups 
 
Groups Gr & Gp 
Data on the length of vein ablated, vein diameter and laser energy used is shown in table 6.6.  
The GSV was ablated in 49/51 (96%) limbs in Group Gr whilst 2 veins had partially recanalised 
by 3 months. In Group Gp 50/51 (98%) veins were successfully treated. The AVVS score 
improved from 14.2 (10.2-18.9) to 3.2(1.2-6.4), p<0.001 in Group Gr and from 15.9 (11.4-22.7) 
to 3.8 (1.1-5.6), p<0.001 in Group Gp. The % improvement in AVVS was 78 % and 76% in 
groups Gr and Gp respectively (p=0.23). Delayed foam sclerotherapy was required in 19/51 
(37%) limbs in Group Gr and in 20/51 (39%, p=0.5) in Group Gp:. Three and 5 patients 
developed symptoms and signs of post-EVLA phlebitis in groups Gr and Gp respectively 
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(p=0.36) and patient satisfaction was similar in both groups Gr-86%, Gp-82% (p=0.32). 
Although neovascularisation was treated with foam sclerotherapy in 24 limbs in Group Gr 19 
still had evidence of persisting groin neovascularisation in the groin at 3 months. In this 
subgroup 23/24 GSVs were completely ablated and this was associated with a significant 
improvement in AVVS from 13.6 (8.5-17.7) to 2.1 (0.5-4.3),  p<0.001, at 12 weeks. The clinical 
severity of the varicose veins in these patients was also assessed by VCSS which improved from 
4 (3-5) to 1 (0-2) and 4 (3-5) to 1 (0-2) in Gr and Gp respectively (table 6.7). 
 
Groups Sr & Sp 
Data on the length of vein ablated, vein diameter and laser energy used is shown in table 6.6.  
 
The SSV was completely ablated in all 24 limbs in both groups and the AVVS improved from 
14.4 (8.2-19.4) to 2.4 (1.9-4.6), p<0.001 in group Sr and from 13.8 (6.3-17.5) to 2.2 (1.2-5.1), 
p<0.001 in group Sp. The % improvement in AVVS was 83% and 84% respectively (p=0.33). 
Delayed foam sclerotherapy was required in 8/24 (33%) and 6/24 (25%), p=0.38 in groups Sr 
and Sp. Post-EVLA phlebitis occurred in 2 and 3 patients respectively (p=0.5) whilst patient 
satisfaction was again similar in both groups: Gr 88%, Gp 90% (p=0.42). The clinical severity 
of the varicose veins in these patients was also assessed by VCSS (table 6.7). 
 
AAGSV 
AAGSV reflux was successfully ablated in all 11 limbs and the AVVS improved from 13.4 
(8.3-16.3) to 3.2 (1.7-4.9), p<0.01. Delayed foam sclerotherapy was required in 6/11 (54%) and 
patient satisfaction was 78%. No reported phlebitis occurred after EVLA although 2 patients 
had phlebitis after adjuvant foam sclerotherapy.  
 
168 
 
   
 
 
Group Gr Group Gp P 
(Gr v 
Gp) 
Group Sr Group Sp P 
(SR v 
SP) 
AAGSV 
 
Number of limbs 
 
51 
 
51 
 
- 
 
24 
 
24 
 
- 
 
11 
Total laser energy  
(J) 
2116   
(IQR 1392-2591) 
1998   
(IQR 1317-2580) 
0.23 1286  
(IQR 910-1520) 
1254     
(IQR 899-1498) 
0.28 1360 
(IQR 990-1642) 
 
Energy Density  
(J/cm) 
61              
(IQR 52-66) 
60             
(IQR 52-64) 
0.32 64       
(IQR 55-69) 
66         
(IQR 56-71) 
0.36 62 
(57-66) 
 
Diameter of the vein  
(mm) 
7.6            
(IQR 5.3-8.0) 
7.7           
(IQR 5.7-8.2) 
0.41 7.4      
(IQR 4.2-8.1) 
7.2       
(IQR 4.1-8.0) 
0.29 6.3 
(4.6-7.4) 
 
Length of vein  
(cm) 
36              
(IQR 28-41) 
34             
(IQR 27-40) 
0.21 20       
(IQR 16-22) 
19       
(IQR 16-21) 
0.43 22 
(IQR 16-28) 
 
 
Table 6.6: Treatment details and vein size for the study (GR, SR) and control (GP, SP) groups. (IQR: inter-quartile range) 
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Groups 
n=patients 
(limbs) 
Pre treatment 
AVVS 
1 yr post-EVLA 
AVVS  
P* 
 
% improvement AVVS Pre EVLA VCSS Post EVLA 
VCSS  
(1 year) 
Gr 
n=42 (44) 
 
14.2  (10.2-18.9) 2.1    (1.1-6.1) <0.001 85 Gr v Gp 
p=0.32 
4 (3-5) 1 (0-2) 
Gp 
n=43 (43) 
 
15.9(11.4-22.7) 2.8  (1.2-5.9) <0.001 82 4 (3-5) 1 (0-2) 
Sr 
n=20 (21) 
 
14.4 (8.2-19.4) 2.2 (1.7-4.7) <0.001 85 Sr v Sp 
p= 0.39 
4 (3-5) 1 (0-2) 
Sp 
n=22 (22) 
 
13.8 (6.3-17.5) 2.0 (1.1-4.9) <0.001 86 4 (3-5) 1 (0-2) 
AAGSV 
n=8 (10) 
 
13.4 (8.3-16.3) 3.2 (1.7-4.9) <0.001 76 4 (2-5) 1 (0-2) 
Perforator 
n=4 (4) 
 
12.1 (6.9-14.5) 3.2 (2.1-6.4) # 74 4 (2-5) (0-2) 
 
* Pre-EVLA versus Post-EVLA (1 year) AVVS  
# insufficient numbers to allow calculation of significance 
 
Table 6.7:  Comparison of AVVS and VCSS scores at 1 year 
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Incompetent perforators 
 
Six patients with incompetent mid thigh perforators were also treated successfully and the 
perforating vein regained competency (unidirectional flow during distal calf compression and 
release) in all 6 patients following EVLA. A diagrammatic representation of such a perforating 
vein before and after EVLA is shown in figure 6.6.  Two patients required delayed foam 
sclerotherapy for residual varicosities. As in the other study groups the AVVS improved from 
12.1 (6.9-14.5) to 4.6 (2.1-6.6) at 3 months and to 3.2 (2.1-6.4) at one year. Patient satisfaction 
was 76%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        Pre-EVLA                                                         Post-EVLA 
 
 
Figure 6.6: Diagram showing the fate of incompetent perforating veins after EVLA of the 
superficial truncal vein. 
DV: Deep vein     IPV: Incompetent perforating vein 
SV: Superficial vein    CPV: Competent perforating vein 
DV 
DV 
IPV 
CPV 
SV 
Ablated SV 
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Similarly all 4 GSV were successfully ablated in those who had residual GSV reflux supported 
by an incompetent external pudendal vein (Figure 6.7). The untreated pudendal vein tributary 
remained patent with minimal reflux (<1s). Only one patient required delayed foam 
sclerotherapy for residual varicose veins and the. AVVS improved from 11.5 (8.9-14.1) to 3.5 
(2.1-4.4) and patient satisfaction was 75%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Diagrammatic representation of recurrent varicose veins due to reflux in a 
residual GSV supported by a pelvic vein. Truncal segment AB was ablated by laser 
treatment 
Previously ligated SFJ 
Reflux from  
pelvic vein 
Residual GSV reflux 
Varicosities 
A 
B 
Pre-EVLA Post-EVLA 
Previously ligated  
SFJ 
Ablated GSV 
Varicosities  
disappeared 
 by 6 weeks 
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No patients had evidence of deep vein thrombosis during follow up. Although 1 patient in group 
Sp had transient numbness in the distribution of the sural nerve this had resolved by 6 months. 
No other neurological symptoms were recorded in this study. The overall incidence of post-
EVLA phlebitis was 8% (8/106) and this was treated with a 1-2 week course of diclofenac 
sodium 50 mg tds.  
 
6.3.4 Discussion  
Recurrence following varicose vein surgery is common after both sapheno-femoral and 
sapheno-popliteal ligation. Most recurrent varicose veins (65%) are due to reflux at the SFJ 
(Jiang et al., 1999) and this may result in reflux into a residual GSV or AAGSV.  
 
Alternative causes of recurrent GSV reflux include an incompetent perforating vein in the thigh 
or proximal calf, or a residual GSV may establish a communication with veins that drain into 
pelvis, often via the perineum.  For these routine re-exploration of groin would be unnecessary.  
 
Recurrence following sapheno-popliteal surgery is relatively more common and occurs in up to 
60% (Jiang et al., 1999) of patients after sapheno-popliteal ligation. The causes include failure 
to ligate the SPJ and the non-stripped SSV regaining a communication with the popliteal vein 
via neovascularisation. Rashid et al found that the former was the case in some 22% of patients 
despite preoperative DUS marking of the SPJ (Rashid et al., 2002). Re-exploration of the SPJ 
can be difficult and has rarely been associated with major nerve injury. Thus minimally invasive 
treatment is an attractive option.  
 
Although GSV stripping is associated with lower recurrence rates (Dwerryhouse et al., 1999)  in 
the absence of pre-operative ultrasound marking and quality control, which is rarely performed, 
Jiang et al
 
in 1999 found that a residual GSV was present in 43% of the patients who had 
previously undergone high tie with GSV stripping. Similarly, in many patients with recurrent 
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GSV varicosities in this series it appeared as if the GSV had not been stripped despite the belief 
that it had. Whilst some of these patients may have had a duplex saphenous system the 
prevalence of this was not known in this series.  
 
In the majority of patients with recurrent GSV reflux this was secondary to groin 
neovascularisation although a few had a relatively normal appearance to the SFJ on DUS when 
it appeared that the tributaries had been previously ligated but not the GSV. This is likely to 
reflect inadequate primary surgery. 
 
In patients with groin neovascularisation attempts were made to obliterate the neo-vessels with 
STD foam administered via the laser catheter. Although ablation of all refluxing veins was 
rarely achieved (5/24)  it is possible that the extent of reflux was reduced in  some patients with 
persistent neo-vessels on follow up DUS and thus no re-recurrence or compromise in clinical 
outcome was documented due to persisting neovascularisation at 1 year. As the degree of 
neovascularisation was not formally measured in this study, it is not possible to comment 
further upon the effectiveness of foam sclerotherapy in the treatment of neovascularisation. 
Importantly however, there was no evidence of DVT following the use of foam sclerotherapy to 
treat neovascularisation. In respect of all other potential complications these were similar in 
both patients with primary varicose veins and those undergoing treatment for recurrence.  
 
Although not employed in this study it might also be reasonable to employ catheter-directed 
foam sclerotherapy at the time of EVLA for GSV reflux which is originating from incompetent 
pelvic veins, particularly since these seemed to exhibit persistent (but reduced) reflux following 
EVLA. 
 
In the UK SSV stripping is not routinely performed and thus most recurrent varicose veins due 
to SSV reflux were suitable for laser ablation which is now the preferred method of treatment 
for SSV related varicosities in our institution. In most patients the SPJ had been ligated at the 
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original surgery and SSV reflux was the result of communication between the truncal vein and 
the popliteal vein via neovascularisation. Thus it was not possible to achieve a flush SSV/SPJ 
ablation in most cases. Foam sclerotherapy was not employed for neovascularisation at this site 
since it was decided to examine its safety and efficacy in patients with SFJ neovascularisation.  
 
Although flush ablation of the truncal/deep vein junction was not possible in most patients with 
SSV/GSV reflux all had a significant improvement in their symptoms scores (AVVS, VCSS). 
Whilst there may be some debate about the optimum site for distal cannulation of the truncal 
vein it is our policy to commence ablation at the lowest point of reflux when feasible. Although 
previous studies have reported transient sural nerve damage in 1-4% of patients following SSV 
EVLA (Chapter 6.1; Gibson et al., 2007), no instances of nerve injury occurred in patients with 
recurrent GSV or SSV varicosities in this study even when the SSV was ablated from the ankle.  
Careful attention to the administration of tumescent anaesthesia is likely to be the key to this.  
 
Incompetent perforator veins may be associated with distal truncal vein reflux and recurrent 
varicose veins. In this series successful treatment was achieved by ablation of the truncal veins 
without specific intervention for the incompetent perforator. These regained competency 
following truncal vein ablation and this was associated with a symptomatic improvement.  
Although endovenous ablation of incompetent perforators has been reported by others 
(Proebstle et al., 2007) this was not performed in our unit during the study period. 
 
 
Ablation of an incompetent truncal vein that connects distal varicosities with a proximal source 
of reflux (groin or popliteal fossa neovascularisation, incompetent perforating veins) appears to 
improve symptoms as measured by AVVS and to control the majority of visible varicosities 
provided cannulation is performed at or distal to the lowest point of reflux. For residual 
varicosities post-EVLA sclerotherapy was performed at the 6 week follow up if requested by the 
patient. Similar results were obtained even when the recurrent varicosities arose from pelvic 
veins, even though the feeding vein remained patent (but with <1s reflux). Failure to recognise 
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pelvic communications during the initial ultrasound assessment may result in unnecessary groin 
re-exploration (in surgical patients) since accurate ligation is almost impossible to achieve by 
this means. Clearly, varicosities arising from pelvic veins without an interim truncal vein are 
unlikely to be suitable for currently available endovenous laser ablation techniques.  
 
Critics of this study might argue that the outcome of EVLA for recurrent varicose veins should 
have been compared with that of surgical treatment. Given the different patterns of reflux that 
are responsible for recurrent varicose veins and our previous experience in attempting to 
randomise patients between EVLA and conventional surgery for primary varicose veins 
(Darwood et al., 2008) it was felt that it would be impossible to recruit sufficient numbers to 
such a trial. Further surgical stripping of a residual GSV/SSV is not always possible during re-
exploration of the groin or popliteal fossa since it may not be easily accessible. If left in-situ 
further recurrence is likely (Figure 6.5).   
 
Although technical difficulty was not formally assessed, unlike the difference between recurrent 
and primary surgery, the techniques employed for EVLA were no different to those used when 
treating primary varicose veins. Further, since it was often difficult to pass the guide-wire from 
the truncal vein into the deep vein when treating recurrent varicose veins the safety of the deep 
veins was guaranteed.  
 
Conclusions 
In appropriate patients EVLA is a safe and effective treatment for recurrent varicose veins due 
to recurrent SFJ and SPJ reflux, perforator incompetence and pelvic vein reflux. Ablation of the 
responsible truncal vein improves symptoms as measured by AVVS and is associated with high 
levels of patient satisfaction. This was apparent at both 3 month and 1 year follow-up.  Since the 
technique is relatively straightforward and is not associated with more complications than 
EVLA for primary varicose veins, the technique could be preferred to conventional surgical 
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treatment whenever the anatomy is suitable. Long term follow is required, particularly to assess 
the significance of persisting neovascularisation after EVLA.  
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6.4 Laser ablation for paradoxical reflux in Giacomini vein 
6.4.1 Introduction 
The Giacomini vein, described in 1873, is a proximal extension of the SSV in the thigh. It is 
present in 50-80% of the population (Moosman and Hartwell, 1964; Vasdekis et al., 1989; 
Labropoulos et al., 1994), and in >50% of the patients it communicates with the GSV
 
in the 
thigh (Delis et al., 2004). This inter-saphenous connection may transmit reflux from the 
proximal GSV to the SSV (descending or orthodox reflux) or from the sapheno-popliteal 
junction (SPJ) to the GSV (ascending or paradoxical reflux; Georgiev et al., 2003). In 
paradoxical reflux, blood from the SPJ ascends through the Giacomini vein to the GSV in the 
thigh and feeds more distal varicosities associated with the GSV. Ante-grade flow through the 
Giacomini vein during both systole (compression) and diastole (relaxation) of the calf muscle is 
an unusual striking feature of this type of reflux which is responsible for about 1% of primary 
varicose veins (Georgiev et al., 2003). Although there is no consensus regarding the best 
treatment for this type of reflux, surgical division of the Giacomini vein flush with the SSV and 
the GSV has been described (Escribano et al., 2005). 
 
This article describes a new approach to treat varicose veins due to paradoxical Giacomini vein 
reflux by endovenous laser ablation of the incompetent segment of GSV. The relevant fluid 
mechanics underlying this method of treatment are discussed.  
 
6.4.2 Methods 
Two patients aged 46 and 52 years (1 male, 1 female) presented with symptomatic primary 
varicose veins (aching, pruritus), without skin changes. Duplex ultrasonography (DUS) 
confirmed that the SFJ, proximal GSV and SSV were all competent. There was reflux at the SPJ 
and in the distal GSV. A Giacomini vein, which terminated at the GSV, was identified in both 
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patients and ante-grade flow was noted during both calf muscle squeeze and release. DUS also 
confirmed that the varicosities were not arising from the SSV.  
 
Endovenous laser ablation (810 nm diode laser, 12W power, 1 second pulse with 0.1 second 
intervals 60-72J/cm) of the GSV was performed from the mid-calf proximally beyond the 
junction with the Giacomini vein. Following treatment a non-stretch compression bandage was 
applied for one week followed by a class 2 support stocking for a further week. Both patients 
were prescribed 50 mg diclofenac sodium tds for 3 days to reduce inflammatory phlebitis in the 
GSV and encouraged to resume their daily activities (including work) as soon as possible.  
 
Both patients were reviewed at 6 and 12 weeks post-treatment. This included objective 
assessment using the AVVS scores, VCSS and DUS. Reflux status of the SPJ, GSV, SSV and 
Giacomini vein were all recorded.     
 
6.4.3 Results 
At six weeks, DUS confirmed that both GSVs were occluded throughout the treated length and 
that the SPJs had become competent. The majority of varicosities had disappeared although one 
patient required sclerotherapy for a residual varicosity. The improvement in symptom severity 
scores are shown in table 6.8. Symptoms had resolved fully in both patients.  No reflux was 
demonstrated in the SSV in either patient, and the Giacomini vein had decreased in diameter 
(see table 6.9) with minimal ante-grade blood flow during calf muscle squeeze and no flow 
following calf release. At 12 weeks the results were similar, although the treated GSV was non-
visible on DUS. No residual or recurrent varicose veins were present. The SFJ, SPJ, Giacomini 
vein and SSV were all competent. The duplex ultrasound scan findings in both patients are 
summarized in table 6.9. 
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  Patient 1 Patient 2 
Pre AVVS 16.5 12.7 
Post AVVS 2.1 0 
Pre VCSS 3 3 
Post VCSS 0  0 
Sclerotherapy requirement  One session None 
Table 6.8: Standard outcome measurements before and 12 weeks after EVLA  
AVVS: Aberdeen varicose vein score  VCSS: Venous clinical severity score 
 
 
 
 Pre treatment Post treatment: 3months 
SFJ Competent Competent 
Proximal GSV (proximal to Giac v) Competent Competent 
Distal GSV (Distal to Giac v) Reflux Occluded/not seen 
SPJ Incompetent Competent 
SSV Competent Competent 
Giac v Ante-grade flow during 
both calf muscle 
squeeze and release  
Ante-grade flow during 
calf muscle squeeze, no 
flow during release  
Diameter of the Giac v in Patient 1 6.2 mm 3.4 mm 
Diameter of the Giac v in Patient 2 5.9 mm 3.6 mm 
Table 6.9: DUS findings before and after treatment 
SFJ:   Sapheno-femoral junction   GSV:   Great saphenous vein 
SPJ:  Sapheno-popliteal junction   SSV:  Small saphenous vein 
Giac v:   Giacomini vein  
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6.4.4 Discussion 
Blood flows as a continuous column and therefore reflux in one segment of vein is filled by 
ante-grade or retrograde blood flow in another vein. Appreciation of this is necessary to 
understand the pattern of reflux and to plan effective treatment for varicose veins. In 
paradoxical reflux, although the blood from SPJ ascends through Giacomini vein against 
gravity, the blood eventually flows downwards to fill the GSV varicosities that are located 
below the SPJ. Even though blood appears to flow against gravity initially, the overall net-travel 
effect is in the direction of gravitational force. Thus, the cardinal sign of paradoxical reflux in 
these patients was the cephalad flow in the Giacomini vein during calf muscle release. In this 
type of paradoxical reflux, the SSV is competent due to a healthy valve in the proximal SSV, 
even though the SPJ becomes incompetent. A competent SFJ and proximal GSV are the other 
characteristic features of this type of reflux (Figure 6.8).  
 
This type of paradoxical reflux can be simulated in a simple experimental model of water flow 
(Figure 6.9). Water ascends through the tube segment “AB” before it descends in tube segment 
“CD”. The water flow in this model is only possible as long as the point D is lower than the 
point A, effectively working as a siphon.  Abolition of segment CD would prevent this siphon 
effect and stop flow from A to C. 
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Figure 6.8: Diagrammatic representation of paradoxical reflux in a Giacomini vein 
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Reflux in distal GSV 
Varicosities connected to GSV 
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Figure 6.9: The siphon effect  
(A simple model consisting of a water container and tubing demonstrates that the water column 
rises in segment AB before it falls with gravity in segment CD) 
 
 
 
This provides the rationale for treating this type of paradoxical reflux by removal or ablation of 
the GSV. The post-treatment DUS findings confirm that such a strategy was effective since the 
Giacomini vein diminished in size and the SPJ regained competency. A Doppler spectral trace 
(DST) of paradoxical reflux in a Giacomini vein before and after GSV EVLA is shown in figure 
6.10 and 6.11. Although it might be considered that the SSV might be at increased risk of 
becoming incompetent once paradoxical reflux in the Giacomini vein had been abolished, this 
did not seem to be the case as it remained competent on the 12 week follow-up DUS.   
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Figure 6.10: Doppler spectral trace (DST) of a Giacomini vein before GSV EVLA 
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Figure 6.11: Doppler spectral trace (DST) of a Giacomini vein 12 weeks after GSV EVLA 
 
The findings in these two patients highlight the necessity of carrying out a detailed DUS 
assessment to determine the pattern of reflux in each limb before planning a definitive 
treatment, particularly when EVLA is to be employed. Further studies with longer follow up are 
required to establish a standardized minimally invasive treatment for this pattern of paradoxical 
reflux. The main alternative to the technique described here would be ablation of the Giacomini 
vein. However, unless the GSV is also ablated it is likely that reflux would persist with 
proximal filling via GSV tributaries.  
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Chapter Seven: 
 
7. Recurrence Following EVLA 
 
7.1 Introduction 
Varicose vein recurrence is common following conventional great saphenous vein (GSV) 
surgery, occurring in 13-29% of patients (Jones et al., 1996; Dwerryhouse et al., 1999; Turton et 
al., 1999) in the medium term but in 62-70% when follow-up is extended to 10-11 years 
(Campbell et al., 2003; Winterborn et al., 2004a). Further, some 20% of interventions for 
varicose veins are for recurrent varicosities following previous surgery (Dark, 1992; Ruckley, 
1997). Although the causes of recurrence include incompetent perforators, para-reflux and 
inadequate primary surgery, groin neovascularisation is believed to be the commonest of these 
(Jones et al., 1996).  
 
Currently, there is increasing interest in the use of minimally invasive treatments for varicose 
veins, including foam sclerotherapy and both radiofrequency and endovenous laser ablation. 
Critics of these techniques suggest that recurrence rates may be higher than that for 
conventional surgery. The aim of this current prospective cohort study was to compare the rates 
of recurrence and neovascularisation rates 2 years following either conventional surgery or 
endovenous laser ablation (EVLA) for varicose veins.  
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7.2 Methods 
Consecutive patients undergoing treatment for primary varicose veins due to SFJ and GSV 
reflux between January 2004 and May 2005 were included in this study. Patients with a 
previous deep vein thrombosis, recurrent varicose veins, and those who also had reflux in 
another truncal vein (AAGSV, perforators or SSV) were excluded. All patients were suitable for 
either surgery or EVLA and were allowed to choose their treatment option. Of the 127 patients 
treated, 118 (129 limbs, 72 females, 46 males, median age 48 [32-68]) have completed 2 year 
follow up after either conventional surgery (Group A: 60 limbs) or EVLA (Group B: 69 limbs).  
 
Interventions 
Surgery for participants in group A was performed by a consultant vascular surgeon under 
general anaesthesia. A standard technique of high tie, where all tributaries at the SFJ were 
ligated, stripping of the GSV to the knee and multiple phlebectomies was used. Although the 
cribriform fascia was closed no additional surgical strategies such as a PTFE patch or over-
sewing of the saphenous trunk were used to try and reduce the risk of neovascularisation.  
 
Group B underwent standard EVLA as described previously in chapters 2 and 3 (810nm diode 
pulsed laser at 12W power). The GSV was ablated from the knee to the SFJ. Total laser energy 
(J) and energy density (J/cm) were all recorded prospectively. During follow up at 6 and 12 
weeks, any residual varicosities that were palpable and >3mm in size were treated with direct 
injection of foam sclerotherapy if requested by the patient (ultrasound guided foam 
sclerotherapy to the truncal vein was not undertaken in this study).   
 
Data collection and follow-up 
Patients‟ pre-treatment clinical severity (CEAP) and treatment details were recorded 
prospectively (Patients‟ initial pre-treatment data was collected by my predecessor Miss Rossie 
Beale until Feb 2005). All patients underwent clinical and DUS using a portable ultrasound 
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(TITAN® Sonosite Inc, Bothell, USA) before the treatment and at 6, 12, and 52 weeks after 
treatment. The maximum GSV diameter was measured (DUS: avoiding focal dilatations) while 
standing prior to the intervention. The reflux status of the deep and all truncal veins were 
documented at each visit. Compressibility and detectable blood flow during calf squeeze / 
release in the treated vein were also recorded. A further DUS assessment was performed at 2 
years when patients were also examined to determine the presence of recurrent varicose veins. 
Clinical recurrence was defined as the presence of palpable varicosities that measured >3mm on 
the treated leg that had been noticed by patient and confirmed by a clinician.  
 
The DUS performed at 2 years again assessed the presence of reflux in the femoral vein, the SFJ 
or within the treated GSV. Neovascularisation (serpentine venous channels) in the groin was 
also identified by careful DUS assessment, with the probe held longitudinally, horizontally and 
at different angles. The largest diameter and the duration of reflux in these channels were 
documented. When present, neovascularisation was classified (Jones et al., 1996) as those of 
small size (<4mm) with reflux of <1s duration (Grade 1) and those with larger (≥4mm) veins 
and prolonged reflux (>1s; Grade 2). All recurrent varicosities were traced with DUS to detect 
the source of reflux including perforating veins in the thigh or calf.  Patient satisfaction scores at 
2 years were derived using a visual analogue scale as described earlier. 
 
Statistical analysis 
Recurrence and neovascularisation rates were compared between groups using a Fisher‟s exact 
test. Patients‟ satisfaction was compared using a Mann-Whitney U test. A p value of <0.05 was 
considered significant. All analyses were performed using the statistical package SPSS® for 
Windows (SPSS (14), Chicago, Illinois, USA). 
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7.3 Results 
Patients‟ demographic details and pre-treatment disease severity are shown in table 7.1. 
Recurrence and neovascularisation rates are compared in table 7.2. At one year clinical 
recurrence was evident in 2 (group A) and 5 (group B) patients whilst DUS confirmed the 
presence of neovascularisation in 7 (group A) and one (group B) patients. At 2 years 
neovascularisation was detected in 11/60 (18%) patients following surgery and 1/69 (1%) after 
EVLA (p=0.001). Of the group A patients with neovascularisation 6/11 (55%) were classified as 
grade 1 and 5/11 (45%) grade 2.   The single patient in group B had grade 2 neovascularisation. 
Overall clinically apparent, cumulative recurrence rates up to 2 years were 4/60 (6.6%) and 5/69 
(7%) following surgery and EVLA respectively (p=0.631).  
 
In group A, 2 patients developed recurrence due to an incompetent thigh perforator by 1 year 
and 2 were due to neovascularisation promoting reflux in a persisting incompetent GSV 
(inadequate/inaccurate stripping) at 2 years. A further 9 patients showed evidence of groin 
neovascularisation on DUS but without clinical recurrence at 2 years.  
 
All recurrences in group B were evident by one year and 3/5 (60%) occurred following early 
GSV re-canalisation by 12 weeks. These patients all received <50J/cm laser energy during 
EVLA. Of these 3, one patient also had grade 2 neovascularisation associated with GSV re-
canalisation. The remaining 2/5 (40%) recurrences were due to an incompetent mid-thigh 
perforator (n=1), and reflux into the anterior accessory great saphenous vein (AAGSV, n=1). At 
2 years, patients‟ satisfaction rates were 90% and 88% in groups A and B respectively (p=0.37). 
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Patients  Group A (n=60) 
(Surgery group) 
Group B (n=67) 
(EVLA group) 
p 
Age (median ± iqr) 46 (32-60) 49 (30-78) 0.43 
Male: Female 39:21 45:22 0.49 
Previous DVT 0 0 - 
Number of limbs 64 73  
Pre-treatment C of CEAP* 
C2 39 43  
 
0.42 
C3 12 13 
C4 12 14 
C5/6 1 3 
GSV diameter (mm, 
median ± iqr) 
7.8 (iqr 5.8-9.1) 8.1 (iqr 5.9-9.3) 0.24 
Table 7.1: Baseline characteristics of patients in Group A (surgery) and Group B (EVLA) 
 * Pre treatment C of CEAP classification (EAP of CEAP were the same in all      
   patients, see exclusion criteria)   
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1 year (n=limbs) Group A (n=63) Group B (n=71) p  
Clinical recurrence  2/63          (3%) 5/71          (7%)  
Incompetent perforator 2               (3%) 1               (1%)  
Re-canalisation / residual GSV 0                  - 3               (4%)  
Reflux into the AAGSV 0                  - 1               (1%)  
Neovascularisation  7/63      (11%) 1/71          (1%)  
2 years (n=limbs) Group A (n=60) Group B (n=69) p  
Clinical recurrence  4/60          (7%) 5/69          (7%) 0.44 
Incompetent perforator 2               (3%) 1               (1%) 0.45 
Re-canalisation / residual GSV 2               (3%) 3               (4%) 0.36 
Reflux into the AAGSV 0                  - 1               (1%) 0.53 
Neovascularisation  11/60      (18%) 1/69          (1%) 0.001 
Table 7.2: Comparison of recurrence patterns and neovascularisation rates between 
groups A and B 
AAGSV: Anterior accessory great saphenous vein 
 
Two patients in group B had an active leg ulcer and a further patient in this group and one 
patient in group A had healed ulcers prior to the treatment. Following treatment, the active 
ulcers healed by 12 weeks in one patient and by 6 months in the other. All healed ulcers 
remained healed at 2-year follow up.  
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7.4 Discussion 
Overall recurrence rates were similar for both conventional surgery and EVLA 2 years after 
treatment. However, DUS detectable groin neovascularisation was significantly more common 
after surgery. In contrast, most recurrences following EVLA reflected inadequate primary 
treatment and it is likely that these could have been prevented by the administration of ≥70J/cm 
laser energy to the vein
 
(Chapter 3).  The different patterns of recurrence following EVLA and 
surgery are summarised figure 7.1 and 7.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selective laser ablation of GSV                Possible patterns of recurrence after EVLA 
Figure 7.1: Possible patterns of reflux after EVLA 
1: Re-canalisation,  2: Para-reflux (AAGSV),  3: Perforator incompetence 
1 
3 
3 
2 
DV DV 
Ablated GSV 
SFJ SFJ 
ASV 
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Surgical high tie                                           Possible patterns of recurrence 
and stripping                                                following surgery 
Figure 7.2: Possible patterns of reflux after surgery 
1: Neovascularisation 
2: Incompetent perforating vein 
3: Persisting GSV/ new vessel formation 
4: Para-reflux (AAGSV) connecting via neovascularisation 
 
 
Varying frequencies (8-60%) (Jones et al., 1996; Nyamekye et al., 1998; van Rij et al., 2004; De 
Maeseneer et al., 2005; Egan et al., 2006; Perrin et al., 2006) of neovascularisation have been 
reported after surgery which probably reflects the duration of follow-up, possibly differences in 
surgical technique, and the sensitivity of DUS and the operator. Neovascularisation was 
detected in 18% (11/60) of this series with 5/11 (45%) having grade 2 neovascularisation which 
is more likely to be associated with a higher risk of recurrence. Although clinically obvious 
SFJ 
 
PV 
SFJ 
DV 
1 
4 
3 
2 
Stripped GSV 
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recurrence was not documented in most patients, Maeseneer et al. in 2005 have shown that 
neovascularisation rates at 1 year predict the development of clinical recurrence at 5 years.  
 
Histological studies have suggested that neovascularisation is the result of angiogenesis 
following surgery (Nyamekye at al., 1998). Techniques that have tried to reduce this risk have 
produced varying results.  Over-sewing the stump (Winterborn and Earnshaw, 2007) or 
covering it with a pectineus flap (Gibbs et al., 1999) have not proved successful although the 
use of a silicon patch to separate the SFJ from the GSV tract may be of benefit after surgery for 
recurrent varicose veins (de Maeseneer et al., 2004a). However the latter has been associated 
with femoral vein stenosis (de Maeseneer, 2004b) and the same author (de Maeseneer et al., 
2007) now recommends closure of the cribriform fascia although this technique has not been 
subject to vigorous assessment in a randomised clinical trial. Finally although de Maeseneer 
found that a silicone patch reduced the risk of further recurrence Earnshaw‟s group reported no 
benefit following implantation of a PTFE patch.  
 
As EVLA ablates the target vein from within the outer vein wall should remain largely intact 
and thus exposure of endothelial cells to the healing peri-venous tissue and subsequent 
neovascularisation should be less frequent.  Nevertheless one patient in this series did developed 
neovascularisation following EVLA and vein wall perforation and haematoma formation are a 
likely explanation for this. This reduction in neovascularisation has also been reported following 
radiofrequency ablation (Kianifard et al., 2006)
 
and although there are no studies examining its 
frequency following DUS guided foam sclerotherapy it seems likely that the results would be 
similar to those for the other endovenous techniques.  
 
Residual varicosities that persist after EVLA should be differentiated from recurrent varicose 
veins that subsequently appear. The presence and extent of residual varicosities depend on their 
pre-EVLA anatomical distribution and the haemodynamic relationship with the incompetent 
truncal vein. Varicosities that are directly connected to the incompetent truncal vein tend to 
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shrink when the index truncal vein is ablated both below and above their origin.  However 
varicosities that have an additional cross communication with another vein tend to remain as 
residual varicosities.  A previous study has shown that laser ablation of the GSV from below the 
lowest point of reflux, and therefore distal to the lowermost varicosity reduces the requirement 
of foam sclerotherapy to 17% (Chapter 5).  
 
Following ablation of a single incompetent truncal vein, neo-reflux into another truncal vein, is 
theoretically possible. This occurred in one patient in this study who developed AAGSV reflux 
following GSV ablation. This could either represent new reflux or the failure of pre-treatment 
DUS to identify concomitant AAGSV incompetence. The latter may be more likely since 
previous studies have shown that SFJ tributaries remain competent following selective EVLA of 
refluxing truncal veins (chapters 4.2 and 6.2).
 
 
 
Re-canalisation may occur in up to 4% of limbs following EVLA, although most are not 
associated with recurrent varicose veins unless it occurs within 6 weeks of treatment (primary 
treatment failure) (Proebstle et al., 2004 ). When re-canalisation occurs early it is almost always 
associated with the delivery of low energy densities (<60J/cm). Given the current 
recommendation to employ ≥70J/cm, it is anticipated that of this type of recurrence would be 
uncommon in the future. 
 
 
A residual GSV was responsible for recurrence in 2 patients in group A. This could reflect 
either incomplete stripping or the presence of a duplex GSV. Whilst both veins can be easily 
stripped when the GSV is duplicated from the groin, this becomes more difficult when a duplex 
GSV arises some distance from the surgical incision. This highlights the potential benefit of 
ultrasound control both pre- and intra-operatively in patients undergoing conventional surgery.  
In contrast, EVLA is performed under ultrasound control and thus both veins can be easily 
ablated regardless of the anatomical site of the duplex system.  
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Incomplete groin dissection, usually by trainee surgeons, has also been implicated in the 
pathogenesis of recurrent varicose veins
 
(Negus, 1993; Redwood and Lambert, 1994). Certainly, 
in this study this should not have been a factor since all surgery was performed by a consultant 
vascular surgeon. Further, with increasing sub-specialisation within general surgery and the 
imminent separate specialty status for vascular surgery future recurrences resulting from 
inadequate surgery should be less likely. Moreover incomplete stripping of the incompetent 
truncal veins due to varying GSV anatomy, unidentified perforator incompetence or groin 
neovascularisation are likely to assume increasing importance. Thus the outcome of surgery 
might be improved by ensuring complete GSV stripping by employing DUS guidance, 
particularly when a duplex GSV is present.  
Incompetent perforating veins were the cause of recurrence following both surgery and EVLA 
and have been reported as the principle factor in up to 14% of patients with recurrent varicose 
veins following surgery (Redwood and Lambert, 1994). Such a pattern of reflux may occur 
following neovascularisation within strip-tract haematoma or after incomplete stripping of the 
incompetent truncal vein. It is therefore important that pre-treatment imaging identifies any 
perforators and that stripping or laser ablation is performed from the groin to a point distal to the 
perforating vein. In this respect, a potential advantage of EVLA is the ability to ablate an 
incompetent GSV beyond possible sites of perforating veins such as Boyd‟s perforators in the 
proximal calf without a significant risk of saphenous nerve injury which may occur following 
surgical stripping. Although some authors claim that untreated incompetent perforator vein 
become competent following surgical stripping due to changes in the venous haemodynamics 
(Blomgren et al., 2005), others claim that even after ligation of an incompetent perforator up to 
75% of limbs will develop new perforator reflux at 3 years (van Rij et al., 2005).  Similar 
studies after thermal ablation are not available at present. Thus it is not clear if recurrences due 
to incompetent perforators following EVLA occurs from perforators that were incompetent 
prior to treatment or if this has developed de novo. Whilst the former could be a satisfactory 
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explanation following above-knee EVLA and subsequent below-knee perforator reflux the latter 
may be more relevant in patients who re-present with and incompetent perforator in the thigh.  
 
In conclusion, different patterns of recurrence occur after EVLA and surgery. Although the 
overall recurrence rates for both techniques were similar at 2 year follow-up re-canalisation 
after laser ablation should be minimised by modifying laser energy delivery. In contrast 
neovascularisation is likely to remain a significant problem following conventional surgery 
although more widespread use of careful ultrasound assessment might ensure more complete 
stripping of the GSV and any associated incompetent truncal veins. Nevertheless the very low 
incidence of neovascularisation following EVLA suggests that recurrence rates might be lower 
with this technique after successful ablation of incompetent truncal veins.  
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Chapter 8: 
8. Summary and Concluding Comments 
 
Most studies in my thesis apart from that presented in chapter 5 consist of non-randomised 
consecutive sampling. Further, small sample size, lack of randomisation or prospective 
controls and lack of long term follow-up are considerable weakness of most studies in this 
thesis. However, there are now many studies confirming the safety and efficacy of EVLA in the 
treatment of varicose veins. Further, studies included in this thesis have shown that the 
technique can be applied to a range of patients with superficial venous incompetence rather than 
simply those with GSV reflux as initially conceived.  
EVLA is a minimally invasive thermal ablation technique that is effective in treating varicose 
veins of the lower limb. It abolishes reflux at the deep to superficial vein junction by ablating 
the incompetent superficial truncal vein. It can be used for the treatment of both primary and 
recurrent varicose veins arising from the sapheno-femoral and sapheno-popliteal junctions 
including the anterior accessory great saphenous vein. In addition it can also be used to ablate 
incompetent perforator veins and treat patients with paradoxical reflux. The procedure improves 
symptoms and disease specific quality of life with outcomes that are at least as good as surgery 
when the techniques have been compared in randomised trials. Work in this thesis has also 
shown that the maximum improvement in disease specific quality of life is achieved by ablation 
of the truncal vein to the lowest point of reflux and that this can be safely achieved without 
concomitant nerve injury, the latter being an important complication of below-knee GSV 
stripping.  
 
As with any new technique long term outcome data is still required to confirm the durability of 
the procedure. However it is now clearly recognised that EVLA results in irreversible damage to 
the ablated vein and that truncal vein occlusion is the result of progressive fibrosis and 
198 
 
  
obliteration of the vein rather than thrombotic occlusion. Thus the treated vein becomes 
invisible within 6-12 months provided that sufficient energy has been delivered to the vein. In 
patients where recanalisation does occur this is usually evident within 6 (technical failure) to 12 
weeks (inadequate energy delivery resulting in thrombosis rather than fibrotic occlusion). 
Thereafter recanalisation is uncommon, and if it occurs the truncal vein is small with only flash 
or no reflux.  
 
In respect of the future risk of recurrent varicose veins concerns about the role of the tributaries 
of the SFJ that are not always disconnected from the junction by EVLA but are ligated during 
surgery appear unfounded as shown earlier in this thesis. Similarly the development of neo-
vascularisation at the SFJ is markedly less common than that after surgical ligation in patients 
followed up 2 years after both treatments. These findings would again imply that the risk of 
developing recurrent varicosities may be lower for EVLA than surgery. Again longer follow-up 
is needed.  
 
A further and unexpected advantage of the newer minimally invasive techniques for the 
treatment of varicose veins has been the widespread use, after appropriate training, of duplex 
ultrasound by surgeons. This has led to a greater understanding of the pathophysiology of 
venous disease and improved decision making in terms of selecting the most appropriate 
treatment modality for patients. It has also improved patient care with many clinics now 
performing ultrasound assessment at the patient‟s first visit and making a definitive treatment 
recommendation at that time. This thesis also describes a new method of determining reflux 
severity in a truncal vein based on the ultrasound findings which has the potential to further aid 
accurate decision making in patients presenting with varicose veins.   
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8.1 Future advances in the endovenous management of superficial venous 
incompetence                         
 
Although 80% or more of new patients presenting with varicose veins are suitable for EVLA the 
remainder are not. Generally these patients either have no significant truncal vein that is present 
for treatment (e.g. varicosities arising directly from the SFJ after previous surgery, an AAGSV 
that is varicose from the SFJ) or the incompetent truncal vein is considered too tortuous to allow 
passage of a guidewire and sheath.  For the former it is difficult to imagine that future technical 
advances will provide a method for achieving endovenous ablation other than by ultrasound 
guided sclerotherapy. For the second group there are various techniques that might improve the 
rate of successful cannulation. These include the use of hydrophilic guidewires and using DUS 
to help steer the guidewire away from tributaries. It should also be possible to enhance 
cannulation rates by using sheaths of differing shape/angle at the tip to steer the guidewire 
through the vein.  
   
8.1.1 Modification on laser physics  
Earlier in this thesis the potential benefits of longer wavelength lasers has been considered. 
Preliminary evidence would suggest that these target laser energy at the vein wall, particularly 
in combination with a radial fibre and that successful ablation can be achieved with less energy. 
This appears to be associated with a marked reduction in post-treatment discomfort. Further, it 
was initially proposed that with these reduced energy levels tumescent anaesthesia might not be 
required although this has not proved the case.  
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8.1.2 Predicting residual varicosities  
An important and widely debated dilemma associated with the use of EVLA has been is 
whether the varicosities should be treated concomitantly with the laser therapy or after a delay 
to allow spontaneous resolution following correction of the venous hypertension. The 
arguments surrounding this issue have been considered earlier in the thesis. Similarly the choice 
of either sclerotherapy or phlebectomy for residual veins has also been considered. The ability 
to predict which varicosities are likely to remain after successful endovenous therapy would 
allow suitably tailored treatment to be undertaken at the time of EVLA and further clinical 
studies examining this possibility are required. 
 
8.2  Is surgery obsolete? 
The increasingly widespread use of minimally invasive endovenous therapies for varicose veins 
has markedly reduced the requirement for conventional surgery. This has important implications 
in respect of both the direct and indirect costs of treatment. For the latter there is a negligible 
requirement for community nursing services and generally a more rapid return to normal 
activities including work. Within secondary care cost savings are associated with the need for 
fewer staff and the use of a treatment room rather than an operating theatre for the procedure. 
These are all powerful incentives favoring the adoption of minimally invasive therapy. 
 
However, it has already been considered that up to 20% of patients are not suitable for EVLA 
for anatomical reasons. For these surgery is often considered the most appropriate alternative. 
Nevertheless the majority of these patients are likely to be suitable for ultrasound guided foam 
sclerotherapy. Whilst this technique is easy to employ the main drawback is the relatively high 
risk of recanalisation of the treated vein and the reappearance of the varicosities. Despite the 
comparatively low cost of treatment some surgeons consider it counterintuitive to offer a 
therapy that may be less successful in the medium or long term despite potential savings. This 
would not be the case if the efficacy of sclerotherapy could be enhanced. 
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Current research in this field is directed at developing a clearer understanding of the 
mechanisms by which sclerotherapy works and in enhancing the damage that is inflicted on the 
vein wall so that permanent ablation is achieved.  If this proves successful the surgery may 
become obsolete! 
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10. Appendix 
A1: RCT Protocol 
Protocol for Randomized Controlled Trial of standard EVLA versus standard EVLA with 
below-knee foam sclerotherapy versus above and below-knee EVLA for varicose veins.
  
(Endovenous laser ablation: EVLA) 
 
Background 
 
Varicose veins are common, affecting up to 20 % of the population.  Patients seek treatment for 
aching legs, poor cosmesis, or complications (eczema, phlebitis, lipodermatosclerosis or 
ulceration). Their treatment incurs significant cost to both the NHS and employers. The majority 
(at least 70%
1
) are the result of sapheno-femoral (SF) and long saphenous vein (LSV) 
incompetence and standard treatment (SF ligation, LSV stripping, multiple avulsions), requires 
day unit or overnight admission (particularly for bilateral varicose veins) and a general 
anaesthetic.  
 
Minimally invasive techniques have been developed as alternatives to surgery, in an attempt to 
reduce the morbidity from surgery and to reduce recovery time. Recently Endovenous Laser 
Ablation (EVLA) has been developed as a minimally invasive method for treatment of varicose 
veins. This technique is effective and safe and is used routinely for treating patients within the 
Leeds teaching Hospitals NHS Trust. However modification to this technique might improve 
clinical outcome. 
 
Following abolition of reflux in the above knee LSV by EVLA the distal varicose varicosities 
diminish in size or become non-visible. For those that are still apparent delayed foam 
sclerotherapy is performed approximately 6 weeks after LSV ablation. In our experience about 
50% of patients require sclerotherapy and some may need up to three sessions. 
 
 
Potential changes to the EVLA technique, which might reduce the requirement for sclerotherapy 
for below-knee varicosities includes: 
1) Laser ablation of the below-knee LSV 
2) Foam sclerotherapy of the below-knee LSV at the same time as EVLA (laser 
ablation of the above-knee LSV) 
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Proposed Study 
 
This study will compare the safety and efficacy of EVLA in a randomised study of three groups 
of patients 
1) Standard above-knee EVLA and delayed sclerotherapy if required 
2) Standard above-knee EVLA with synchronous foam sclerotherapy to below-knee 
LSV and delayed sclerotherapy if required 
3) Above and below knee EVLA and delayed sclerotherapy if required 
 
A potential complication of below-knee laser ablation might be an increased incidence of 
saphenous nerve injury. Such injury occurs following heat transfer from LSV to the adjacent 
saphenous nerve or one of its branches. However the nerve remains intact and our experience 
with above-knee laser therapy indicates that the nerve always recovers spontaneously. This is in 
contrast to surgery when persistent numbness may occur (up to 10% of patients) due to 
irreversible damage to the saphenous nerve.  
 
The endpoints of this study will be: 
 Technical success of EVLA (duplex ultrasound assessment) 
 Number of follow up sclerotherapy sessions required 
 Improvement in symptoms (Aberdeen Vein Score) 
 Improvement in overall quality of life (SF-36 and EuroQol) 
 Post-operative mobility (medical outcomes study physical functioning measure) 
 Post-operative pain – daily visual analogue score for pain and analgesia diary 
 Assessment of saphenous nerve function (mapping and follow-up of any cutaneous 
numbness) 
 Time to return to work 
 Patient satisfaction 
 Improvement in cosmesis  - patient and independent assessor (quantitative assessment of 
pre and post procedure photographs) 
 Rate of complications – nerve injury, haematoma, phlebitis, infection, deep vein thrombosis 
(duplex documentation) 
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Patients 
 
Inclusion criteria:  
 
Consecutive consenting patients presenting to the vascular clinic for treatment of below- knee 
varicose veins (with or without thigh varicosities) that are due to LSV reflux. 
 
Exclusion Criteria: 
 Failure to obtain consent 
 Patients under 18 years of age 
 Patients having no below-knee varicose veins 
 Known allergy to sclerosing agent 
 
Randomisation: Block randomisation will be performed into the three groups described above.  
 
Randomising method: Sealed envelope, opened when the patient has consented to take part in 
the trial. 
 
Blinding: Unfortunately it will not be possible to blind the patient or the operator to the type of 
procedure. However the independent assessor, who can be blinded, will assess the pre and post 
procedure photographs.  
 
Treatment Schedules 
 
Treatment will be carried out at one of three centres: Leeds General Infirmary, St James 
University Hospital or BUPA Hospital at Leeds. All patients will be under the care of the 
consultant vascular surgeons at the General Infirmary at Leeds. 
 
 
Group 1- Standard EVLA alone  
This uses an 810nm bare-tipped, pulsed laser (Diomed Inc) at a power of 12 watts. The standard 
technique for EVLA will be used employing a laser density of 5 pulse/cm. Delayed foam 
sclerotherapy up to 5 ml of 0.2-1% STD will be used as required at the follow up clinic visit/s. 
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Group 2- Standard EVLA and on table foam sclerotherapy 
The same EVLA technique as for group 1 will be used except that the LSV will be cannulated 
below-knee (mid-calf) and a 70 cm sheath inserted. The LSV will be ablated (EVLA) to the 
level of the knee joint following which 5ml 1% STD (2 ml 1% STD, 3 ml air) will be injected 
into the below knee LSV via the sheath as it is withdrawn.  Delayed foam sclerotherapy up to 5 
ml of 0.2-1% STD will also be used as required at the follow up clinic visit/s. 
 
Group 3- Above and below-knee EVLA 
The LSV will be cannulated below-knee (mid-calf) and the whole length of the LSV ablated 
using the standard EVLA technique. Delayed foam sclerotherapy up to 5 ml of 0.2-1% STD will 
also be used as required at the follow up clinic visit/s. 
 
Pre-treatment Assessment 
 Basic demographic data  - age, sex, occupation, anti-platelet medication 
 Ultrasound duplex assessment - site of reflux, size of the long saphenous vein 
 Symptom Assessment   - Aberdeen Vein Questionnaire (disease-specific 
quality of life measure)       
 Severity of Venous Disease   – VCSS Score and CEAP score 
 
 
Post treatment assessment 
 
At 1 week: Daily Visual Analogue Score for pain 
 Analgesia diary 
Time to normal activity – time to return to work 
Assessment of post-treatment complications 
 
Duplex assessment of LSV and deep veins for evidence of DVT 
 
At 6 weeks: Outstanding data from week 1 
Late complications  
Time of return to work if >1 week 
Injection sclerotherapy as required in all patients 
Duplex assessment of LSV 
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At 12 weeks: Any outstanding data (as above) 
  Aberdeen Vein Questionnaire (disease-specific quality of life measure) 
  Duplex Ultrasound Assessment  
SF-36 questionnaire 
EuroQol questionnaire 
Cosmetic assessment – Visual Analogue Score completed by patient 
   - Photograph for assessment by blinded observer 
  Patient satisfaction 
  Injection Sclerotherapy as required in EVLA patients 
  Record of injection sclerotherapy 
Duplex assessment 
 
At 6 Months:  Questionnaire on recurrence and Aberdeen Vein Questionnaire (to ascertain  
recurrence rates).  Invitation for follow-up venous duplex scan. 
 
 
Outcome Measures 
 
A) Primary outcome measures 
 
1.  Technical success: determined by duplex ultrasound of LSV. 
 Successful  - Occlusion and non compressibility of the LSV without  
   blood flow throughout the treated length 
 Partial response - Segmental occlusion of LSV and abolition of distal reflux 
 Failure  - Reflux in treated LSV any time after treatment 
 
2.  Improvement in symptoms, using the Aberdeen Vein Questionnaire, a previously validated 
disease-specific quality of life instrument. 
 
3. The total number of follow up foam sclerotherapy needed to complete the treatment. 
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B) Secondary Outcome Measures 
 Post-procedure pain - patient analgesia diary 
- daily Visual Analogue Score for pain during the first week 
 Cosmesis   - as scored by the patient and an independent assessor on a                
  visual analogue score (VAS) 
 Complication rates  - wound infection, haematoma, nerve injury, DVT 
 Patient satisfaction  - would they have the same treatment again if required? 
 Overall Quality of Life - SF-36 questionnaire 
 
Analysis of data 
 
1) Comparing improvement in Aberdeen Vein Score in between groups: 
 
This is to compare the improvement in symptoms across groups, to see whether one treatment is 
better than another for improving symptoms.  Analysis would therefore be performed using a 
two-group crossover t-test for equivalence. 
 
2) Post procedure outcome: 
 
Technical success, the number of sclerotherapy sessions, cosmoses, post treatment 
complications (phlebitis, saphenous nerve injury, DVT) will be compared in the three groups. 
The power calculation will be based on sharing equivalence.   
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3) Power Calculations 
 
Comparing the requirement of follow-up sclerotherapy sessions  
 
This is to compare the follow-up sclerotherapy requirement across groups, to see if one 
modified treatment technique is significantly better than the other technique. From our pilot 
study we found that the standard EVLA require follow-up sclerotherapy in 48% and the mean of 
the required sclerotherapy sessions was 0.66 with standard deviation of 0.812. For this study we 
are expecting that the sclerotherapy requirement would be half with the modified technique. 
Analysis will be performed using two sample t-tests of equal proportions. Power calculations 
are for 80% power at the 5% level of significance 
 
This results in number per group of 32. 
 
 
4) Recruitment/time scale of randomised trial 
 
Currently approximately 450 interventions for varicose veins are performed each year. 
Recruitment is planned over 24 months during which time an estimated 450 patients (50% of 
550) should be suitable for this study. The study group sizes allow for a 36% failure to obtain 
informed consent.  Total patients required from power calculations = 288 
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Flow chart 1- Below-knee VV Trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-participants 
Participants 
Consecutive patients presenting to vascular 
clinics at LGI / BUPA Hospital (Leeds) 
with below knee varicose veins due to LSV 
reflux and who are suitable for EVLA. 
Excluded …. 
 Failure to obtain consent 
 Patient under 18 years of age 
 Patients with no below-knee 
varicose veins 
 Known allergy to sclerosing agent 
 Patients are invited to take 
part in the study 
Randomisation into 3 
treatment groups 
Group 2 
Above-knee EVLA 
and sclerotherapy 
Standard EVLA 
Outpatients appointment at 1 week 
 
Outpatients appointment at 6 week 
 
Group 3 
Above & below-
knee EVLA 
 
Outpatients appointment at 3 months 
Postal Questionnaire once a year 
Group 1 
Standard EVLA  
(above-knee laser) 
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A2: Consent form 
Patient identification number for this study:………………………………………………….. 
Consent Form for Research Study 
 
EVLA TECHNIQUE TRIAL - Is modified Laser technique the Best Way of Treating 
below-knee Varicose Veins? 
 
Researcher: Mr Nada S Theivacumar 
 
 I have read the information sheet for the above study                        
 
 I have had the opportunity to ask questions about the study,  
and to discuss it with family and friends.                                                                        
 
 I understand the purpose of the study and how I will be involved                       
 
 I understand, and accept, that as is explained in the information sheet the treatment I will 
receive may possibly have some side effects.                        
 
 I give permission for responsible individuals from regulatory authorities to have access to  
my medical notes where it is relevant to my taking part in the research.  This is on the 
understanding that no personal details which might identify me will be presented or 
published without my permission.                                                                             
 
 I confirm that I will be taking part in this study of my own free will, and I understand that I 
may withdraw from it, at any time and for any reason, without my medical care or my legal 
rights being affected.                                
 
I agree to take part in the above study. 
 
Patient Signature:____________________________________________ 
Patient Name:_______________________________________________ 
Date:______________________________________________________ 
 
I have explained the trial to the patient and given them the opportunity to ask questions. 
 
Doctor Name:_____________________________________________________ 
 
Doctor Signature:__________________________________________________  
 
Date:____________________________________________________________ 
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A3: Patient Registration Sheet 
 
Please complete at ultrasound clinic visit for all patients eligible for entry to trial. 
 
Date  
 
 
Hospital Number 
 
 
Surname 
 
 
Forename 
 
 
Date of Birth 
 
 
 
Sex 
 
   Male                                           Female                                       
 
Side to be treated 
 
 
   Right                                           Left 
Telephone number (and time 
can contact) 
 
 
Ultrasound Assessment 
 
Diameter LSV (while 
standing) in mm 
 
 
Echogenicity LSV 
 
 
Compressibility LSV 
 
 
Flow LSV above-knee 
 
 
Flow LSV below-knee 
 
 
SFJ competence 
 
 
2cm distal to SFJ                        Medial to knee 
 
Below-knee 
 
 
Iso                              Hyper                      Hypo 
 
 
Not                         Partially               Completely 
 
 
No flow                       <1sec                      >1sec  
                                    reflux                     reflux 
 
 No flow                      <1sec                      >1sec  
                                    reflux                     reflux 
 
   Competent                          Incompetent 
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To be completed on consent and randomisation: 
 
 
 
 
Consent to enter trial 
 
 
 
  
  Yes                                              No 
 
 
Treatment Allocation 
 
 
 
 EVLT 1                       EVLT 2                        EVLT 3 
 
Standard EVLT      A/K&B/K EVLT         EVLT &Foam 
 
 
GP Details 
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A4: Baseline Data 
 
To be collected when patient attends for treatment. 
 
 
 
Name 
 
Hospital Number 
 
Date of Birth 
 
(or ID label) 
 
 
 
Patient Occupation 
 
 
 
Family History (1
st
 degree relative) 
 
 
       Yes                            No 
 
Anti-platelet medication? 
 
 
 
VCSS score 
 
 
________/30 
 
CEAP Score 
 
 
C______      E______      A______      P______             
 
Check –    SF-36 
           -    EuroQol 
- Aberdeen Vein Score 
- Photo 
 
 
 
 
 
 
 
Please turn over…. 
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A5: Treatment Data 
 
Please ensure patients have the analgesia diary and pain scores to complete. 
Date 
 
 
Hospital Number  
 
Treatment Group 
 
Standard            Full length                EVLT & Foam 
EVLT                   EVLT 
     (1)                         (2)                           (3)       
 
Start Time (apply prep) 
 
 
Total Laser Dose (EVLT) 
 
 
Total Length Vein Treated 
(EVLT)  
 
 
                                        cm 
 
Rate of Pullback (EVLT) 
 
 
                                   Pulse/cm 
 
Length of vein foamed 
 
 
__________________cm 
 
Volume of Sclerosant / air 
 
 
Sclerosant: ___________ml     Air ____________ml 
 
Ratio: ________________ 
 
 
Surgeon/Laser operator 
 
 
 
Assistant present? 
 
Yes                                             No 
 
Finish Time (patient off table) 
 
 
Any comments 
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A6: EVLT Technique -TRIAL  – FOLLOW UP 1 
 
Please complete for all trial patients at first follow-up appointment (1 week). 
Also collect ANALGESIA DIARY and PAIN SCORES. 
Date (today)  
Patient Details 
(ID label if available) 
Name: 
 
DOB: 
 
Hospital number: 
 
Side of Treatment 
 
 
Left                                  Right 
LSV Phlebitis 
(clinical assessment) 
 
Yes                                       No 
Time to work 
 (if employed) in days 
 
Time to normal activity 
(days) 
 
Ultrasound Assessment 
 
Diameter LSV (while 
standing) in mm 
 
 
Echogenicity LSV 
 
Compressibility LSV 
 
 
Flow LSV above-knee 
 
 
Flow LSV below-knee 
 
 
SFJ competence 
 
 
2cm distal to SFJ                          Medial to knee 
 
Below-knee 
 
 
Iso                              Hyper                         Hypo 
 
Not                           Partially                Completely 
 
 
No flow                       <1sec                      >1sec  
                                    reflux                     reflux 
 
 No flow                      <1sec                      >1sec  
                                    reflux                     reflux 
 
   Competent                          Incompetent 
 
 
Complications;Eg: 
sensory loss, infection, 
haematoma (describe any 
and outcome) 
 
 
Thank you.  Any queries please contact Nada Theivacumar, Research Fellow, Vascular Surgery 
Unit, LGI. 
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A7: EVLT Technique  RCT– FOLLOW UP 2 
 
Please complete for all trial patients at second follow-up appointment (6 weeks). 
 
Date  
Patient Details 
(ID label if available) 
Name: 
 
DOB: 
 
Hospital number: 
 
Side of Treatment 
 
Left                                   Right 
LSV Phlebitis 
(clinical assessment) 
 
Yes                                       No 
Time to work 
 (if employed) in days 
 
 
Time to normal activity 
(days) 
 
 
Complications eg neuritis, 
infection, haematoma 
(describe any and outcome) 
 
Injection sclerotherapy 
required 
 
Yes                                       No 
Number of visits for 
sclerotherapy 
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Ultrasound Assessment 
 
Diameter LSV (while 
standing) in mm 
 
 
Echogenicity LSV 
 
 
Compressibility LSV 
 
 
Flow LSV above-knee 
 
 
Flow LSV below-knee 
 
 
SFJ competence 
 
 
 
2cm distal to SFJ                         Medial to knee 
 
Below-knee 
 
 
Iso                              Hyper                        Hypo 
 
 
Not                          Partially                 Completely 
 
 
No flow                       <1sec                      >1sec  
                                    reflux                     reflux 
 
 No flow                      <1sec                      >1sec  
                                    reflux                     reflux 
 
 
        Competent                      Incompetent 
 
 
 
Thank you.  Any queries please contact Nada Theivacumar, Research Fellow, Vascular Surgery 
Unit, LGI. 
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A8: EVLT Technique RCT – FOLLOW UP 3 
 
Please complete for all trial patients at third follow-up appointment (12 weeks).    
 
 
Date (today) 
 
 
 
Patient Details 
(ID label if 
available) 
 
Name: 
 
DOB: 
 
Hospital number: 
 
 
Side of Treatment 
 
Left                                                           Right 
 
 
 
Patient satisfaction 
(with overall 
treatment) 
 
 
Very                                                                                          
Completely satisfied                                                       unsatisfied                                                                                      
                                                                                                                                   
 
 
 
Patient view on 
cosmesis 
 
 
 
Not at all                                                                                          Very 
pleased                                                                                  pleased 
 
 
Complications eg 
neuritis, infection, 
haematoma 
(describe any and 
outcome) 
 
 
Sclerotherapy 
required 
 
 
    Yes                                           No 
 
Number of visits 
for sclerotherapy 
 
 
VCSS score 
 
________/30 
 
 
CEAP Score 
 
C______      E______      A______      P______    
          
 
PLEASE TURN OVER….. 
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Number Days in 
Hospital/DCU 
 
 
 
Number of Outpatients Visits 
 
 
 
Ultrasound Assessment 
 
Diameter LSV (while 
standing) in mm 
 
 
Echogenicity LSV 
 
 
Compressibility LSV 
 
 
Flow LSV above-knee 
 
 
Flow LSV below-knee 
 
 
SFJ competence 
 
 
2cm distal to SFJ                        Medial to knee 
 
Below-knee 
 
 
Iso                              Hyper                         Hypo 
 
 
Not                           Partially               Completely 
 
 
No flow                       <1sec                      >1sec  
                                    reflux                     reflux 
 
 No flow                      <1sec                      >1sec  
                                    reflux                     reflux 
 
   Competent                          Incompetent 
 
 
 
 
 
Please also check: 
 
 Aberdeen Vein Score 
 EuroQol 
 Photo 
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A9: EVLT Technique RCT – FOLLOW UP 4 
 
Please complete for all trial patients at third follow-up appointment (1 year).    
 
 
Date (today) 
 
Patient Details 
(ID label if available) 
Name: 
 
DOB: 
 
Hospital number: 
 
Side of Treatment 
 
Left                                                           Right 
VCSS score ________/30 
 
CEAP Score 
 
C______      E______      A______      P______             
 
Residual vvs? (Dr) 
 
    Yes                                           No 
 
Residual vvs? (Pt) 
 
    Yes                                           No 
Further Treatment? 
(had or awaiting – details) 
 
 
Ultrasound Assessment 
 
Diameter LSV (while 
standing) in mm 
 
 
Echogenicity LSV 
 
 
Compressibility LSV 
 
 
Flow LSV above-knee 
 
 
Flow LSV below-knee 
 
 
SFJ competence 
 
2cm distal to SFJ                          Medial to knee 
 
Below-knee 
 
 
Iso                              Hyper                         Hypo 
 
 
Not                           Partially                Completely 
 
 
No flow                       <1sec                      >1sec  
                                    reflux                     reflux 
 
 
 No flow                      <1sec                      >1sec  
                                    reflux                     reflux 
 
   Competent                          Incompetent 
 
CHECK:   Aberdeen Vein Questionnaire complete 
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A10: Daily visual analogue score (pain) 
 
Each day please mark a cross on the line in the box to show any pain you have from your 
varicose vein treatment.  If you don‟t have any pain, mark a cross at the left-hand end of the 
line. The more severe your pain is, the further to the right you mark a cross. 
 
 
 
 
Thursday 
(day of 
treatment) 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
 
 
 
Friday 
 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
 
 
 
Saturday 
 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
 
 
 
Sunday 
 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
 
 
 
Monday 
 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
 
 
 
Tuesday 
 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
 
 
 
Wednesd 
 
 
                                                                                                                         Worst 
No                            pain 
pain                                                                                imaginable 
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A11: Analgesia Diary 
 
For each day please write down how many painkillers and what painkillers you took, if any.  If 
you didn‟t need to take any painkillers or if you took the painkillers for something else other 
than your legs (eg a headache) please leave the space blank. 
 
 
 Name of Painkiller Dose of each tablet Number of tablets 
taken (over 24hrs) 
 
 
Thursday (day 
of treatment) 
 
 
 
 
  
 
Friday 
 
 
 
  
 
Saturday 
 
 
 
  
 
Sunday 
 
 
 
  
 
Monday 
 
 
 
  
 
Tuesday 
 
 
 
  
 
Wednesday 
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A 12: Laser vein follow-up proforma 
 
 
Date of treatment 
 
 
 
Side treated 
 
 
 
Time to return to normal activity 
 
 
 
Analgesic requirement 
 
 
 
„LSV phlebitis‟ (Y/N) 
 
 
 
Injections needed (Y/N) 
 
 
 
Injections completed (Y/N) 
 
 
 
Total number of visits for 
injections (if completed) 
 
 
 
LSV scan result: 
1. Mainstem? – measure length 
any patent vein 
2. Tributaries? 
 
 
 
Patient view on cosmesis 
 
 
 
Would patient have laser therapy 
again? 
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A13: Patient Questionnaire (one year follow-up) 
 
Name……………………………………………………………… 
 
Date of Birth……………………………………………………… 
 
For each question please place a tick in the box which best applies to you. 
 
 
1. For each of the following symptoms please indicate whether you had these before laser treatment and 
whether the treatment helped make them better? 
 
Before   After 
   Treatment  Treatment 
  Yes No   Gone   Improved     Same       Worse 
(i)   Aching or  
       painful legs 
(ii)  Itching legs 
 
(iii) Ankle swelling 
 
(iv) Did you wear a  
support stocking?          Yes  No 
 
 
 
2.  Would you describe your laser treatment overall as successful? Yes  No 
 
If not, why do you feel it was unsuccessful?…………………………………………… 
 
…………..……………………………………………………………………………… 
 
…..……………………………………………………………………………………… 
 
 
3. On the scale below, please mark with an “X” how satisfied you are with the results of your laser 
treatment: 
 
Very         Completely 
Disappointed        Satisfied 
 
 
4. Did you have any problems following the laser treatment?  Yes  No 
 
If so please describe:…………………………………………………………………… 
 
………………………………………………………………………………………… 
 
………….……………………………………………………………………………… 
 
 
 
 
3.   Do you have any varicose veins now (on the same leg that was 
      treated)?  If “no” go to question 5       Yes  No 
4.   If you do have varicose veins now, are these: 
 
a) new veins that have appeared since your laser treatment     Yes  No 
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b) veins that were there when you had your laser treatment  Yes  No 
 
c) compared to before your laser treatment are they:  Better             Worse          Same 
  
 
 
5.  Have you had any further treatment for varicose veins since the 
 laser treatment?       Yes  No 
 
If you have had further treatment, what did you have done? 
 
a) injections   b) an operation   c) further laser treatment 
 
Please add any details………………………………………………………………… 
 
………………………………………………………………………………………… 
 
………………………………………………………………………………………… 
 
    
 
4. If you needed treatment for varicose veins again (eg for the  
other leg) would you have laser treatment again?   Yes  No 
 
If not, please explain why not:……………………………...………………………….. 
 
………………………………………………………………………………………….. 
 
………………………………………………………………………………………….. 
 
 
 
5. Would you recommend laser treatment to a friend with 
 varicose veins?         Yes  No 
  
Thank you very much for your time. 
 
Mr. Nada Theivacumar (Research Fellow) 
Mr M J Gough /Mr A I D Mavor        
Vascular Surgery Unit 
The General Infirmary at Leeds  
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B1:  CEAP Classification 
 
C – Clinical Signs 
 
C0: No visible or palpable signs of venous disease 
 
C1: Telangiectases or reticular veins 
 
C2: Varicose veins 
 
C3: Edema 
 
C4: Skin changes ascribed to venous disease (eg pigmentation, venous eczema,  
  lipodermatosclerosis) 
 
C5: Skin changes as defined above with healed ulceration 
 
C6: Skin changes as defined above with active ulceration 
 
Telangiectases are defined as dilated intradermal venules of up to a diameter of approximately 
1mm, and reticular veins are defined as dilated subdermal veins up to a size of about 4mm that 
are not palpable. 
Varicose veins are palpable, dilated subcutaneous veins usually larger than 4mm.   
 
 
E – Aetiology 
 
 
Congenital         EC 
Primary (undetermined cause)       EP 
Secondary (known cause – post-thrombotic, post-traumatic, other))  ES  
 
 
A – Anatomy 
 
Superficial  AS  
Deep   AD 
Perforator  AP 
 
 
P – Pathophysiology 
 
Reflux    PR 
Obstruction   PO 
Reflux and Obstruction PR,O 
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B2: Venous Clinical Severity Score 
 
Score each attribute (0-3), then sum these scores to produce an overall score (0-30).  
 
ATTRIBUTE ABSENT = 0 MILD = 1 MODERATE = 2 SEVERE = 3 
 
PAIN 
None Occasional, not 
restricting 
activity or 
requiring 
analgesics 
Daily, moderate 
activity limitation, 
occasional 
analgesics 
Daily, severe 
limiting activities or 
requiring regular 
use of analgesics 
 
VARICOSE 
VEINS1 
None Few, scattered: 
branch varicose 
veins 
Multiple: LSV 
varicose veins 
confined to calf or 
thigh 
Extensive: thigh 
and calf or LSV 
and SSV 
distribution 
 
VENOUS 
OEDEMA2 
None Evening ankle 
oedema only 
Afternoon oedema, 
above ankle 
Morning oedema 
above ankle and 
requiring activity 
change, elevation 
 
SKIN 
PIGMENTATION3 
None or focal, 
low intensity 
(tan) 
Diffuse, but 
limited in area 
and old (brown) 
Diffuse over most 
of gaiter 
distribution (lower 
⅓) or recent  
pigmentation 
(purple) 
Wider distribution 
(above lower ⅓) 
and recent 
pigmentation 
 
INFLAMMATION 
None Mild cellulitis, 
limited to 
marginal area 
around ulcer 
Moderate cellulitis, 
involves most of 
gaiter area (lower 
⅓) 
Severe cellulitis 
(lower ⅓ and 
above) or 
significant venous 
eczema 
 
INDURATION 
None Focal, circum-
malleolar 
(<5cm) 
Medial or lateral 
leg, less than lower 
⅓ leg 
Entire lower ⅓ leg 
or more  
 
NO. OF ACTIVE 
ULCERS 
0 1 2 >2 
 
ACTIVE 
ULCERATION, 
DURATION 
None <3mths >3mths, <1yr Not healed >1yr 
 
ACTIVE ULCER, 
SIZE4 
None <2cm diameter 2-6cm diameter >6cm diameter 
 
 
COMPRESSIVE 
THERAPY 
Not used or 
not compliant 
Intermittent use 
of stockings 
Wears elastic 
stockings most days 
Full compliance: 
stockings + 
elevation 
1. “Varicose” veins must be >4mm diameter to qualify so that differentiation is ensured between C1 
and C2 venous pathology. 
2. Presumed venous origin by characteristics (e.g. Brawny [not pitting or spongy] oedema), with 
significant effect of standing/limb elevation and/or other clinical evidence of venous aetiology (i.e. 
varicose veins, history of DVT).  Oedema must be regular finding (e.g. daily occurrence).  
Occasional or mild oedema does not qualify. 
3. Focal pigmentation over varicose veins does not qualify. 
4. Largest dimension/diameter of largest ulcer. 
5. Sliding scale to adjust for background differences in use of compressive therapy. 
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B3: Aberdeen Varicose Veins Questionnaire 
(Andrew Garratt, 1996, Health Services Research Unit, Department of Public Health, University of 
Aberdeen)               
 
  
YOUR VARICOSE VEINS 
 
 
 
 
1. Please draw in your varicose veins in the diagram(s) below:- 
 
 
       Legs viewed             Legs viewed 
 
         from front                from back 
 
2. In the last two weeks, for how many days did your varicose veins cause you pain or ache? 
(Please tick one box for each leg) R Leg L Leg 
None at all    
Between 1 and 5 days    
Between 6 and 10 days    
For more than 10 days    
 
3. During the last two weeks, on how many days did you take painkilling tablets for your 
varicose veins? 
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(Please tick one box)                                                                     None at all  
Between 1 and 5 days  
Between 6 and 10 days  
For more than 10 days  
 
 
4. In the last two weeks, how much ankle swelling have you had? 
 (Please tick one box)                                                                     None at all   
Slight ankle swelling  
 
Moderate ankle swelling 
(eg. causing you to sit with your 
 
         feet up whenever possible) 
 
Severe ankle swelling 
(eg. causing you difficulty 
 
                putting on your shoes) 
 
5. In the last two weeks, have you worn support stockings or tights? 
 (Please tick one box for each leg) R Leg L Leg 
No    
 
Yes, those I bought myself without 
a doctor's prescription 
   
 
Yes, those my doctor prescribed for 
me which I wear occasionally 
   
 
Yes, those my doctor prescribed for 
me which I wear every day 
   
 
6. In the last two weeks, have you had any itching in association with your varicose veins? 
 (Please tick one box for each leg) R Leg L Leg 
No    
Yes, but only above the knee    
Yes, but only below the knee    
Both above and below the knee    
 
7. Do you have purple discolouration caused by tiny blood vessels in the skin, in association 
with your varicose veins? 
(Please tick one box for each leg) R Leg L Leg 
No    
Yes    
 
8. Do you have a rash or eczema in the area of your ankle? 
 (Please tick one box for each leg) R Leg L Leg 
No    
 
Yes, but it does not require any treatment  
from a doctor or district nurse 
   
 
Yes, and it requires treatment from  
my doctor or district nurse 
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9. Do you have a skin ulcer associated with your varicose veins? 
 (Please tick one box for each leg) R Leg L Leg 
No    
Yes    
 
10. Does the appearance of your varicose veins cause you concern? 
(Please tick one box)                                                                                 No  
 
Yes, their appearance causes 
me slight concern 
 
 
Yes, their appearance causes  
me a great deal of concern 
 
  
11. Does the appearance of your varicose veins influence your choice of clothing including 
tights? 
 (Please tick one box)                                                                                 No  
Occasionally  
Often  
Always  
 
12. During the last two weeks, have your varicose veins interfered with your work/ housework 
or other daily activities? 
(Please tick one box)                                                                                 No  
 
I have been able to work but my work  
has suffered to a slight extent 
 
 
 I have been able to work but my work  
has suffered to a moderate extent 
 
 
My veins have prevented me from  
working one day or more 
 
 
13. During the last two weeks, have your varicose veins interfered with your leisure activities 
(including sport, hobbies and social life)? 
(Please tick one box)                                                                                 No  
 
Yes, my enjoyment has suffered  
to a slight extent 
 
 
Yes, my enjoyment has suffered 
to a moderate extent 
 
 
Yes, my veins have prevented me taking  
part in any leisure activities 
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Scoring grid 
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Recoding the Questionnaire 
 
 
 
 
Question 
 
 
Left Leg 
 
 
 
Right Leg 
 
Maximum score 
per question 
 
    
1. Score per box 0.172 0.172 22.016 
    
2 0 0  
 0.500 0.500  
 1.000 1.000  
 1.812 1.812 3.624 
    
3 0 0  
 0.812 0.812  
 1.625 1.625  
 2.437 2.437 2.437 
    
4 0   
 1.250   
 1.875  1.875 
    
5 0 0  
 1.374 1.374  
 2.000 2.000  
 5.496 5.496 10.992 
    
6 0 0  
 1.374 1.374  
 1.437 1.437  
 2.748 2.748 5.496 
    
7 0 0  
 2.000 2.000 4 
    
8 0 0  
 2.624 2.624  
 6.121 6.121 12.242 
    
9 0 0  
 9.118 9.118 18.236 
    
10 0   
 1.625   
 3.249   
 5.248  5.248 
    
11 0   
 1.625   
 2.624   
 3.998  3.998 
    
12 0   
 1.625   
 3.373   
 5.496  5.496 
    
13 0   
 1.625   
 2.437   
 3.998  3.998 
    
  Maximum possible 
score 
 
99.658a 
    
 
aDue to rounding errors the maximum possible score does not reach 100.   
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